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Abstract 
 
 Diabetes mellitus is emerging as one of the major health 
problems in the 21st century .Neuropathies are among the most 
common complications. The purpose of this study is to determine the 
prevalence and characteristics of peripheral neuropathy in Yemeni 
patients including 155 patients.  
 The clinical examination included a full history and physical 
examination. The relative laboratory investigations were performed. 
Electrophysiological studies were conducted. All data were subjected 
to statistical analysis .  
 There were 79 female and 76 male diabetic patients. The mean 
duration was 10.43 #.59 years, being higher in males. The mean blood 
sugar levels were also higher in males, while cholestrol and 
triglycerides were higher in females.  
 The complications including polyneuropathy, small vessel 
disease, hypertension, renal and heart disease, peripheral artery 
occulosion and strocke were all presented.  
 The risk factors for the development of diabetic 
polyneuropathy included: duration of D,M, higher glucose levels , 
other systemic involvements, higher lipids and Qat chewing .  
 Nerve conduction studies showed that lower limbs were 
affected more than upper limbs.  
 The recommendations suggested extension of this study to 
other population groups to implement population –based measure 
for prevention, and aggressive control of blood sugar and lipids and 
life-style changes . 
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 ﻣﺴﺘﺨﻠﺺ
  .ﻴﻌﺘﺒﺭ ﺩﺍﺀ ﺍﻟﺴﻜﺭﻱ ﻤﻥ ﺃﻫﻡ ﺍﻟﻤﺨﺎﻁﺭ ﺍﻟﺼﺤﻴﺔ ﺍﻟﺘﻲ ﺘﻭﺍﺠﻪ ﺍﻟﻌﺎﻟﻡ ﻓﻲ ﺍﻟﻘﺭﻥ ﺍﻟﻭﺍﺤﺩ ﻭﺍﻟﻌﺸﺭﻴﻥ
  .ﻤﻥ ﺍﻟﻤﺭﻀﻲ% 05ﺎﻋﻔﺎﺕ ﺍﺫ ﻴﺼﻴﺏ ﺍﻹﻋﺘﻼل ﺍﻟﻌﺼﺒﻲ ﺍﻟﻤﺤﻴﻁﻲ ﻴﻤﺜل ﺃﻫﻡ ﺍﻟﻤﻀ
ﺍﻟﻬﺩﻑ ﻤﻥ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﺘﺒﻴﺎﻥ ﺍﻨﺘﺸﺎﺭ ﺍﻹﻋﺘﻼل ﺍﻟﻌﺼﺒﻲ ﺍﻟﻤﺤﻴﻁﻲ ﻭﻅﻭﺍﻫﺭﻩ ﻋﻨﺩ ﺍﻟﻤﺭﻀﻲ ﺍﻟﻴﻤﻨﻴﻴﻥ 
  . ﻤﺭﻴﻀﺎﹰ 551ﺍﻟﻤﺼﺎﺒﻴﻴﻥ ﺒﺎﻟﻨﻭﻉ ﺍﻟﺜﺎﻨﻲ ﻤﻥ ﺍﻟﺴﻜﺭﻱ ﻭﺸﻤل ﺫﻟﻙ 
ﻭﺸﻤﻠﺕ . ﺨﻀﻌﺕ ﻜل ﺍﻟﺤﺎﻻﺕ ﻷﺨﺫ ﺍﻟﺘﺎﺭﻴﺦ ﺍﻟﻤﺭﻀﻲ ﺍﻟﺸﺎﻤل ﻭﺍﻟﻜﺸﻑ ﺍﻟﻔﻴﺯﻴﺎﺌﻲ ﺍﻟﻜﺎﻤل
  .ﻤﻌﻤﻠﻴﺔ ﻨﺴﺏ ﺍﻟﺴﻜﺭ ﻭﺍﻟﺩﻫﻨﻴﺎﺕ ﻭﺍﻻﺨﺘﺒﺎﺭﺍﺕ ﺍﻷﺨﺭﻯ ﺍﻟﻤﻼﺌﻤﺔﺍﻟﻔﺤﻭﺼﺎﺕ ﺍﻟ
ﺘﻡ ﺃﺨﺘﺒﺎﺭ ﺴﺭﻋﺔ ﺍﻟﺘﻭﺼﻴل ﺍﻟﻜﻬﺭﺒﺎﺌﻲ ﻭﺘﻨﻅﻴﺭ ﺍﻟﺸﺒﻜﻴﺔ ﻭﺭﺴﻡ ﺍﻟﻘﻠﺏ ﺍﻟﻜﻬﺭﺒﺎﺌﻲ ﻭﺍﻷﺸﻌﺔ ﺍﻟﻤﻘﻁﻌﻴﺔ ﻓﻲ 
  .ﺒﻌﺽ ﺍﻟﺤﺎﻻﺕ
  .ﺘﻡ ﺘﺠﻤﻴﻊ ﺍﻟﻨﺘﺎﺌﺞ ﻭﺃﺨﻀﻌﺕ ﻟﻠﺘﺤﻠﻴل ﺍﻹﺤﺼﺎﺌﻲ 
  :ﺘﺒﻴﻥ ﺍﻷﺘﻲ 
ﺘﻭﺴﻁ ﻋﻤﺭ ﺍﻟﻤﺼﺎﺒﻴﻥ ﺃﻋﻠﻲ ﺒﻴﻥ ﺍﻟﺫﻜﻭﺭ ﻭﻜﺫﻟﻙ  ﻭﻤ67 ﻭﻤﻥ ﺍﻟﺫﻜﻭﺭ 97ﻋﺩﺩ ﺍﻟﻤﺼﺎﺒﻴﻥ ﻤﻥ ﺍﻹﻨﺎﺙ 
ﺍﻟﻔﺘﺭﺓ ﺍﻟﺯﻤﻨﻴﺔ ﻟﻺﺼﺎﺒﺔ ﻭﻨﺴﺏ ﺍﻟﺴﻜﺭ ﻓﻲ ﺍﻟﺩﻡ ﺇﻻ ﺃﻥ ﻨﺴﺒﺔ ﺍﻟﻜﻠﻭﺴﺘﺭﻭل ﻭﺍﻟﺩﻫﻭﻥ ﻜﺎﻨﺕ ﺃﻋﻠﻲ ﻋﻨﺩ 
  .ﺍﻹﻨﺎﺙ 
ﺒﻴﻨﺕ ﺍﻟﺩﺭﺍﺴﺔ ﻨﺴﺒﺔ ﺍﻹﺼﺎﺒﺔ ﺒﺎﻹﻋﺘﻼل ﺍﻟﻌﺼﺒﻲ ﻭﻜﺫﻟﻙ ﻨﺴﺏ ﺍﻟﻤﻀﺎﻋﻔﺎﺕ ﺍﻷﺨﺭﻯ ﻭﺩﺭﺠﺔ 
  .ﺍﻟﺨﻁﻭﺭﺓ ﻓﻲ ﻜل ﺤﺎﻟﺔ 
ﻡ ﺍﻟﻌﻭﺍﻤل ﺍﻟﻤﺅﺩﻴﺔ ﻟﺤﺩﻭﺙ ﺍﻹﻋﺘﻼل ﺍﻟﻌﺼﺒﻲ ﻫﻲ ﻤﺘﻭﺴﻁ ﺍﻟﻌﻤﺭ، ﺍﻟﺠﻨﺱ ﺒﻴﻨﺕ ﺍﻟﺩﺭﺍﺴﺔ ﻜﺫﻟﻙ ﺃﻥ ﺃﻫ
، ﻤﺩﺓ ﺍﻹﺼﺎﺒﺔ ﺒﺎﻟﺴﻜﺭﻱ ، ﻨﺴﺏ ﺍﻟﺴﻜﺭ ﻓﻲ ﺍﻟﺩﻡ ، ﻭﺠﻭﺩ ﺍﻟﻤﻀﺎﻋﻔﺎﺕ ﺍﻷﺨﺭﻱ ﻭﻨﺴﺒﺔ ﺍﻟﻜﻠﺴﺘﺭﻭل 
  .ﻭﺍﻟﺩﻫﻨﻴﺎﺕ ﻭﻤﻀﻎ ﺍﻟﻘﺎﺕ 
ﻴﻘﺘﺭﺡ ﺃﻥ ﺘﻤﺘﺩ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻟﺘﺸﻤل ﻓﺼﺎﺌل ﺃﺨﺭﻱ ﻤﻥ ﺍﻟﻤﺠﺘﻤﻊ ﺍﻟﻴﻤﻨﻲ ﻟﻜﻲ ﺘﺒﻨﻲ ﺠﻬﻭﺩ ﺍﻟﺤﺩ ﻤﻥ 
ﻭﺘﻭﺼﻲ ﺍﻟﺩﺭﺍﺴﺔ ﺒﻨﺸﺭ ﺍﻟﻭﻋﻲ ﺍﻟﺼﺤﻲ .  ﺍﻟﺴﻜﺭﻱ ﻭﻤﻀﺎﻋﻔﺎﺘﻪ ﻋﻠﻲ ﻗﻴﺎﺱ ﺍﻟﻘﺎﻋﺩﺓ ﺍﻟﺴﻜﺎﻨﻴﺔﺍﻨﺘﺸﺎﺭ
  .ﻟﺩﻱ ﺍﻟﻤﺭﻀﻲ ﻭﻀﺭﻭﺭﺓ ﺍﻻﻨﺘﻅﺎﻡ ﻓﻲ ﺍﻟﻌﻼﺝ ﻭﻨﻅﺎﻡ ﺍﻷﻜل ﻭﺍﻟﻔﺤﺹ ﺍﻟﺩﻭﺭﻱ 
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Introduction 
In 1864, Marchal de Calvi associated neuropathy with diabetes, and 
symptoms were clearly reported by Frederick Pavy in 1885 (1). The concept 
that improved glycaemic control could delay or prevent the appearance of 
diabetic micro vascular complications was strengthened by studies by Jean 
Pirart and others during the 1970s and 1980s, and was conclusively proven 
in both type 1 and type 2diabetes by the Diabetes Control and Complications 
Trial (DCCT) and the UK Prospective Diabetes Study, respectively, in 1993 
and 1998 (1, 2, 3). 
Diabetes mellitus is one of the major public health issues facing the 
world in the 21st century (4).  
Diabetes, although worldwide in distribution, used to be more seen 
commonly in the developed European countries and UAS. Recently, 
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however, most gulf countries have noticed increase prevalence, with the 
evolving trend particularly alarming in Jordan and Egypt. Saudi Arabia is by 
no way lagging behind (5) 
Diabetes mellitus is an incurable life-long disease characterized by 
persistent hyperglycemia. It is a multi-system disease with wide-ranging and 
devastating complications such as renal failure, blindness, neuropathy, 
peripheral vascular disease with gangrenous complications, coronary artery 
disease and cerebrovascular disease which end up in severe disability and 
death (6). 
Diabetes mellitus is a major impact on the lifestyle of the individual 
(whether insulin or non-insulin dependent) (7). 
The type 2 diabetes mellitus is one of the commonest chronic 
conditions in UK; and recently the King’s Fund stated that the financial, 
medical and personal impacts of the condition are greatly underestimated 
(8).  
Between two and three percent of the UK population has diabetes 
mellitus (9), and one per cent of hospital beds are occupied by diabetic 
patients with foot problems, and one third of below-knee amputations are 
carried out in diabetic patients (10). 
Diabetes is one of the diseases being brought to the forefront in 
developing countries, through the demographic and epidemiological 
transitions associated with the advent of urbanization, industrialization and 
mechanization. 
 Major difficulties facing diabetic people throughout the developing 
world range from the infective complications of diabetes (e.g. severe foot 
sepsis, tuberculosis and pneumonia) to inadequate and under-resourced 
health care systems in which delayed diagnosis and the lack of insulin and 
other drugs lead to high rate of diabetic comas. Indeed, many patients do not 
live long enough to fall victim to chronic diabetic complications. Overall, 
diabetes and its complications constitute a major health-care burden in most 
developing countries and even in regions awaiting economic development, 
where the disease is currently rare(11,12,13). 
There have been major developments both in understanding diabetes 
and its causes and in approaches to management since 1993 (14). Diabetic 
awareness and education will lead to better health for diabetics in any part of 
the world (15)  
Chronic diabetic complications are firmly entrenched in the 
consciousness of patients and their therapeutic teams. In past, diabetic 
neuropathy (DNP) was usually relegated to the role of a neglected stepsister. 
But this attitude in no way reflects its impacts on quality of life, problems of 
 21
diabetes managements, sequelae such as oligosymptomatic myocardial 
ischemia and foot syndrome, disease costs, or the prognosis for survival. 
One reason for the tendency to underestimate DNP may be that the 
functional disturbances of the nervous system can run a subclinical course 
for some time. The patient has no obvious distress, and the physician finds 
evidence of the neuropathy only by conducting specific tests. The 
physician’s efforts may lack focus due to the absence of a positive nosologic 
definition and generally accepted diagnostic criteria and standards, and 
because the clinical manifestations of DNP are so diverse. Finally, 
therapeutic options for DNP were, until recently, unsatisfactory (16).  
  For many years, then, DNP was not a matter of serious concern in 
any of the clinical or theoretical biomedical disciplines. This changed only 
during the last three decades. In 1978, the first international symposium was 
held dealing with autonomic DNP (23). A special expression of the growing 
interest in DNP was the foundation of NEURDIAB, the Diabetic 
Neuropathy Study Group of the European Association for the Study of 
Diabetes (EASD) in 1989. Since that time, this group has staged annual 
meetings at a high scientific level, attended by scientists from all over the 
world. This study group may well be the most effective channel for the 
rapid, critically attended exchange of information on advances in DNP 
research (16).   
 
 
Diabetes mellitus 
Definition of diabetes mellitus 
 Diabetes mellitus is defined by American Diabetes Associations 
(ADA) Expert Committee in their 1997 recommendations as a group of 
metabolic disorders characterized by hyperglycemia resulting from defects 
in insulin secretion, insulin action or both. The chronic hyperglycemia is 
associated with long-term damage, dysfunction and failure of various 
organs, especially the eyes, kidney, nerves, heart and blood vessels. Thus, 
diabetes covers a wide range of heterogeneous diseases (17, 18).    
                        
Diagnosis and Classification of DM 
A cardinal feature in preventing the complications of diabetes mellitus 
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is early diagnosis. This is particularly important in type 2 or late-onset 
autoimmune type 1 diabetes because this disorders start with a relatively 
asymptomatic period that lasts as long as 5-10 years. About 30% of all 
people with type 2 diabetes in United States are undiagnosed. Unfortunately, 
this relatively symptom-free undiagnosed period is not benign; ~50% of 
newly diagnosed patients with type 2 diabetes already have evidence of early 
chronic complications (19). 
 Type 1 diabetes is caused by absolute lack of insulin, and its 
treatment is based on insulin replacement. It is not the most frequent form of 
diabetes (20). Typically, type 1 DM is characterized by rapid onset of 
clinical symptoms requiring prompt insulin replacement (21).It is       
diagnosed by the sudden appearance of weight loss, 1 or 2 kg/week, 
accompanied by abundant urine, particularly during the night, and intense 
thirst in a young lean subject, typically 10-20 years of age (generally before 
the age of 25-30 years) (20).On the other hand, some degree of insulin 
secretion is preserved in type 2 diabetes although it is inappropriate for the 
prevailing glucose concentration, patients do not depend on exogenous 
insulin and are not prone to ketosis. These patients may require insulin to 
control hyperglycemia if this is not achieved by diet alone or with oral 
hypoglycemic agents (23, 22).    
 Most cases of type 2 DM present after 40 years of age 
and peak age are 60-70 years. Recent data from several 
countries show that type 2 diabetes is increasingly becoming a 
problem among adolescents and even children (24-28). The 
disease usually affects overweight or obese individuals (80% of 
cases in Europe) (29).  
The diagnosis of diabetes mellitus is based on clinical symptoms 
(weight loss, polyuria, thirst, muscular weakness and fatigue) and persistent 
hyperglycemia. The criteria for diagnosis of hyperglycemia and the 
classification of diabetes mellitus are not uniformly accepted. Some 
physicians use the criteria of the United States National Diabetes Data 
Group of 1979,which was endorsed by the World Health Organization Study 
Group on Diabetes Mellitus in 1985 (30),  or the final WHO report 1999 
(31), while others prefer the criteria of the Expert Committee on the 
Diagnosis and Classification of Diabetes Mellitus of the American Diabetes 
Association 1998 (32) Table1. 
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Table 1: Criteria for the diagnosis of diabetes according to the 
World Health Organization (31) and the American Diabetes 
Association (32) 
World Health Organization American Diabetes Association 
Clinical : 
Increased  thirst and urine volume, 
unexplained weight loss, established by 
casual blood glucose 
                      Or 
 Biochemical: 
The casual blood glucose, 5.5-
Clinical: 
1- Polyurea, polydepsia and unexplained 
weight loss plus casual plasma or capillary 
blood glucose ≥ 200 mg/dl (11.1 mmol/l)  
 Or 
Biochemical: 
2- Fasting plasma glucose ≥ 126 mg/dl 
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11.1mmol/l(100-200mg/dL);fasting 
glucose ≥7.0 mmol/L(126 mg/dL) and/or a 
2- h glucose ≥ 11.1 mmol/L (200 mg/dL) 
after glucose load. 
(7.0 mmol/l) or capillary blood glucose ≥ 
110 mg/dl. 
or  
3- 2 h plasma or capillary blood glucose ≥ 
200 mg/dl (11.1 mmol/l) during an oral 
glucose tolerance test 
 
• Casual is defined as any time of day without regard to time since last 
meal. 
• Fasting is defined as no caloric intake for at least 8h.  
• Criteria 2 and 3 should be confirmed by repeat testing on separate 
day.  
  The disease usually has a gradual and insidious onset. The diagnosis 
is made incidentally (during insurance screening or during hospital visits for 
other medical problems) in almost one-third of cases (33), and almost one-
half do not complain of obvious diabetic symptoms. Common presentations 
are with genital candidiasis (particularly in women), or urinary tract or skin 
infections (33). A significant number of type 2 diabetic patients already have 
one or more chronic complications at time of diagnosis, notably diabetic 
retinopathy and macro vascular disease (34, 35). It has been estimated , by 
back-extrapolating the progressive increase numbers of microaneurysms that 
appear after presentation, that type 2 diabetes generally start 4-7 years before 
the diagnosis is made (29). 
 The diagnostic criteria and classification serve two main purposes: 
firstly and primarily to identify and classify individuals who have diabetes 
and so provide appropriate treatment; and secondly to provide a tool for 
epidemiological study to determine the prevalence and incidence of diabetes 
and its risk factors, for public health planning and research into causations 
(24).  
Diabetes was subdivided on clinical grounds into diabete maigre (lean 
subjects) and diabete gras (obese) by Etienne Lancereaux in 1880, and 
during the 1930s by Wilhelm Falta and Harold Himsworth into insulin-
sensitive and insulin-insensitive types. These classifications were the 
forerunners of the etiological classification into type 1 (insulin-dependent) 
and type 2 (non-insulin-dependent) diabetes (1). 
The diagnostic criteria and the classification of diabetes were put on a 
formal basis firstly by the report of the (WHO) in 1965 (36), then by the 
National Diabetes Data Group (NDDG) in 1979(37), and this was followed 
by simplified recommendations by WHO in 1980(38). 
 25
In the classification by the National Diabetes Data Group (30) and 
WHO in 1980 (38), the terms type І and type П diabetes were also adapted 
as synonyms for IDDM and NIDDM respectively. However, in the 1985 
W.H.O classification, only the terms IDDM and NIDDM appear because the 
terms type І and type П diabetes were suggested to represent the pathogenic 
mechanism. Nevertheless, these terms are still being used synonymously 
(39).                    
 The current classification distinguishes type 1 (used to be called as 
insulin dependent diabetes mellitus, IDDM) and type 2 (non-insulin 
dependent diabetes mellitus, NIDDM).This classification is important 
because the two types are distinct both in causation and management and is 
thus of direct clinical relevance (18, 40). 
The latest recommendations have been published by the ADA in 1997 
and by the WHO in 1999, and in essence the two agree (10, 41). 
The new classification of patients with diabetes is based on etiology 
(Table 2). The new classification eliminates the terms insulin-dependent and 
non-insulin-dependent and replaces them with type 1 and type 2 diabetes 
Table 2: Classification of Diabetes Mellitus (42) 
 
  Epidemiological studies often use only the 2-h glucose, because it is 
difficult to be certain that the subjects are fasting (17). 
 
The Epidemiology of Type 2 Diabetes 
Diabetes mellitus is a major health problem in modern 
society not only because of its increasing prevalence, but, 
more important, because of its dramatic influence on the 
incidence of cardiovascular complications. Diabetes mellitus 
affects millions of individuals around the world and several 
Type 1 diabetes . Genetic defects in insulin action 
. immune-mediated . Diseases of endocrine pancreas 
. idiopathic . Endocrinopathies 
Type 2 diabetes . Drug- or chemical-induced 
. May range from predominantly insulin-
resistant to predominant insulin-deficit 
. Infections 
. Uncommon forms of immune-mediated 
diabetes 
Other specific types .Other genetic syndromes sometimes 
associated with diabetes 
. Genetic defects of β-cell function Gestational diabetes 
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hundred thousands die each year because of it. As the disease 
progresses, micro vascular and macro vascular complications 
develop, causing progressive disability and death in many 
cases (43).  
The epidemiology of diabetes mellitus shows considerable 
regional variation, so that when data from different regions are 
compared, the ethnicity, gender, and age structure of the 
groups that have been studied need to be considered-but 
frequently these have not been stressed. 
 These problems are more relevant to studies on type 2 than 
type 1 (44). 
 Type 2 diabetes is a global health problem of enormous 
magnitude that is calculated to affect 5-7% of the world’s 
population (45, 46-48).This prevalence may be an 
underestimate, because many cases-perhaps 50% in some 
populations-remain undiagnosed. 
 Type 2 DM is more common with increasing age, obesity, 
and in certain ethnic groups, affecting one in three Asians over 
65 years of age, compared with one in 10 Caucasians. In Asian 
and Africo-Carbibeans, it presents, on average, 10 years earlier 
than in Caucasians (49). 
Type 2 diabetes is by far the commonest form of the disease globally, 
accounting for about 85% of cases in predominantly Caucasian populations 
and for at least 95% in other ethnic groups.  
Type 2diabetes has now reached epidemic proportions in most parts of 
the world; rapidly developing countries are the forefront of this epidemic, 
nearly all cases fall into this category (22, 50) but few societies or ethnic 
groups are spared. 
 Current estimates-almost certainly conservative-are that at least 150 
million people worldwide have diabetes, of whom two-thirds live in 
developing countries (50). The total number of people with diabetes is 
predicted to rise to about 300 million by 2025, with one third of affected 
individuals living in India and China alone (47). 
 The prevalence of type 2 diabetes is rising steadily in many regions, 
the main causes being diabetogenic lifestyle factors (physical inactivity and 
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high fat and energy intakes) that lead to obesity. Increasing life expectancy 
also contributes in many populations, as the incidence of type 2 diabetes 
increases with age (51). 
The reported prevalence of type 2 diabetes varies from zero in Togo 
(Africa) (52), 9% in Egypt (53) to 50% in Pima Indians (UAS) (54) and 40% 
of the Nauru an Islanders (Micronesia) (55). Particular ethnic groups (e.g.  
South Asian, Native American and Mexican-Americans) are highly 
susceptible to type 2diabetes, and this may be revealed when such groups 
migrate into relatively affluent settings. Regional and ethnic differences in 
the prevalence of type 2diabetes probably related to both the extent of 
lifestyle change and underlying genetic susceptibility (51). 
Prevalence rates are relatively high (3-8%) in Sudan and Tunisia as 
well as Egypt (53). 
Recently, however, most gulf countries have noticed an increase in the 
disease prevalence, with the evolving trend particularly alarming in Jordan 
and Egypt (53, 5). 
In the Kingdom of Saudi Arabia, the prevalence of  4.95% and 4.30% 
was reported in urban and rural populations during 1985-87 (56). 
In Yemen, the crude prevalence of known diabetes was 6.57% (57). In 
another study done in Yemen, showed that the relative frequencies of 
clinical classes of diabetes seen were: 10.5% for IDDM, 58.6% for non-
obese NIDDM, 26.2% for obese NIDDM, and 4.7% for IGT (58). 
In many regions, type 2 diabetes remains commoner in urban than in 
rural populations. Social deprivation, unemployment and poverty in city-
dwellers are associated, possibly through their co segregation with 
diabetogenic lifestyle factors (51). The study which was done in Yemen 
showed that most of the patients came from urban settings (58). 
Type 2 diabetes mellitus is the most common form of diabetes among 
children and young adults in developed countries, and it is rare in developing 
populations (22).                                                                                                                        
Type 2diabetes now present in young people, including children and 
adolescents. In developing countries, the peak age at diagnosis is now 40-45 
years compared with >60 years in developed countries. 
Children with type 2 diabetes, which develops on a background of 
severe obesity and a positive family history, are mainly seen in highly 
susceptible groups (e.g. Native Americans) but increasingly in the general 
population; type 2 diabetes accounts for 39% of new diabetes in adolescents 
in parts of the USA, and for 80% of childhood and adolescent cases in Japan 
(59, 60, 61). 
The epidemiology of diabetes in elderly individuals (over 65 years 
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old) is related to two phenomena; the population is ageing due to progress 
made in medicine and in lifestyle (in many developed countries, 20% of the 
population is over 65 years of age) (62, 63) and the prevalence of diabetes 
greatly increases with age (64). Elderly diabetic patients represent half of 
diabetic patients. Half of these patients are thought not to be diagnosed (65). 
 
 
 
 
Causes and Risk Factors in  Type 2 DM 
Type 2 diabetes is a heterogeneous disorder due to a combination of 
genetic and environmental factors that adversely affects β-cell function and 
tissue insulin sensitivity (66, 67). 
Risk factors for type 2 diabetes (68) 
Major risk factors 
Demographic factors 
• Race and ethnic background (e.g. Africa-American, Hispanic-
American, Asian-American and Native American; Australian 
aborigines, Polynesian islanders). 
• Age ≥ 45% years 
• Family history: first-degree relatives with type 2 diabetes 
• Obesity: BMI ≥ 27 kg/m2, with central fat distribution 
• History of impaired fasting glucose or impaired glucose tolerance 
• History of gestational diabetes or delivery of a baby weighting > 4 kg 
• Hypertension (blood pressure ≥ 140/90 mmHg) 
• HDL cholesterol level ≤ 0.90mmol/L and/or a triglyceride level ≥ 2.8 
mmol/L 
Other risk factors  
- Malnutrition in the first year of life, and particularly in utero 
- Lifestyle factors 
• Physical inactivity 
• High-fat, low-carbohydrate diet 
• Alcohol (heavy consumption) 
• Smoking 
 BMI, body-mass index; HDL, high-density lipoprotein      
Nutritional and lifestyle factors have long been recognized as 
important in the pathogenesis of type 2 diabetes. There are powerful 
epidemiological associations between type 2 diabetes and obesity; together, 
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overweight and obesity account for about two-thirds of cases of type 2 
diabetes (69).The risk of diabetes begins to rise once the body-mass index 
(BMI) is greater than 23 kg/m2, and the relative risk is 40-90-fold higher in 
subjects with a BMI > 40 kg/m2. Weight gain in adult life is also a 
significant risk factor (70). A truncal distribution of body fat due to visceral 
fat accumulation confers the greatest risk of developing the disease (71, 72). 
Over all, obesity is a major risk factor for the development of type 2 
diabetes, but it is neither necessary nor sufficient to cause the disease (69). 
 Recent evidence suggests that accumulation of triglyceride at sites 
other than in adipose tissue depots-notably skeletal muscle, liver and the 
pancreatic β cells–is also associated with the development of diabetes (73, 
74, 75, and76). 
Weight loss has been shown in several studies to decrease the risk of 
progressing from impaired glucose tolerance to diabetes; this is particularly 
the case if combined with increased physical activity. Weight loss is also an 
effective component of treatment of patients with type 2 diabetes. Prevention 
of weight gain in childhood and adult life through dietary restraint and 
increased physical activity are likely to protect against the development of 
type 2 diabetes (77, 78). 
Diabetes affects 10-25% of elderly people (>65years) worldwide, with 
particularly high rates in populations such as Pima Indians, Mexican-
Americans and South Asians. Type 2 diabetes account for > 90% in most, 
and almost 100% of cases in some populations. Late onset autoimmune 
diabetes of adults (LADA) is relatively common in northen Europe. Glucose 
tolerance worsens with age, the main factor being impairment of insulin-
stimulated glucose uptake and glycogen synthesis in skeletal muscle (79). 
Pathophysiology of DM 
Type 1diabetes is an immune-mediated disorder that leads to 
destruction of the Islets of Langerhans causing profound insulin deficiency 
(80-82). Absolute insulin deficiency is accompanied by abnormal 
concentrations of counter-regulatory hormones (glucagons, growth hormone, 
catecholamine) which lead to multiple metabolic abnormalities. Most of 
these abnormalities may be corrected by physiological insulin replacement. 
 The pathogenesis of type 2 diabetes mellitus is complex and 
incompletely understood. It appears to be caused by an interaction of genetic 
and environmental factors that lead to defects in insulin secretion, insulin 
action and glucose effectiveness. People with type 2 diabetes mellitus 
exhibit fasting and postprandial hyperglycemia. Insulin secretion in response 
to meal ingestion is decreased and delayed. Glucagons concentrations are 
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inappropriately elevated and glucose effectiveness and insulin action are 
impaired. Together, these abnormalities cause fasting and postprandial 
hyperglycemia in people with type 2 diabetes mellitus (23).       
The precise molecular mechanisms leading to chronic hyperglycemia 
are largely unknown (83).   
Several pathogenic processes are involved in the development of 
diabetes. These range from autoimmune destruction of the beta-cells of the 
pancreas with consequent insulin deficiency to abnormalities that result in 
resistance to insulin action. The basis of the abnormalities in carbohydrate, 
fat, and protein metabolism in diabetes is deficient action of insulin on target 
tissues. Deficient insulin action results from inadequate insulin secretion 
and/or diminished tissues responses to insulin at one or more points in the 
complex pathways of hormone action (23) 
There are currently four major hypotheses about how hyperglycemia 
causes diabetic complications, namely (84):  
• Increased flux of glucose and other sugars through the polyol pathway. 
• Increased intracellular formation of advanced glycation end-products 
(AGEs). 
• Activation of protein kinase C (PKC) isoforms. 
• Overactivity of the hexosamine pathway.  
Diabetes particularly affects tissues in which glucose uptake increases 
during hyperglycemia, leading to raised intracellular glucose concentrations. 
High glucose levels may cause cumulative and progressive tissue damage 
through irreversible alterations of structural proteins and other long-lived 
molecules, or (e.g. in the retina) through the summation of micro vascular 
occlusions (85). 
The targeting of specific tissues by hyperglycemia can largely be 
attributed to the failure  of those cells to down-regulate their uptake of 
glucose when extra cellular glucose concentrations are elevated (86). 
Much of the impact of chronic diabetes falls on the microcirculation. 
With long-standing disease, there is progressive narrowing and eventual 
occlusion of lumina, resulting in impaired perfusion, ischemia and 
dysfunction of the affected tissues (87, 88) 
 Diabetic retinopathy, nephropathy, and neuropathy occur in all 
clinical forms of diabetes mellitus regardless of the cause of the disease (89). 
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Complications of  DM 
The chronic complications of diabetes are straining health-care 
systems throughout the world (90), and pose particular problems in the 
developing world (91). 
 In diabetes, it is difficult to separate the effects of hyperglycemia 
from the associated metabolic and hormonal disturbances typical of the 
disease. Hence, the physiological basis underpinning the theory of, high 
blood glucose leading to diabetic complications is still relatively weak; 
chronic blood glucose elevation cannot persist without several other major 
systems also being chronically disturbed (92).  
Recently, the understanding of the relationship between glycemic 
control and the chronic complications of diabetes has been greatly enhanced 
by the results of several recent seminal intervention studies. Those studies 
demonstrated that microvascular complications are highly correlated with 
mean glycemic control, as measured by by glycated hemoglobin (A1C), and 
that improvement in glycemic control results in reduction in all 
microvascular complications. In contrast, they failed to show a significant 
reduction in macrovascular complications with improved glycemic 
control,suggestingthat macrovascular complications are the result of 
multiple metabolic abnormalities (93). 
Subjects with type 2 diabetes have increased rate of micro vascular 
complications (retinopathy, renal disease, and neuropathy) and macro 
vascular disease (coronary heart disease (CHD), cerebrovascular disease, 
and peripheral vascular diseases). However, macro vascular disease 
(especially CHD) is by far the leading cause of morbidity and mortality in 
subjects with type 2 diabetes. Type 2 diabetes is associated with a 2-to 4-
fold increased risk of CHD (94). 
Previous study done in Yemen by Gunaid et al.1997, showed that of 
the complications of DM 24.2% were hypertensive, 28% were with large 
vessel disease, 45% were with small vessel disease, and 40.7% were with 
peripheral neuropathy. Epidemiologic data suggest a similar course and 
prevalence of diabetic microvascular complications in persons with either 
IDDM or NIDDM and a strong relation to glycemic control (95).  
   Epidemiological data shows that the natural history of retinopathy is 
similar in both types of diabetes (96, 97-100); however, the prevalence is 
higher and the severity is greater in persons with IDDM than in those with 
NIDDM (97, 98).  
Maculopathy is an especially common form of retinopathy in type 2 
diabetes and may threaten vision. By contrast, proliferative retinopathy-the 
 32
commonest cause of blindness in type 1 diabetes-is less frequent (101). 
pathological changes characterizing diabetic nephropathy–glomerular 
basement membrane thickening and expansion of the glomerular 
mesangium–are similar in IDDM  and NIDDM (102).The risks for 
developing nephropathy and especially end-stage renal disease are lower in 
type  2 than in type 1 diabetes, mainly because most type 2 diabetic patients 
(being older) have a short exposure to hyperglycemia  (101).   
  Less is known about the epidemiology of diabetic neuropathy in 
persons with IDDM and NIDDM. Data from one study, suggest similar 
prevalence of symptomatic polyneuropathies in both types of diabetic 
persons, although those with IDDM had higher frequency of a more severe 
stage of polyneuropathy than those with NIDDM (103). However, a cross-
sectional multicenter study of English diabetic patients showed that the 
prevalence of neuropathy in persons with NIDDM was higher (32%) than in 
those with IDDM (23%) (104).  
 Intensive glycemic control can delay the onset and progression of the 
early stages of diabetic retinopathy, nephropathy, and neuropathy in type 2 
patients, just like it does in type 1 patients (105). 
Recently, the United Kingdom Prospective Diabetes Survey (UKPDS) 
addressing whether good glycaemic control will influence the outcome in 
Type 2 diabetes published important new results (3). Its results clearly 
demonstrated the harmful effects of both high blood pressure and high blood 
glucose in Type 2 diabetes (3, 106). 
   The risks of both macrovascular and microvascular damage 
increased substantially for every 10mmHg increase of systolic blood 
pressure, and every one per cent increase of HbA1c. The considerable 
benefits of tight control of both glycaemia (fasting glucose <6mml/l) and 
blood pressure (<150/85) in Type 2 diabetes are at last clear cut (106).    
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Diabetic   Polyneuropathy 
Derangement of the CNS and peripheral nervous system is common in 
diabetes. Involvement of the CNS may be transient; coma, convulsions or 
even focal neurological signs may occur during a hypoglycemic attack and 
focal epilepsy during hyperglycemic hyperosmolar coma. More permanent 
CNS effects may result from cerebrovascular accidents, which have an 
increased incidence in diabetic patients (107). 
 The neurological complications in both types of diabetes are similar; 
the presence of neurological disease is roughly correlated with the duration 
and severity of the disease and is commonly associated with other tissue 
complications of diabetes, such as retinopathy and nephropathy (108). 
A wide variety of disturbances affecting the central and peripheral 
nervous systems, either directly or indirectly, may be encountered in patients 
with diabetes mellitus (40).  
 Diabetic neuropathy is a heterogeneous condition that encompasses a 
wide range of dysfunction and, whose development might be attributed to 
diabetes per se or to factors associated with the disease (109).  
Individuals may not be diagnosed or treated for diabetes mellitus until 
complications such as neuropathy arise (110).  
The neurological complications of diabetes were first recognized in 
1798, and until 1864, diabetes was considered an effect of neuropathy (111).  
Neuropathic symptoms in diabetic patients had been mentioned by 
Rollo at the end of the 18th century, and Marchal de Calvi concluded in 
1864 that nerve damage was a specific complication of diabetes. In 1885, the 
Guy’s Hospital physician, Fredrick Pavy (1829-1911), gave a description of 
neuropathic symptoms which would grace any modern textbook (1).  
Various different neuropathy syndromes may be encountered in 
patients with diabetes, this probably reflecting a range of underlying disease 
mechanism. These syndromes can occur in isolation or in combination. 
Distal predominant sensory polyneuropathy is frequent (40). 
Generally, the intensity and extent of neuropathy parallel the degree 
and duration of hyperglycemia (112). Since nerves are freely permeable to 
glucose; they are susceptible to glucose toxicity. Indeed, acute 
hyperglycemia decreases nerve function and chronic hyperglycemia is 
associated with the loss of myelinated and unmyelinated fibers, Wallerian 
degeneration, and blunted nerve-fiber reproduction (112). Altogether, 
several observations suggest that high glucose levels give rise to neuropathy 
(113). 
Diabetes mellitus is the most frequent cause of neuropathy in the 
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United State and western world (114).  
Two types of polyneuropathy are recognized and may coexist: 
symmetrical sensorimotor and autonomic. Various focal neuropathies occur, 
including diabetic proximal neuropathy, mononeuropathies of cranial and 
peripheral nerves, and truncal neuropathies (133,134).Two or more of these 
neuropathies commonly coexist within the same patient (115). 
 
 
 
 
Definition 
Diabetes peripheral neuropathy: the presence of symptoms and/or 
signs of peripheral nerve dysfunction in people with diabetes, after exclusion 
of other causes (116). 
Diabetic symmetrical distal polyneuropathy (DSDP) is characterized 
by length-related, distally pronounced distribution of sensory and motor 
symptoms and signs in patients with manifest diabetes mellitus (116-118) 
Anatomy and Physiology of Peripheral Nerves 
It is important to have a clear concept of the extent of the peripheral 
nervous system (PNS) and the possible mechanisms whereby it can be 
affected by disease. The PNS includes all neural structures lying outside the 
pial membranes of the spinal cord and brain stem (119). 
Motor nerve fibers originate from the anterior horn cells of the spinal 
cord through the anterior nerve root. The sensory fibers originate from 
neurons in the posterior root ganglia and enter the spinal cord through the 
posterior nerve root. The anterior and posterior nerve roots unite distal to the 
cord to form a mixed spinal nerve. Both anterior and posterior nerve roots 
are covered by dura as they leave the spinal cord up to the point of exit from 
the spinal canal where the dura becomes continuous with the epineurium 
covering the mixed spinal nerve. The mixed spinal nerves unite in the 
cervical and lumbar area to form the cervical, brachial, and lumbosacral 
plexuses. Each plexus gives rise to a number of individual mixed nerves, 
which are distributed to the periphery to supply muscle, skin, and blood 
vessels (120). 
Peripheral nerves are composed of many axons bound together by 
connective tissue. A mixed nerve contains, motor, sensory, and autonomic 
axon. The blood supply to these bundles is by means of small nutrient 
vessels within the epineurium-the vasa nervorum (121). 
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 The somatic nervous system is subdivided into motor and sensory 
components. The motor division is concerned with control of skeletal muscle 
contraction, and hence of voluntary movement and of posture and reflexes. 
The somatosensory division is a collection of receptors, tracts, and nuclei 
that convey the sensations of light touch, vibration, temperature, and pain 
(nociception) to the consciousness. It also conveys information about 
movements and position of the body (proprioception and kinesthesia). 
Somatosensory receptors are found in the skin, muscles, joints, and viscera. 
In addition to providing sensation, the somatosensory division has a critical 
role in motor control, through feedback about muscle length and tension, 
joint position, velocity of muscle and limb movement, and contact with 
external surfaces (122,123). 
The vasculature of peripheral nerve is relatively unique. Peripheral 
nerve and its spinal dorsal and ventral roots have a good vascular supply 
composed of two integrated but independent systems, termed extrinsic and 
intrinsic circulations (124,125,126).  
Epidemiology of Diabetic Neuropathy 
Neuropathies are common in both type 1 and type 2 diabetes and there 
are no major structural differences in the pathology of the nerves in the two 
diabetes types (95). But there are some important clinical distinctions. Thus 
symptomatic autonomic neuropathic syndromes almost invariably occur in 
established long duration type 1 diabetic patients in middle age. By contrast 
the reversible mononeuropathies occur much more often in older men with 
type 2 diabetes. There are no known reasons for these clinical differences 
(40) 
Epidemiology has an important role in elucidating patterns in the 
occurrence of diseases and determining risk factors and etiology (127) 
Diabetic neuropathies undoubtedly represent major health problems 
for which improved prevention and treatment are needed. However, despite 
many scientific reports on diabetic neuropathies, much uncertainly, and even 
misinformation, exists about their frequency, classification, natural history, 
morbidity, mortality, and health and work outcomes, as well as the 
underlying mechanism, risk factors, and optimal measures for prevention or 
treatment (128). 
The lack of epidemiologic data as of mid-1980 has been reviewed. 
Most information available at the time was from clinic-and hospital-based 
studies, with prevalence of neuropathy range from 5%-80%. Fortunately, 
this situation has improved and population-based studies are now available 
(118,129). 
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Estimates of the prevalence of diabetic polyneuropathy vary widely in 
different studies (130-132).This may be related to factors including the small 
sample size in most series, the use of different diagnostic criteria, the 
differing populations at risk, and the different methods of patient selection 
(133). 
There is some information on the frequency and risk factors for 
diabetic neuropathies (103,134 -141), but there is little longitudinal data on 
change in severity of diabetic polyneuropathy (DP) over time, especially 
from population-based diabetic cohorts. This lack exists because 
investigations did not measure quantitative symptoms, neurological deficit, 
tests of nerve dysfunction, and health and work outcomes longitudinally in 
population-based cohorts of diabetic patients and control subjects. In 
addition, they did not use composite measures of severity of DP, using 
reference value from large nondiabetic populations (142). 
Improved methods to determine the incidence, prevalence, and course 
of diabetic peripheral neuropathy have been precisely described and applied 
in large longitudinal studies (2, 143-149). 
In a cohort of 4400 patients with diabetes studied for 20 to 25 years, 
45% developed neuropathy during the course of their disease (150). 
 In another study the prevalence of neuropathy is 20-50% in various 
studies, and sequelae such as foot ulceration and amputation are responsible 
for much morbidity and mortality (151,152). 
In a study of nearly 6500 diabetic patients in hospital clinics 
throughout the UK, 28% had clinical evidence of neuropathy. Prevalence 
increases with the duration of diabetes, and poor glycaemic control. Another 
large study using clinical criteria found a prevalence of 7.5% on discovery of 
diabetes, increasing to about 50% after 25 years (107). 
The previous study which was done in Yemen (Gunaid et al. 1997) 
showed the presence of peripheral neuropathy in 40.7% of the diabetic 
population investigated, mostly among non-obese NIDDM patients (58). 
Several large studies have examined the prevalence in hospital-based 
populations. A number of these are in fairly close agreement, and reveal 
prevalence of DSP at approximately 30%, amongst both European and 
African populations (153,154-156). However, other hospital based studies 
have produced figures closer to 20% (157). And a prevalence of 50% was 
reported from a US veterans population (158). The higher figure in this 
study may relate to the age of the participants, and to the fact that they were 
almost all males.  
The most comprehensive population based investigation so far 
reported was undertaken by Dyck et al. on residents of Rochester, MN, 
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USA, with diabetes, of whom 26.8 % were type 1 and 73.2 % type 2. 
Neuropathy was assessed by a combination of clinical and 
electrophysiological criteria. Of patients with type 1diabetes, 66 % had some 
form of neuropathy, in 54 % of whom it was diabetic polyneuropathy. In 
type 2 patients, 59 % had various neuropathies, of which polyneuropathy 
was in 45 %. (40,103).   
In the Rochester Diabetic Neuropathy Study the prevalence of 
neuropathies other than DSP was low: symptomatic carpal tunnel syndrome 
in 9% of type 1 and 4% of type 2 patients, proximal asymmetric neuropathy 
in 1% each of type 1 and type 2 patients, ulnar neuropathy in 2% each of 
type 1 and type 2 patients, peroneal neuropathy in one type 2 patient, lateral 
femoral cutaneous neuropathy of thigh (meralgia paresthetica) in 1% each of 
type 1 and type 2 patients. Cranial neuropathy or truncal neuropathy was not 
present in any of the patients at the time of examination. Approximately 
10% of diabetic patients had neurological deficits attributed to nondiabetic 
causes (103). 
Table 3: Risk Factors for Diabetic Neuropathy (159) 
• Age 
• Duration of diabetes 
• Glycemic control 
• Cholesterol/triglyceride level 
• Hypertension 
• Other micro vascular complications 
• Smoking 
Diabetic polyneuropathy is one of the commonest long-term 
complications of diabetes mellitus and the most common cause of 
neuropathy in industrialized nations (160,161,162). The exact cause of the 
polyneuropathy is not clear despite considerable knowledge of chemical, 
physiological and histological alterations in diabetic nerves (163). 
The elderly are at greater risk of polyneuropathy because many 
neurological abnormalities, including signs of peripheral nerve involvement, 
are increasingly common with advancing age (159,164) and many clinical 
conditions known to be associated with peripheral neuropathy tend to be 
more prevalent in the aged (165). 
The central role of hyperglycemia has been demonstrated in a range of 
studies. Mean HbA1c was approximately 1% higher in men with newly 
diagnosed type 2 diabetes who went on to develop DSP 10 years later, than 
in those who did not(166). The risk of developing DSP has been calculated 
to rise by approximately 10-15% for every 1 mmol/l rise in fasting plasma 
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glucose or every 1% rise in HbA1c (158,167). 
The association between disease duration and the risk of diabetes is 
strong, and has been  confirmed in a variety of studies in type 1 and type 2 
diabetes, and remains after adjustment for age (168,154, 169). In a UK 
study, the prevalence of DSP rose from 21% in those with a diabetes 
duration of less than five years to 37% in people with a duration of over 10 
years (153). 
Hypertension has been associated with distal symmetrical 
polyneuropathy in several studies, most notably in the data from the 
Pittsburgh cohort of type 1 diabetes (169). In the EURODIAB Prospective 
Complications Study, systolic blood pressure was shown to be one of the 
predictors of the development of DSP after adjustment for age, duration of 
diabetes, and HbA1c(170). 
Studies in type 2diabetes, however, do not provide such compelling 
support, and have conflicting data, although the observation that treatment 
with angiotensin-converting enzyme (ACE) inhibitors improved nerve 
function in patients with type 1 and type 2 diabetes might be seen as further 
support for the association (171). 
Partanet et al. have suggested a link between hypoinsolinemia and 
DSP, which they believed resulted from the possible beneficial effects of 
insulin and c-peptide on neuronal metabolism and function. They found that 
baseline fasting and 2-hour insulin levels were lower in newly diagnosed 
Finnish male subjects with type 2 diabetes who developed DSP 10 years 
later than in those remained free of DSP (166,172).  
Several population-based studies suggest that high insulin levels are 
associated with disturbed autonomic nervous system activity (173). 
Smoking was also found to carry an independent risk in the San Luise 
Valley study of type 2 diabetes (174), but was actually associated with a 
protective effect in US veterans (158), and had only a weak (and not 
independent) association in the study from Mauritius (168). 
Alcohol consumption has been associated with DSP on a number of 
occasions (158), but it may be difficult, at least in epidemiological study, to 
differentiate between diabetic neuropathy in which alcohol is a risk factor, 
and alcohol neuropathy in a person with diabetes (175).  
High total cholesterol (167) and elevated triglycerides (154) have 
been reported as independent risk factors for DSP. In type 2 diabetic patients 
the link between DSP and dyslipidemia must, however, remain tentative at 
this stage, as several studies have failed to observe such a relationship 
(168,166).        
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Pathogenesis and Pathology of Diabetic Neuropathy 
The neuropathies associated with diabetes are heterogeneous (176). 
Perhaps the most common variety is diabetic sensorimotor polyneuropathy 
(DSPN). This variety appears to be caused by chronic hyperglycemia and 
associated metabolic derangements, damaging neurons (axons) or Schwann 
cells (or myelin) directly or indirectly by functional and structural alterations 
of microvessels or the blood nerve barrier. Inflammation, perhaps from 
immune mechanisms, may also be implicated in some cases (176, 177).  
 Peripheral neuropathy, the most common complication of diabetes, 
has been linked to hyperglycemia-induced oxidative stress. Complete 
characterization of the development of oxidative stress and the neuronal 
innate defense systems will allow better understanding of the disease 
pathogenesis (178). 
Diabetic polyneuropathy sometimes involves only large or small 
nerve fibers selectively, but in the majority of patients, disturbances in 
function and morphology of fibers of all diameters are present (179,1 80). 
There are essentially only three pathologic processes by which nerves 
react to disease. Theses processes are not disease specific and may be 
present in different combinations in any given patient; 
In wallerian degeneration (degeneration follows transection of an 
axon by crushing or injury), there is degeneration of both the axis cylinder 
and the myelin sheath, distal to the site of axonal interruption. The cell body 
becomes rounded and its chromatin disperses (chromatolysis). 
In segmental degeneration, axons are preserved so that there is no 
valerian degeneration and no chromatolysis in nerve cell bodies. 
Remyelination restores function. This process is most prominent in 
diphtheritic and Guillian-Barre polyneuropathies. 
Axonal degeneration is characteristic of metabolically determined 
polyneuropathies, which are the common pathological changes in peripheral 
neuropathy. There is degeneration of myelin as well as axis cylinders, 
progressing from distal to proximal segments ‘’dying back’’ neuropathy 
(181). 
The importance of micro vascular factors in the development of 
diabetic nerve damage particularly polyneuropathy has become apparent in 
recent years (182,183). 
Several investigators have described the following changes: closed 
capillaries, microvascular thrombosis, basement membrane thickening, 
endothelial cell reduplication, and multifocal loss of myelinated fibers. 
Despite this evidence, it is controversial whether microangiopathy is the 
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cause of early human diabetic polyneuropathy because these changes occur 
in already established neuropathy (184-191).  
Using in vivo techniques of sural nerve photography and fluorescein 
angiography, investigators have recently demonstrated the presence of 
severe epineurial nutrient vessel disease including arteriovenous shunting 
and abnormal nerve fluorescein angiography suggesting impaired nerve 
blood flow in subjects with chronic diabetic neuropathy (192). These 
observations are supported by the demonstration of reduced nerve oxygen 
tension (193), considerable histological evidence from human nerve 
pathology (194-196) and studies in animal models (197, 198). 
The true cause of diabetic neuropathy remains enigmatic. However, 
evidences from large trials such as the Diabetes Control and Complications 
Trials and the United Kingdom Prospective Diabetes Study clearly implicate 
chronic hyperglycemia as the prime abnormality that results in many of the 
mechanism summarized in Table 4 (159). 
Table 4 :Proposed Pathogenetic Mechanisms forNeuropathy 
• Hyperglycemia 
• Nonenzymatic glycation 
• Oxidative stress 
• Ischemic/hypoxic factors 
• Nerve Growth Factors (NGF) abnormalities 
• Polyol pathway activation 
• Immunological abnormalities 
Although each of these mechanisms could be pathogenetically 
important, they all contribute to oxidant stress, which could comprise the 
final common pathogenetic efferent pathway (199).  
Pathological features of diabetic nerve damage include distal fiber 
loss and demyelination, with slowing of the conduction velocity, which is 
initially reversible with correction of hyperglycemia (200, 201, and 202). 
Myelinated fibers may be relatively protected by the high density of ion 
channels at the nodes of Ranvier and/or closer proximity to Schwann cells 
(203). Longest axons may be most affected, because of cumulative 
biochemical and/or ischemic damage that interfere with transport from the 
neural cell body (204,205). 
The development and progression of diabetic peripheral neuropathy 
are related to the duration and severity of hyperglycemia (3). Glucose could 
damage nerve cells via increased glucose flux through the polyol pathway, 
non-enzymatic glycation of proteins and other long-lived macromolecules, 
and oxidative stress (206). 
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 The polyol pathway, governed by the rate-limiting enzyme aldose 
reductase, becomes overactive under hyperglycaemic conditions and 
converts glucose to sorbitol which remains trapped intracellularly. Sorbitol 
accumulation may cause osmotic damage (offset by decreased myoinositol 
uptake), and polyol pathway over activity consumes reduced glutathione, 
causing oxygen free radicals to build up (207). 
Non-enzymatic glycation of neuronal proteins, leading to irreversible 
formation of advanced glycation end-products (AGEs), may damage the 
axonal cytoskeleton (208,209). Moreover, interaction of circulating AGEs 
with specific receptors for advanced glycosylation end-products (RAGEs) 
may exacerbate oxidative stress and microvascular damage (210,211).  
Nerve blood flow is reduced in human diabetic neuropathy, but 
endoneurial hypoxia is not closely related to either the severity or 
progression of nerve dysfunction. Nerve ischemia probably accelerates 
neuropathic damage, but is unlikely to be its primary cause (212,213).  
In summary, evidence exists for metabolic and vascular causes of 
neuropathy. It now seems probable that pathogenesis is multifactorial, with 
complex interplay and interactions between the proposed metabolic and 
vascular factors (171). 
 Diagnosis and Classification of Diabetic Neuropathy 
The peripheral nervous system is composed of multiple cell types and 
elements that subserve diverse motor, sensory, and autonomic functions. The 
clinical manifestations of neuropathies depend on the severity, distribution, 
and functions affected. Peripheral neuropathy and polyneuropathy are terms 
that describe syndromes resulting from diffuse lesions of peripheral nerves, 
usually manifested by weakness, sensory loss, and autonomic dysfunction 
(214,215).  
It must be assumed in type 1 and type 2 diabetic patients with DSDP 
that there has already been a disorder of glucose metabolism over a long 
period, mostly over several years before manifestation of neuropathic 
symptoms and/or deficits (117). The time of onset of the disease is usually 
well defined in type 1 diabetes, so that the interval between the beginning of 
the disease and the first signs of DSDP can be determined relatively 
precisely. However, this is difficult in type 2 patients, since the diabetes may 
have present for many years before diagnosis. In particular, Dyck working 
group has pointed out that DSDP should only be diagnosed when other 
diabetic complications such as diabetic retinopathy or nephropathy can also 
be demonstrated. For this purpose, the fundus of the eye should be 
investigated with dilated pupils, and the total protein in 24-hour urine should 
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be determined or microalbuminuria looked for (117,133).      
Impaired glucose tolerance is also associated with peripheral 
neuropathy. A 2-hour glucose tolerance test is the preferred method to 
screen for diabetes or impaired glucose tolerance in patients with 
neuropathy, being preferable to a fasting glucose or hemoglobin A1c (215) 
The diagnosis of DSDP is based on two elements: (1) on the 
subjective symptoms of the patients and on the signs found on clinical 
examination, and (2), on the detection of abnormalities in clinical 
neurophysiologic tests (quantitative sensory tests, electromyography and 
nerve conduction studies, and autonomic testing) (103,216).  
In 1988 a joint conference of the American Diabetes Association and 
the American Academy of Neurology adopted standardized nomenclature 
and criteria for diagnosis of neuropathy in diabetes. This classification 
recognized subclinical and clinical neuropathy. Subclinical neuropathy is 
defined by an abnormal electro diagnostic test, quantitative sensory 
threshold, or autonomic function test in the absence of clinical signs and 
symptoms. Clinical neuropathy is defined as symptoms and signs together, 
or as symptoms or signs alone plus abnormal test results (118,217). 
 A wide variety of syndromes affecting the peripheral nervous system 
may be encountered in patients with diabetes mellitus. This is probably a 
reflection of a range of underlying disease mechanism. These syndromes 
may develop in isolation or in combination (218). 
The broad diversity of neurological complications in patients with 
diabetes mellitus can be considered to consist of two distinct types. In one 
form, the symptoms and signs are transient; in the other, they progress 
steadily. The transient category includes acute painful neuropathies, 
mononeuropathies, and radiculopathies. The painful type starts abruptly with 
a disabling and continuous pain, often a burning sensation in a stocking 
distribution. The progressive type comprises sensory motor    
polyneuropathies with or without autonomic symptoms and signs (215).  
Distal symmetrical polyneuropathies affect both motor and sensory 
nerves, but sensory manifestations (often with autonomic dysfunction) 
usually predominate. Deficits begin distally in the feet and advance 
proximally (‘glove-and-stocking’ distribution), with loss of sensation 
mediated by both large and small fibers. Both right and left, upper and lower 
extremities involved. Neurogenic pain, paraesthesias and contact sensitivity 
(allodynia) may develop; all symptoms may vary considerably with time 
(219). The detailed neurophysiological studies show that they are often 
mixed sensorimotor neuropathies (220). 
These neuropathies generally have a progressive course with few (if 
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any) spontaneous remissions (221). The patient may experience symptoms 
ranging from mild paraesthesia to severe unrelenting pains (222). 
In DSDP, depression and loss of tendon reflexes, sensory loss, and 
disturbances of the autonomic nervous system are most prominent, but 
motor deficits may also be present (103,223, 224). 
It may be asymptomatic and discovered incidentally on 
examination or when patients present with a neuropathic 
complication. When symptomatic, it gives rise to sensory 
manifestations that are most evident distally in the lower limbs, 
consisting of numbness, tingling, and pain. It is often 
accompanied by autonomic neuropathy, which is usually mild 
in patient with type 2 diabetes (225).  
  The primary neurological complication of DM is peripheral 
neuropathy. This includes mononeuropathies (peripheral and cranial nerves), 
polyneuropathy, autonomic neuropathy, radiculopathies, and entrapment 
neuropathy (median, ulnar, and peroneal nerves).  
 Mononeuropathies are attributed to vascular lesions of peripheral 
nerves. Onset of symptoms is rapid, and pain is common in both 
mononeuropathies and radiculopathies caused by DM. Common cranial 
neuropathies involve the oculomotor and abducens nerves and are also a 
result of vascular lesions. The prognosis of recovery from mononeuropathy 
or radiculopathy is good. 
Diagnosis of diabetic polyneuropathy is aided by nerve conduction 
studies that show a mixed demyelinating and axonal neuropathy. CSF 
protein content is usually elevated but may be normal (226). 
Persistent or episodic pain may be present in these patients, 
predominantly in the feet. The pain is most often described by the patients as 
“burning/hot,” “electric,” “sharp,” “achy,” and “tingling,” and is worse at 
night time and when the patient is tired and stressed (227).                                                       
Sensory symptoms usually commence in the legs. The hands are also 
involved in more severe cases. In established cases vibration and joint-
position sensations are impaired at the toes. These patients may have sensory 
gait ataxia and positive Romberg’s signs. Involvement of autonomic fibers 
impairs sweating and prevents skin blood-flow regulation distally in the 
limbs, leading to a warm, dry foot with hard skin vulnerable to cracking. 
Neuropathic joints may develop. Motor loss is less common in diabetic 
polyneuropathy in comparison with the degree of sensory loss. Distal muscle 
weakness and wasting may be encountered in long-standing cases. However 
marked motor involvement should provoke consideration of other possible 
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contributing causes to the neuropathy apart from diabetes (115). 
The neuropathy develops slowly and is related to the duration of 
diabetes, but not all patients are so affected. Once present, it does not resolve 
or significantly recover. Intensive glucose control limited complications 
including peripheral neuropathy in the diabetes control and complication 
trial (DCCT) with significant differences in nerve conduction values 
between intensive and standard glucose control group (215).     
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Diabetic neuropathy is an umbrella term encompassing two distinct 
groups of disorders, focal and diffuse neuropathies, with different etiologies, 
progressions, and treatment (221). 
Numerous classifications of variety of syndromes affecting the 
peripheral nervous system in diabetes have been proposed in recent years. 
Some have been based on presumed etiology, topographical features, or 
pathological features. However, until we have a clear understanding of the 
etiopathogenesis of neuropathy, classifications based on the clinical 
manifestations are most commonly used (228-231).     
Table (5): Classification of the diabetic neuropathies (229,230) 
• Hyperglycemic neuropathy (reversible reduction in nerve 
conduction, transient sensory symptoms)  
• Generalized neuropathies 
              Sensorimotor polyneuropathy 
              Acute painful sensory neuropathy 
              Acute motor neuropathy 
              Autonomic neuropathy 
• Focal and multifocal neuropathies 
             Cranial neuropathies e.g. third nerve palsy 
             Thoracolumbar radiculopathy 
             Proximal motor diabetic neuropathy 
• Focal limb neuropathies (including entrapment and compression 
neuropathies e.g. carpal tunnel syndrome). 
• Superimposed chronic inflammatory demyelinating polyneuropathy 
• Hypoglycemic neuropathy  
 
Three slightly different clinical classifications are presumed in Table 
6. Table 6A describes a purely clinical classification (151, 228), whereas 
Table 6B based its classification on a mixture of clinical and anatomical 
findings (231). Table 6C is based on the premise that DN is not a unitary 
condition but it is the result of a number of disturbances in the peripheral 
nervous system as a consequence of hyperglycemia (229,230). 
Table 6: Three classification systems for DNs (diabetes 2005) 
A: Clinical Classification of DNs 
 Polyneuropathy                                              Mononeuropathy 
Sensory                                                            Isolated peripheral 
• Acute sensory 
• Chronic sensorimotor                                        Mononeuritis multiplex 
Autonomic 
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• Cardiovascular                                             Isolated peripheral 
• Gastrointestinal 
• Genitourinary                                               Truncal 
• Other 
Proximal motor (amyotrophy) 
Truncal 
Adapt from Boulton and Ward (228) and Boulton Malik (151) 
B: Patterns of Neuropathy in Diabetes 
Length-dependent diabetic polyneuropathy 
• Distal symmetrical sensory polyneuropathy 
• Large fiber neuropathy 
• Painful symmetrical polyneuropathy 
• Autonomic neuropathies 
Focal and multifocal neuropathies 
• Cranial neuropathies 
• Limb neuropathies 
• Proximal DN of the lower limbs 
• Truncal neuropathies 
Nondiabetic neuropathies more common in diabetes 
• Pressure palsies 
• Acquired inflammatory demyelinating polyneuropathy 
Adapt from Said (231). 
C: Classification of DN 
Rapid reversible 
• Hyperglycemic neuropathy 
     Generalized symmetrical polyneuropathies 
• Sensorimotor (chronic) 
• Acute sensory 
• Autonomic 
Focal and multifocal neuropathies 
• Cranial 
• Thoracolumbar radiculopathies 
• Focal limb 
• Proximal motor (amyotrophy) 
Superimposed chronic inflammatory demyelinating neuropathy 
Adapt from Thomas (229,230). 
Hyperglycemic Neuropathy 
The older literature (232) described the occurrence of uncomfortable 
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sensory symptoms experienced distally in the limbs in poorly controlled or 
newly diagnosed diabetics, or following an episode of diabetic ketosis. 
These consist of tingling paresthesias, pain, or hyperesthesia. They rapidly 
subside following establishment of euglycemia. More recently such 
symptoms have been referred to as hyperglycemic neuropathy (233). Their 
explanation has not been established. Diabetic nerve has been found to be 
hypoxic (234). 
It is also known that nerve conduction velocity is reduced in poorly 
controlled diabetic patients. This improves rapidly on correction of 
hyperglycemia (235, 236). 
 A further feature of hyperglycemic neuropathy is an abnormal 
resistance to ischemic conduction failure (237). This may be noticed by 
patients who find that they have a reduced tendency to develop ischemic 
paresthesia on nerve compression. This may be related to a switch by 
diabetic nerve to anaerobic glycolysis (238). 
Diabetic Distal Sensory or Sensorimotor Polyneuropathy    
This is the most frequent form of diabetic neuropathy. It is usually 
insidious in onset and may be the presenting feature in patients with type 2 
diabetes. It may be asymptomatic and discovered incidentally on 
examination or when patients present with a neuropathic complication. 
When symptomatic, it gives rise to sensory manifestations that are most 
evident distally in the lower limbs, consisting of numbness, tingling, and 
pain. It is often accompanied by autonomic neuropathy, which is usually 
mild in patients with type 2 diabetes. A mild distal motor neuropathy may 
also coexist (230).  
Most evidence suggests that small nerve fibers, both myelinated and 
unmyelinated, are affected first. Thus, pain and temperature sensation 
transmitted through the smallest fibers may be affected before the large-fiber 
modalities (vibration, light touch, position sense) (215). 
Late sequelae of neuropathy, which include insensate foot ulceration, 
Charcot (neuropathic) arthropathy, and occasionally even amputation (239)     
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Acute Painful Diabetic Neuropathy 
Acute painful diabetic neuropathy is a separate entity from distal 
symmetric diabetic sensory polyneuropathy (229,230,240). Its onset is acute 
or subacute, with burning pain experienced mainly in the lower limbs but 
sometimes in the upper limbs or on the trunk. There is usually distressing 
contact hyperesthesia of the skin. Motor signs, tendon reflex depression, and 
autonomic dysfunction are not prominent, but impotence may develop in 
males. The patients also complaint of deep aching pain and many experience 
sudden, sharp, stabbing, or “electric shock”—like sensations in the lower 
limbs (230).  
The syndrome can be precipitated by the initiation of treatment or be 
associated with precipitous weight loss. Recovery occurs with continued 
glycemic control over a matter of months (Diabetes 2005) (230). 
Autonomic neuropathy 
Is also common, though rarely severe symptomatic (241)      
 Autonomic neuropathy normally is an accompaniment of diabetic 
sensory polyneuropathy. A very wide range of manifestation may occur 
(233). 
Symptomatic autonomic neuropathy is almost always encountered in 
type 1 diabetic patients who have reached middle age and have had diabetes 
for several years. Once established, it is largely irreversible (230). 
Acute Motor Neuropathy 
Patients have been described who have developed an acute primary 
motor neuropathy accompanied by bilateral facial weakness following an 
episode of diabetic ketosis (242) associated with an elevated cerebrospinal 
fluid protein content. Recovery occurred over the course of a few weeks. 
Such cases have to be distinguished from examples of the Guilllain–Barre 
syndrome and critical illness neuropathy (243). 
Focal and Multifocal Neuropathies 
All the neuropathies under this heading are recognized as being more 
common in older type 2 diabetic patients (241). 
The second broad category of diabetic neuropathies consists of the 
occurrence of isolated peripheral nerve lesions or of multiple isolated 
lesions. These are best separated into focal cranial nerve lesions, truncal or 
thoracolumbar radiculopathy, proximal diabetic neuropathy, and focal 
lesions of limb nerves (230).  
Focal Limb Nerve Lesions 
These are probably more frequent in patients with diabetes than in 
general population, but epidemiological data are scarce. Often they are at 
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common sites of entrapment (e.g., carpal tunnel syndrome), or external 
compression, indicating an increased susceptibility of diabetic nerve to 
compression injury, but they also occur at other locations (230). 
 Recent data suggest that there is a three-fold risk of having diabetes 
in 514 patients with carpal tunnel syndrome compared with a normal control 
group (244).  
Cranial Neuropathies 
Cranial neuropathies in diabetic patients are extremely rare and occur 
in older individuals with a long duration of diabetes (245).  
The focal lesions most commonly affect the nerves to the external 
ocular muscles, particularly the third nerve (3.3%) of diabetic patients (246). 
This usually has an acute onset with pain, and papillary function is 
characteristically spared. Of the other cranial nerves, the seventh is most 
often implicated, but as the frequency of these lesions is low and it is 
difficult to be certain of a clear association with diabetes (241). 
Thoracolumbar Radiculopathy 
This manifestation of diabetic neuropathy consists of the occurrence 
of focal sensory symptoms either unilaterally or bilaterally on the trunk, with 
pain, cutaneous hyperesthesia, and sensory loss in a radicular distribution or 
in the territory of intercostal nerves. Focal weakness of the anterior 
abdominal wall may occur. The onset of symptoms is often acute or 
subacute, and recovery generally occurs over the course of some months 
(241). 
Proximal Diabetic Neuropathy 
Otherwise known as diabetic amyotrophy or lumbosacral plexus 
radiculopathy, this syndrome is encountered most often in older males with 
type 2diabetes aged50-60 years. The onset can be subacute or insidious and 
is commonly accompanied by pain. It can be unilateral or bilateral and, if 
bilateral, asymmetric or symmetric. Radicular sensory loss may be present. 
At times distal lower limb muscles and occasionally those of the upper limbs 
may be also affected (230,247) 
Superimposed Chronic Inflammatory Demyelinating 
Polyneuropathy  
Although case control studies have not been undertaken it seems 
likely that chronic inflammatory demyelinating polyneuropathy CIDP occurs 
more commonly in individuals with diabetes than in the general population 
(248,249). Prominent motor involvement or a reduction of conduction 
velocity into the demyelinating range, particularly if conduction block at 
sites not subject to entrapment is demonstrated, would suggest this 
 50
possibility. 
Confirmation of the diagnosis could be obtained by finding 
oligoclonal IgG bands on examination of the cerebrospinal fluid or by nerve 
biopsy.  
 The important diagnostic findings on nerve biopsy are the presence of 
inflammatory infiltrates and stripping of myelin off axons by macrophages 
(250). 
It is important to recognize that this subgroup, unlike those with 
diabetic polyneuropathy, is treatable (251). 
Hypoglycemic Neuropathy    
Repeated or single episodes of severe hypoglycemia have been 
documented to give rise to a predominantly motor neuropathy or neuropathy 
(252, 253). Severe hypoglycemic episodes are usually either the result of an 
insulinoma or insulin overdose. Whether recurrent hypoglycemic episodes 
that occur during the course of treatment of insulin-dependent diabetes can 
also cause hypoglycemic neuropathy is conceivable but not established 
(254). 
Some authors suggest that frequent hypoglycemic episodes may play 
a role in the pathogenesis of diabetic neuropathy (255,256). Insulinoma 
patients experience a distal axonopathy that affect both sensory and motor 
nerves (257).     
Assessment of Diabetic Polyneuropathy 
From the time of the ancients to well into the eighteen century, 
electricity was regarded as a strange invisible power. Gradually the role of 
electricity in relation to the nervous system was to emerge, first from 
observation of the effect of applying it to the body, and eventually from the 
discovery that both muscle and nerve could themselves be sources of this 
power. The first of these – observation of its application–had had to wait for 
the technical development of instruments to deliver electricity; the second, 
for the more delicate instrumentation necessary for detection of the fine 
currents of nerve. The first became the ancestor of electrotherapy, the second 
of electrical diagnosis (258). 
The several form of electrodiagnosis used in neurology have much 
shorter histories than electrotherapy for they have their basis in fundamental 
neurophysiology rather than quasiquackery. They include 
electroencephalography, electromyography, cerebral and spinal potentials 
evoked by sensory stimulation (EPs), the recording of the action potentials 
of nerve, and the electroretinogram (258).  
         Nerve conduction studies assess peripheral motor and sensory 
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functions by recording the evoked response to stimulation of peripheral 
nerves. Motor nerve conduction studies require stimulation of a peripheral 
nerve while recording from a muscle innervated by that nerve. Sensory 
nerve conduction studies are performed by stimulating a mixed nerve while 
recording from a cutaneous nerve or by stimulating a cutaneous nerve while 
recording from a mixed or cutaneous nerve. In recent years, there has been 
increased use of nerve conduction studies to identify peripheral nerve, and to 
monitor their activities during surgical procedures (259).   
Electrophysiological studies of peripheral nerve function are sensitive, 
reliable, and reproducible, as they do not rely on any response by the patient 
(171).  
Diabetic peripheral neuropathy is a complex disorder in which the 
disease process may affect different sets of nerve fibers to different degree in 
different individuals. Thus, one individual may have an abnormality of 
large-fiber sensory function, which could be detected by measuring the 
vibration perception threshold (VPT), whilst another may have a 
predominantly small-fiber neuropathy that can only be measuring the 
thermal perception threshold (TPT) (129). 
A number of organizations have held consensus meetings to agree on 
standardization of measures that can be used in clinical practice or trials for 
assessment of neuropathy (260). 
Clinical measures:  assessment of symptoms and signs is essential in 
the diagnosis and follow-up of diabetic neuropathy. A number of clinical 
scoring systems have been derived: these include the simplified neuropathy 
disability and symptom scores (NDS and NSS) used in European studies 
(261-263). Other simple scoring systems that can be used in the clinical and 
in clinical trials are the Michigan Instrument (264) and the Toronto Clinical 
Scoring System (265). 
 Quantitative sensory test: simple quantitative tests such as vibration 
perception using the hand-held biothesiometer (Biomedical Instrument 
Company, Newbury, Ohio, USA) or a 10 g monofilament (Bailey 
Instruments, Chorlton, Manchester, UK) can simply, quickly, and cheaply be 
carried out in the office setting, to screen patients for neuropathy and risk of 
foot ulceration (151, 266).  
An important finding of NCS in polyneuropathy is whether the 
process is primarily axonal or demyelinating. This distinction aids in the 
diagnosis, directing therapeutic decisions and prognostication (267-271).  
Variations in the distribution and differences in the type of pathologic 
changes in peripheral neuropathies result in different patterns of abnormality 
in nerve conduction studies. Although the location and severity of nerve 
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disease are well defended by nerve conduction studies, the presence of 
mixed patterns or mild changes precludes characterization of the pathology 
of most peripheral neuropathies by nerve conduction studies. For example, 
in diabetes, small vascular lesions in a multifocal distribution result in a 
wide variety of pattern of abnormality on nerve conduction studies (259). 
Several measures have been developed to encompass the weakness, 
reflex change, and sensory loss in diabetic polyneuropathy. They developed 
the Neuropathic Impaired Score (NIS), which is a standard evaluation of 
muscle weakness, reflex decrease or loss, and sensation decrease or loss 
(272).  
In recent years, protocols have been developed to establish minimum 
criteria for the detection of diabetic neuropathy and criteria for its staging 
(145, 273, 274).These are essential for epidemiological studies and treatment 
trials. Less elaborate schemes are also available, suitable for the recognition 
of neuropathy during patient monitoring in diabetic clinics (266).    
The tests and criteria used to diagnose and stage severity of diabetic 
polyneuropathy are of considerable relevance now because improve 
approaches are needed to (1) determine prevalence in insulin-dependent and 
non-insulin-dependent diabetic patients, (2) assess change in test results or 
stages of severity over time: (3) determine power in controlled clinical trials: 
and (4) estimate risk factors associated with worsening of test results, staged 
severity, or complications or outcomes (145). 
         In the clinic, scoring weakness, the activity of tendon reflexes, 
threshold of sensation, and kind and degree of autonomic dysfunction is 
considered necessary because their abnormalities can be related directly to 
the symptoms and functional deficits of diabetic patients (275) 
At least seven criteria have been employed for the minimal diagnosis 
of diabetic polyneuropathy: (1) the clinical entity that neurologists diagnose 
as neuropathy; (2) absence of lower limb reflexes and decreased vibration 
perception at the lateral malleolus; (276, 277) (3) specific inclusion and 
exclusion criteria; (278) (4) abnormal nerve conduction;  (5) sufficient 
neuropathic symptoms that patients seek medical help; (279) (6) 
neuropathologic abnormality of the sural nerve beyond a given percentile; 
(272,280) and  (7)  abnormalities (beyond a defined level as set from an 
evaluation of  a  control population)  from at least two evaluations among 
scored symptoms, scored neurological deficits, nerve conduction, and 
quantitative sensory evaluation (280). 
There is suggestion that no single measure is sufficiently 
representative that it can be used as the only measure of diabetic 
polyneuropathy. Dyck P.J. 2003; advocated that severity of a patient's 
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diabetic polyneuropathy be assessed by quantitating neuropathic symptoms, 
impairments (including clinical, NC, QST, and QAT), staged severity, and 
health outcomes (225).  
Clinical assessment of neuropathy should form part of annual review 
of the person with diabetes. The objective is to detect the presence of clinical 
neuropathy. Risk factors for the development and progression of neuropathy 
and the development of neuropathic foot ulceration are shown in Table: 7 
(116). 
Patient history: 
Questions should be adjusted according to the age of the patient, of diabetes 
and symptomatology, although in general the following areas should be 
covered: 
• Age  
• Diabetes: type; duration; therapy; level of glycaemic control; knowledge 
of diabetes and its complications 
• Physical factors: inability to see well or reach the feet. 
• Life-style: smoking; alcohol intake; nutrition; employment; sport/leisure 
activities; footwear 
• social circumstances; social support; access to care 
• symptoms 
Symptomatology differs according to the stage and type of neuropathy. 
Patients should be asked about the following: 
- presence/absence of symptoms  
- nature of symptoms, i.e. positive or negative symptomatology 
- duration and progression of symptoms 
- nocturnal exacerbation  
- patients with chronic pain: ask if the pain insidious, intermittent, 
bilateral, related/unrelated to treatment, does it occur on walking or at 
rest; presence of foot ulcers in the past; presence of autonomic symptoms 
- patients with acute pain: presence of neuropathic pain or contact 
hyperaesthesia. 
Other medical conditions/therapies which may be aetiological factors for 
neuropathy: vascular disease, HIV, vitamin B12 deficiency, hypothyroidism, 
weight loss, cancer, leprosy, and syphilis, drug therapy, toxic exposure, 
paraproteinaemia. 
Atypical features not usually related to diabetic neuropathy include rapid 
progression, foot drop, back or neck pain, marked asymmetry, weight loss 
(per se) and family history (116,159). 
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Table 7: Risk factors for development and progression of 
neuropathy and development of neuropathic foot ulceration 
Risk factors for the                                      Risk factors for the    
development and                                          development of 
progression of neuropathy                            neuropathic foot ulceration                                
. Poor glycemic control . Loss of pain sensation 
. Undiscovered Type 2 diabetes . Undiscovered Type 2 diabetes 
. Smoking . Smoking 
. High alcohol intake . High alcohol intake 
. Low socio-economic status . Low socio-economic status 
. Renal failure . Patient live alone 
 . Lack of flexibility/suppleness 
 . ׀׀׀-fitting footwear 
 . Poor foot hygiene/foot care 
 . Denial of condition 
 . Lack of diabetes education 
 . History of previous ulceration or 
amputation 
 . Poor glycaemic control 
 . Peripheral vascular disease 
 . Decreased vibration sensitivity 
 
Examination of the patients (159)  
• Inspection of both feet:  
- skin status: color, thickness, dryness, cracking, trophic changes.  
- sweating,  
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- infection (inter digital fungal infection) 
-  ulceration 
-  calluses/blistering 
-  deformity, e.g. Charcot joint or clawed toes  
- muscle wasting 
-  arches (standing/lying).  
* The feet should be palpated to assess temperature, foot pulse and joint 
mobility. The patient’s gait and shoes should also examine. 
• Neurological examination 
Four tests are recommended (Table 8) (159). All should be done bilaterally 
and the result should be a simple yes/no or normally/abnormal answer. For 
the first three, a proximal site should be compared with a distal site 
(vibration test-only if the result is abnormal). A simple temperature 
assessment may also be made by placing a cold fork on the patient's legs. To 
determine whether the patient has diabetic amyotrophy, look for proximal 
muscle wasting and weakness and loss of knee jerks, often with little sensory 
loss.  
• Vascular examination: systemic blood pressure and pulses 
(posterior tibial and dorsalis pedis) should record. 
• Other investigations, e.g. thyroid function, serum B12, serum 
paraprotein, assessment of metabolic control should be considered 
for medical conditions, other than diabetes, which may be 
etiological factors for the neuropathy (116).  
• Inspection for the presence or absence of characteristics of the “at risk” 
foot   
 
 
 
 
 
 
 
 
Table 8: Neurological tests 
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Pin prick test . Use a disposable instrument. e.g. a 
disposable dressmaker's pin 
. Do not use a hypodermic needle 
. Ask “Is it painful?” not “Can you 
feel it?” 
Light touch . Use a consistent method, ideally a 
cotton wisp 
Vibration test . Use a 128 tuning fork, initially on 
the big toe 
Ankle reflex . Compare the ankle reflex with the 
knee reflex  
Pressure perception . Absence of sensation in the foot to a 
10 g monofilament may be use to 
assess the risk of foot ulceration 
 
 
 
Stages of Neuropathy 
A staging system has been developed for neuropathy to provide a framework 
for diagnosis and management. Staging does not imply automatic 
progression to the next stage and the aim is to prevent, or at least delay, 
progression (Table 9) 
 
 
 
 
 
Table 9: The stages of neuropathy 
 
                 stage Characteristic 
          Stage 0/1: no clinical neuropathy 
          Stage 2: clinical neuropath 
                . chronic painful 
 
 
 
 
• No symptoms or signs 
• Positive symptomatology (increasing at night): 
burning shooting, stabbing pains ±pins and 
needles 
• Absent sensation to several modalities and 
reduced or absent reflexes  
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                . Acute painful 
 
 
 
 
 
 
 
 
             . Painless with complete /partial 
                
sensory loss 
 
 
  
    Stage3: late complications of clinical 
                                    
 neuropathy     
• Less common  
• Diabetes poorly controlled, weight loss 
• Diffuse (trunk) 
• Hyperaesthesia may occur  
• May be associated with initiation of glycaemic 
therapy 
• Minor sensory signs or even normal peripheral 
neurological examination 
 
• No symptoms or numbness /deadness of feet; 
reduced thermal sensitivity; painless injury  
• signs of reduced or absent sensation with absent 
reflexes 
 
• Foot lesions e.g. ulcers  
• neuropathic deformity e.g. charcot joint 
• Non-traumatic amputation  
 
1. Subclinical neuropathy (stage 1). This can only be diagnose in special 
neurophysiological laboratories and such tests are not recommended for 
day –to-day clinical practice .Thus ,stage 1 cannot be differentiated 
clinically from stage 0. 
2. Diabetic amyotrophy. This is predominantly motor disorder, usually 
encountered in elderly patients with undiagnosed or poorly controlled 
type2 diabetes. There is muscle weakness and wasting, mainly affecting 
the proximal lower limb muscles with a subacute onset. Sensory loss is 
slight, but pain, particularly at night, is common (116). 
Neuropathic Pain 
Neurogenic pain is defined as pain due to dysfunction of the 
peripheral or central nervous system, in the absence of nociceptor (nerve 
terminal) stimulation by trauma or disease (281). Other terms used to 
describe some forms of neurogenic pain include neuropathic pain (281). 
Pain is a subjective symptom often caused by an external stimulus that 
frequently results in the patient seeking a medical consultation. In contrast, 
neuropathic pain occurs in the absence of an external painful (nociceptive) 
stimulus, and results from dysfunction of peripheral or central nervous 
system. Although neuropathic pain may be experienced by patients with 
chronic diabetic sensorimotor neuropathy, the majority of patients do not 
experience severely painful symptoms. It is estimated that 10-20% of 
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patients with sensorimotor neuropathy experience painful symptoms at any 
one time (103, 227). The painful symptoms of chronic sensorimotor 
neuropathy tend to last for years, although their severity may fluctuate (93). 
The occurrence of pain in diabetic distal sensory polyneuropathy is 
variable. Most cases are pain-free but in patients with late-onset type 2 
diabetes it may be the presenting feature. It may develop insidiously in 
established cases or occasionally in more troublesome episodes. It is usually 
felt distally in the legs, and is commonly aching in quality, sometimes with 
superimposed lancinating stabs. Burning paresthesias in the feet, especially 
at night, may be experienced. Pain is the dominant feature in acute painful 
diabetic neuropathy (282).  
Table 10: Conditions that Result In Pain in Lower Limbs of Diabetes 
Patients (159) 
• Sensory neuropathy 
              .Acute sensory 
              .Chronic sensorimotor 
• Entrapment neuropathy 
                Meralgia paresthetica 
•  Proximal motor neuropathy (amyotrophy) 
•  Peripheral arterial disease 
                .Intermittent claudication 
                .Rest pain 
    Three general categories for the occurrence of pain. Direct activation of 
receptors that normally signal tissue injury is referred to as nociceptive pain. 
Pain resulting from damage to or dysfunction of the nervous system is 
termed neuropathic or dysesthetic pain. The pain is generated by abnormal 
physiologic mechanism. Hyperalgesia or allodynia consists of the generation 
of uncomfortable or painful sensation by stimuli that are normally not 
painful. Finally, psychogenic pain is a consequence of affective psychogenic 
disorders. Possible mechanisms for the occurrence of pain in diabetic 
neuropathy given in Table 11 (282)      
 
 
 
 
 
 
 
Table 11: Possible mechanism for pain in diabetic neuropathy  
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Nerve trunk pain 
Dysesthetic pain 
      Sensitization of nociceptor ending 
      Damage to Aδ and C fibers    
      Active axonal degeneration 
      Axonal regeneration 
      Axonal atrophy 
      Ephaptic transmission 
      Abnormal behavior of dorsal root ganglion 
      Peripheral blood flow  
      Glycemic control 
      CNS changes secondary to damage to the peripheral nervous system 
            Surround inhibition 
            Presynaptic inhibition 
            Postsynaptic inhibition 
            Dorsal horn deafferentation                                                                                            
People with diabetes experience more chronic pain than the non-
diabetic population. One study found that 25 % of diabetic patients had 
chronic pain, compared to 15% of non-diabetic subjects (283). The 
difference is largely attributable to pain associated with polyneuropathy. 
Diabetic polyneuropathy is encountered in at least one-third of the patients 
with diabetes mellitus (284). Neuropathic symptoms are present in 15-20 % 
of the diabetic patients (284,103), and 7.5 % of all diabetic patients 
experience chronic neuropathic pain (283). Pain associated with diabetic 
neuropathy exerts a substantial impact on the quality of life, particularly by 
causing considerable interference in sleep and enjoyment of life (227). 
Despite this significant impact, one quarter of the diabetic patients and one-
fifth of the nondiabetic subjects had no treatment for their pain in a survey 
dating from 1900 (283). 
According to Asbury and Fields (285) neuropathic pain may be 
subdivided into two types. The superficial dysesthetic or deafferentation 
pain is described as burning, tingling, raw, searing, crawling, drawing, and 
electric of variable constancy, i.e., intermittent, jabbing, lancinating, or 
shooting (285). Dysesthetic pain is a common manifestation in diabetic 
polyneuropathy, particularly in those patients whose small-fiber modalities 
(cutaneous pin prick and temperature sensation and autonomic function) are 
disproportionately affected (285). 
In a model for the treatment of chronic painful diabetic neuropathy, 
Pfeifer et al. suggest muscular pain is a third type of pain that is described as 
cramping, aching, muscles tenderness, or a “drawing sensation”. The muscle 
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cramping and spasms may be secondary to injury to motor nerves or 
attributable to reflex loop (“Livingston's vicious circle”), where a 
nociceptive input activates the motor neuron within the spinal cord leading 
to muscle spasm that in turn activates the muscle nociceptors and feedback 
to the spinal cord to sustain the spasm (286) 
Treatment of Neuropathic Symptoms 
Many patients with severely painful conditions believe that they have 
malignant disease: thus, reassurance that this not the cause and the treatment 
is available for these symptoms, which may will resolve in due course, is an 
important of management. The first step in symptom management is to 
stabilize glycemic control. There is increasing evidence that blood glucose 
flux may exacerbate neuropathic pain, so avoiding swings of glycemia from 
hypoglycemia to hyperglycemia may help. Insulin is not always needed in 
type 2 diabetes patients if controlled is satisfactory on oral agents. Most 
patients will also require some form of pharmacotherapy for the painful 
symptoms (159)  
Painful symptoms in diabetic polyneuropathy may constitute a 
considerable management problem. Efficacy of a single therapeutic agent is 
not the role, and simple analgesics are usually inadequate to control the pain. 
Therefore, various therapeutic schemes have been proposed, but none of 
them has been validated (286, 287, 288). Nonetheless, there is agreement 
that patients should be offered the available therapies in a stepwise fashion 
(289,290). Effective pain treatment aims a favorable balance between pain 
relief and side effects, without implying a maximum effect (282).           
 Studies have indicated that strict metabolic control can improve 
symptoms and signs of neuropathy, and long-term near-normoglycemia may 
prevent or slow the progression of the chronic diabetic complications 
including diabetic neuropathy (291, 292, 293). Several studies have shown 
that successful pancreas and kidney transplantation result in a slight to 
moderate improvement of neuropathy (294-299). 
Education of people with Stage 2 neuropathy and referral of people 
with Stage 3 neuropathy are key factors in the prevention of amputation. For 
optimal care of people with neuropathy, a local multidisciplinary footcare 
team should be established. Although the structure of the team will vary 
according to local health care resourcing, as many as possible of the 
following should be include: 
• Diabetologist 
• Diabetes specialist nurse 
• Chiropodist 
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• Podiatrist 
• surgeon 
Stage 0/1, objective: education to reduce the risk of progression 
Stage 2, objective: prevention of primary lesions and progression to 
late complications of clinical neuropathy (Stage 3) 
Stage 3, objective: prevention of new/recurrent lesions and 
amputation (116,260) 
Table 12: Management of the stages of neuropathy 
Stage Key elements Referral 
.No clinical neuropathy 
(Stage 0/1) 
Education; glycemic 
control. Annual 
assessment 
Chiropodist/podiatrist/special 
nurse 
.Clinical neuropathy 
(Stage 2) 
  Chronic painful 
If disabled, treatment with 
tricyclic drugs; glycemic 
control 
Diabetologist/neurologist  
   Acute painful Simple analgesics/tricyclic 
drugs/NSAIDs/opiates; 
glycemic control 
Diabetologist/neurologist 
  Painless/loss of 
sensation 
Education, especially foot 
care; glycemic control 
Appropriate member of foot 
care team according to needs 
   Diabetic amyotrophy Early referral Neurologist/diabetologist 
. Late complications 
(Stage 3) 
Emergency referral if 
lesions present; otherwise 
referral within 4 weeks 
Diabetologist/neurologist/chrio
podist/podiatrist/ 
diabetes specialist nurse 
 
 
 
 
 
 
 
Therapies to modify the course of diabetic neuropathy  
Strategies to prevent neuropathy from developing (primary 
prevention) and to improve or reverse established neuropathic damage 
(secondary prevention) have been the focus of intense investigation for 
almost three decades. Much work remains at the level of animal models, and 
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the understanding of the pathogenesis of neuropathy is only slowly being 
deepened (219). A variety of experimental studies have provided new 
insights in the putative mechanisms implicated in the pathogenesis of 
diabetic neuropathy (300). Pharmacological treatment approaches have been 
developed to correct the underlying putative abnormality in the diabetic 
nerve (301)        
Measures of established clinical value 
Optimized glycaemic control 
Extensive evidence supports an association between the degree of 
hyperglycemia and both the development (302,303) and severity (304) of 
clinical polyneuropathy. In type 2 diabetes, the UK prospective Diabetes 
Study (UKPDS) (106) has shown that improved glycemic control can reduce 
the overall risk of microvascular complications, include some indices of 
peripheral nerve dysfunction. The effectiveness of normoglycemia in 
improving even very damaged nerves has been documented in some patients 
who have undergone combined pancreatic and renal transplantation (305).               
Measures that may become clinically useful 
Aldose reductase inhibitors (ARIs) 
Excessive polyol pathway activity has long been recognized in 
diabetic patients and may contribute to the development of diabetic 
neuropathy and other complications (219). Aldos reductase inhibitors (ARIs) 
have been developed to reduce the enhanced flux through the polyol 
pathway (306-308). 
However, clinical trials of ARIs in humans have been much less 
convincing (309-311).   This may be because the patient's studies had longer 
durations of diabetes and more advanced nerve damage than experimental 
animals, in which any changes may still be partially reversible. In addition, 
clinical trials have generally employed much lower dosages of ARIs than in 
animal studies, mainly because of anxieties about toxicity. (219) 
Essential fatty acids 
In diabetes, there is a deficit in ∆−6 desaturation of linoleic acid to γ-
linolenic acid (GLA), which may be a rate-limiting step for the synthesis of 
many biologically important prostanoids such as prostaglandin E1 (PGE1), 
PGE2 and prostacyclin. Evening primrose oil is rich in linoleic acid (75%) 
and GLA (8-10%) and could theoretically bypass the desaturation deficit, 
thus enhancing prostanoid production (312,313).. 
Initial clinical trials suggested that evening primrose oil given to 
patients with established neuropathy could improve both symptoms and 
certain objective measures, such as nerve conduction velocity (314,315). 
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Vasodilator drugs 
The rationale for using vasodilator drugs stems from the vascular 
hypothesis regarding the pathogenesis of diabetic neuropathy, which 
implicates ischemia due to occlusion of the vasa nervorum (219). Studies in 
humans have shown that endoneurial vascular abnormalities accompany and 
parallel the severity of diabetic neuropathy (316), and that nerve blood flow 
is reduced (192). The most promising in preliminary trials appear to be ′αı-
adrenergic antagonists, angiotensin-converting enzyme (ACE) inhibitors 
(317) and vasodilator prostanoids; as these drugs are widely used for other 
indications, they should be readily amenable to clinical trials in diabetic 
neuropathy (318).  
 Recent studies suggest that improvement in nerve blood flow may 
also underline the beneficial effects of essential fatty acids (319) and 
electrical stimulation (320) in diabetic neuropathy. 
Strategies under experimental investigation 
Agents are being studies that either interferes with the biochemical 
mechanisms of nerve damage, such as glycation of proteins or oxidative 
stress, or that promote nerve regeneration (219). 
Inhibitors of glycation 
Advanced glycation end-products (AGEs) are likely to play an 
important role in chronic diabetic complications, and evidence from diabetic 
animals points to their involvement in diabetic neuropathy (321). Limited 
studies of aminoguanidine, an inhibitor of non-enzymatic glycation, have 
shows some beneficial effects in experimental diabetic neuropathy (322); as 
aminoguanidine also inhibits aldose reductase, its precise mechanism of 
action remains obscure (323). 
Antioxidants 
Antioxidant drugs such as the free-radical scavenger, glutathione, are 
reported to improve nerve dysfunction in the streptozotocin-diabetic rat 
(324, 325), but their role in human diabetic neuropathy has not been 
established.   
One preliminary trial (326) has reported slight but favourable effects 
on the progression of neuropathic deficits, but not symptoms. Accumulating 
data suggest that the antioxidant alpha-lipoic acid may be beneficial in 
patients with diabetic neuropathy. This drug has been used for many years in 
Germany to treat diabetic polyneuropathy (327) 
Agents that promote nerve growth and repair 
Most therapeutic interventions in diabetic neuropathy target putative 
pathways of neuronal damage. Very little attention has so far been devoted 
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to the capacity of damaged nerves to grow and regenerate. This is an 
important consideration, because in many patients with clinical diabetic 
neuropathy it may already be too late for preventive treatment (301,219). In 
humans, biopsy studies of diabetic sural nerves support the idea that nerve 
degeneration may be defective (328). Neuronal spouting and growth are 
stimulated by nerve growth factor-1 (NGF) and perhaps also by insulin-like 
growth factor-1 (IGF-1). Bioavailability of IGF-1 is decreased in diabetes, 
particularly in patients with neuropathy, partly through alterations in the 
IGF-binding proteins which determine its freely circulating levels (329); 
however, the relevance of these changes to diabetic nerve damage is 
unknown. 
The nerve growth factor (NGF) developed to prevent deficits in 
neurotrophism and axonal transport (330, 331).  
An adrenocorticotrophic hormone (ACTH) analogue, ORG2766, and 
gangliosides (which are normal components of neural membrane) are known 
to promote neuronal regeneration and growth (332, 333), and some evidence 
indicates possible benefit in experimental diabetic neuropathy (323).  
Symptomatic treatments for diabetic somatic polyneuropathy  
Although pain is usually the main complaint in diabetic neuropathy, 
many subjects suffer mainly from profound loss of sensation in the limbs, 
which can lead to neutrophic ulceration and Charcot arthropathy (219).    
Neuropathic pain 
Functional nerve damage can invariably be demonstrated in painful 
neuropathy (328), but routine clinical examination may show little 
abnormality-a discrepancy that must be appreciated by both doctors and 
patients. The pathophysiological mechanisms that generate neuropathic pain 
remain controversial (334, 335), and it is important for the doctor to 
understand the many factors that may contribute to the patient’s own 
experience of pain. 
The symptoms of neuropathic pain are varied, and it is important to 
identify the patient’s most troublesome symptoms to guide the choice of 
treatment. Taking the time to listen to the patient describing his or her 
experience of pain allows the various contributory factors to be evaluated, 
and will reassure the patient that their symptoms are accepted as genuine and 
are being taken seriously (219).        
Lowering glycaemia has been proven to slow the deterioration in 
objective measures of nerve function (220), but there is little convincing 
evidence that improving diabetic control influences the intensity of 
symptoms or the progression of established painful neuropathy. A period of 
poor glycemic control can precipitate acute painful neuropathy, but a sudden 
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improvement can have the same effect; moreover, acute painful neuropathy 
can continue to remit in the face of deteriorating glycaemic control (336). 
Drug treatment of neuropathic pain  
Most patients with severe symptoms benefit from drug therapy. This 
must be administered with confidence and tailored to the patient’s symptom 
profile, focusing on the dominant complaint. Acute painful polyneuropathy 
and the painful mononeuropathies usually remit over a period of up to 18 
months, and it can be explained that the need for treatment will steadily 
decline. Painful neuropathic symptoms usually fluctuate; all the major drugs 
described below ca be used on demand, including the tricyclic agents, whose 
antidepressant action may require several weeks to take effect (287). 
 
 
• Conventional analgesics    
By the time they consult, most patients will already have tried the 
readily available simple analgesics such as aspirin and paracetamol, mild 
opiates (e.g. codeine phosphate), or combinations of these (e.g. co-codamol, 
co-dydramol). As with other neurogenic or causalgic pains (e.g. trigeminal 
neuralgia) (337), it is rare for any of these compounds to have any 
appreciable effect on diabetic neuropathic pain (219). 
• Burning pain  
Tricyclic antidepressants such as imipramine, amitriptylline and 
desipramine are the most effective drugs for controlling burning 
neuropathic pain. Their analgesic effect is probably mediated by 
blockade of norepinephrine reuptake, rather than an effect on mood 
(338), but the levels at which they influence pain transmission are not 
known. Other antidepressant drugs such as mianserin (which does not 
block neurotransmitter reuptake) or fluoxetine (which inhibits 
serotonin reuptake) do not generally cause significant pain relief (338, 
339). Given the drug at bedtime concentrates its effect when the 
intensity of pain is usually worst and also provides helpful sedation. 
Unlike their antidepressant action, the analgesic effect of tricyclics is 
realized as soon as the appropriate plasma level is achieved. An 
effective dosage can be used intermittently thereafter, as required 
(287). Several authors consider the tricyclic antidepressants to be the 
drug treatment of choice for neuropathic pain (340-342). 
            The addition of a phenothiazine, such as fluphenazine, may               
enhance analgesia, but also intensifies the hypotensive effect (343, 344).  
• Capsaicin is an alkaloid found in hot Capsicum peppers, and is 
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responsible for the burning sensation that they cause on contact 
with mucosal surfaces. Capsaicin induces the release of various 
peptide neurotransmitters from nerve endings, leading to depletion 
of the peptides in the terminals and failure of transmission at the 
synapse (219). In diabetic neuropathy, capsaicin cream (o.o75%) 
applied to the skin of the foot twice-daily can significantly reduce 
the pain intensity, especially burning pain (345-346). 
• Contact discomfort (allodynia)  
        Contact discomfort often accompanies burning pain. It can be 
exceedingly distressing and can be precipitated by light contact, even with 
bedclothes. It generally  responds best to a mechanical approach such as a 
bed cradle, careful choice of    clothing next to the skin (e.g. silk pyjama 
trousers), or a protective mechanical barrier such as adhesive film applied to 
the skin (219). 
• Lancinating pain 
 Electric shock-like pains generally respond best to anticonvulsant 
drugs (carbamazepine, gabapentin, phenytoin or valproate), or membrane-
stabilizing drugs such as lidocaine (lignocaine) and its orally active 
analogue, mexiletine (347).  
   Carbamazepine, the traditional first choice, can be started at 100 mg 
once or twice per day and gradually increased to the maximum tolerated 
dosage (some-times 800-1000 mg/day, but often less). Gabapentin, 600-
3600 mg/day, has emerged as a relatively well tolerated and effective 
alternative (348-351) and is now licensed for this indication in several 
countries. Valproate (100-500 mg one to three times) and phenytoin (100-
400 mg once or twice daily) are other options. Lamotrogine also shows 
promise as a useful treatment for symptomatic neuropathy. 
 
• Painful paraesthesia 
 Either tricyclic drugs or anticonvulsant may be tried, but this 
symptom often appears more resistant to drug therapy than other sensory 
phenomena. It is usually most prominent in entrapment neuropathies, when 
surgical relief can be offered (219). 
• Restless legs 
This very distressing symptom may be the dominant complaint or may 
accompany other features, and can seriously disturb sleep or relaxation in 
the evening. Low dosages of the benzodiazepine anticonvulsant, clonazepam 
(0.5-1 mg in the evening or at night) are often effective (219). 
• Cramps 
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 Unpleasant cramps, especially at night may be the only symptom of 
diabetic neuropathy, but commonly affected older people who have neither 
diabetes nor neuropathy. Their aetiology is uncertain, but muscle 
denervation, manifested clinically as fasciculation, may be involved. Cramps 
seem to dominate during periods of poor or changing metabolic control, 
when muscle electrolyte imbalances may contribute (219). The time-
honoured therapy of quinine sulphate (300mg at night) (352) is generally 
effective, although severe and resistant cramps may be require combinations 
of counter-irritation (including transcutaneous electrical nerve stimulation or 
TENS), local massage and relaxation. 
• Pain resistant to standard treatment 
Electrical spinal-cord stimulation has been described as a way of 
relieving chronic diabetic neuropathic pain and improving exercise tolerance 
in patients resistant to other therapies (353). The electrode is implanted in 
the thoracic or lumbar epidural space and stimulates the dorsal columns, thus 
blocking pain transmission by ‘gating’ the spinothalamic pathways (219). 
A preliminary trial of dextromethorphan, a low-affinity N-methyl D-
asparate (NMDA) channel blocker in painful diabetic neuropathy, 
demonstrated a significant 24% reduction in pain scores (354).   
 
Table 13: Drug Treatment of Neuropathic Symptoms (159) 
Group 
           
Drug Daily Dose 
           
Side Effects 
Tricyclics Amitriptyline 
 
    Imipramine 
 
         
25-150mg  
25-150mg 
                          
Drowsiness 
Anticholinergic 
Anticonvulsants Gabapentin 
Lamotrogene 
Carbamazepine 
 
                       
900-3,000 mg divided  
 
 Up to 800mg divided 
                            
Central  side effect: 
dizziness 
somnolence    
 
Anti Arrhythmics 
    
Mexilitene Up to 450 mg divided 
     
Gastrointestinal 
 
 
                           and 
neurologic 
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Objectives of the study 
The objectives of this study are: 
1- General objective: 
-To study peripheral neuropathy and its stages among Yemeni type 2 
diabetic patients in Sana'a, from 2003-2006. 
2- Specific objects: 
     1) To calculate the prevalence of other diabetic complications among          
the Yemeni type 2 diabetes patients  
2) To investigate the risk factors associated with diabetic neuropathy 
among type 2 diabetic Yemeni patients. 
3) To evaluate association of diabetic neuropathy with microvascular and 
macrovascular complications (eye, kidney, IHD, HTN, PAOD, and 
stroke) among type 2 diabetic Yemeni patients.  
        
 
 
 
 
 
 
 
complaints     
Opioid-Like Tramadol 50-400 mg divided 
    
Nausea, constipation 
 
 
                   drowsiness 
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Patients and Methods 
 
Sample size and sampling procedure: 
A total of 155 consecutive Yemeni patients with type 2 DM were 
included in this study. The study was carried out in a diabetic center in 
Sana'a, Yemen under the supervision of Professor Abdullah Gunaid. Patients 
of both sexes, and various age groups with different duration of the disease 
were included in this study from 2003-2006. 
Inclusion Criteria: 
A. Criteria for diagnosis of diabetes mellitus (19): 
1. Symptoms of diabetes plus casual plasma glucose concentration ≥ 200 
mg/dl (≥11.1 mmol/l): 
The classic symptoms of diabetes include 
• Polyuria 
• Polydipsia 
• Unexplained weight loss 
      Or 
2. FBG≥126mg/dl (7.0 mmol/l):  
 Or 
3. 2-h plasma glucose ≥ 200 mg/dl (≥11.1 mmol/l) during an oral 
glucose tolerance test. 
B. Members of an International Consensus on the out outpatient diagnosis 
and management Diabetic Peripheral Neuropathy agreed on a simple 
definition of diabetic neuropathy as ″the presence of symptoms and/or 
signs of peripheral nerve dysfunction in people with diabetes after 
exclusion of other causes(116) 
C. Diabetic symmetric distal polyneuropathy (DSDP) is characterized by 
length-related, distally pronounced distribution of sensory and motor 
symptoms and signs in patients with manifest diabetes mellitus 
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(116,117,118).  
Exclusion criteria; 
 - Type 1 DM. 
 - Other specific types (genetic defects of β-cell function, genetic defects in 
insulin action, diseases of the exocrine pancreas, endocrinopathies, drug-or 
chemical-induce, infections, uncommon forms of immune-mediated 
diabetes, other genetic syndromes sometimes associated with diabetes). 
- Gestational diabetes mellitus. 
The importance of excluding nondiabetic causes was emphasized in the 
Rochester Diabetic Neuropathy Study, in which up to 10% of peripheral 
neuropathy in diabetic patients was deemed to be of nondiabetic causation 
(103). 
- Hereditary neuropathy 
- Heavy metal poisoning/environment toxins 
- Malignant disease,  
- Metabolic (e.g. uremia) 
- Infection  
- Medication-related (e.g., isoniazid, chemotherapy) 
- Vitamin B6 intoxication 
- Pernicious anaemia 
- Alcohol abuse 
- Focal and multifocal diabetic neuropathies. 
-Proximal neuropathy 
-Autonomic neuropathy not involved in this study. 
Procedures used in the study: 
Every patient fulfilling the inclusion criteria was subjected to the following:  
1- Clinical history 
2- Examination and investigation 
The Michigan Neuropathic Program designed to diagnose and grade 
the severity of diabetic neuropathy (355), was adopted in the history, 
examination, and investigation. 
The Michigan Neuropathy Program 
The Michigan Neuropathy Program is a simple 2-step screening and 
staging program to diagnose and grade the severity of diabetic neuropathy 
(Diabetes Care, 17: 1281-1289, 1994).  
A. Michigan Neuropathy Screening Instrument (MNSI), designed to screen 
patients for the presence of diabetic neuropathy. 
- The fist part of screening instrument consists of 15 self-administrated 
″yes or no″ questions on foot sensation such as pain, numbness, and 
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sensitivity to temperature (Table A) (327). 
-  The second part of the MNSI is a brief physical examination (Table 
B). 
Patients screening positive on the clinical portion of the MNSI 
(greater than 2 points on an 8 points scale) are considered 
neuropathic and referred for administration of the Michigan Diabetic 
Neuropathy Score (MDNS).  
B. The Michigan Diabetes Neuropathy Score (MDNS) 
The MDNS designed to grade the severity of diabetic Neuropathy. It 
consists of 2 parts, both of which are easy conducted in routine clinical 
practice: 
• A clinical neurological examination (Table C).  
Sensation (vibration at big toe, pin prick on dorsum of great toe, and a 
10-g. filament), tendon reflexes, and muscle strength. 
• Non-invasive nerve conduction (sural, peroneal motor, median 
sensory and motor, and ulnar sensory) (Table D, E).  
1) Clinical history. 
Questionnaire was designed in which information was obtained focusing on: 
- Name, age at diagnosis, sex, address, place of birth, place of present 
residence, occupation, and marital state 
-  Current history of smoking, alcohol intake, and qat chewing. 
-   Symptoms related to diabetes mellitus and its complications  
-   Duration of DM. 
-   Current treatment  
        -Diet only  
        -Diet and hypoglycemic drugs 
        -Diet and insulin 
        -No treatment. 
-    Family history of DM (FH). 
- The first component of the Michigan Neuropathy Screening Instrument 
(MNSI), which consists of 15 self-administrated ″yes or no″ questions on 
foot sensation including pain, numbness and temperature sensitivity, was 
included.  The questions were chosen from those in Neuropathy 
Screening Profile of Peter Dyck that showed the highest degree of 
specificity and sensitivity for diabetic neuropathy among normal subjects 
and those with a variety of neuromuscular disorders (Neurology, 
36:1300-1380, 1986).  
2) Examination and investigation 
A-Measurement of the blood pressure 
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The blood pressure was measured in the morning after the patients had been 
sitting for at least ten minutes. A standard mercury sphygmo-manometer was 
used for this purpose, and was regularly maintained.  Normal <140/90       
Abnormal ≥140/90  
B-The second part of the MNSI was a brief physical examination involving:  
1-Inspection of the feet for deformities, dry skin, hair or nail abnormalities, 
fissures, callous or infection (right and left). 
If normal appearance    (0)         Abnormal appearance    (1) 
2- Ulceration of feet (rt. &lt.):    Absent   (0)   Present      (1)                          
 3- Vibration sensation at the dorsum of the great toe.  
Procedure: 
Vibration sensation was performed with the great toe unsupported. 
Vibration sensation was tested bilaterally using a 128 Hz tuning fork placed 
over the dorsum of the great toe on the boney prominence of the DIP joints. 
Patients, whose eyes were closed, were asked to indicate when they can no 
longer sense the vibration from the vibrating tuning fork. 
In general, the examiner should be able to feel vibration from the hand 
held tuning fork for 5 seconds longer on his distal forefinger than a normal 
subject can at the great toe (e.g. examiner’s DIP joint of the first finger 
versus patient’s toes). If the examiner feels vibration for 10 or more seconds 
on his or her finger, then vibration is considered decreased. A trial should be 
given when the tuning fork is not vibrating to be certain that the patient is 
responding to vibration and not pressure or some other clue.  
Vibration was scored as: 
1) Present if the examiner senses the vibration on his or here finger for 
< 10 seconds    (0)  
2) Reduced if sensed for ≥ 10               (0.5) 
          3) Absent (no vibration detection)          (1) 
 4- Muscle Stretch Reflexes (grading of ankle reflexes). 
 
 
Ankle Reflexes  
The procedure:    
The ankle reflexes examined using an appropriate reflex hammer. The 
ankle reflexes were elicited in sitting position with the foot dependent and 
the patient relaxed. The foot was passively positioned and the foot 
dorsiflexed slightly to obtain optimal stretch of the muscle. The Achilles 
tendon was percussed directly.  
-    If the reflex is obtained, it is graded as present (0). 
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-   If the reflex is absent, the patient is asked to perform the Jendrassic 
maneuver (i.e. hooking the fingers together and pulling). Reflexes 
elicited with the Jendrassic maneuver alone are designated "present with 
reinforcement" (0.5). 
-   If the reflex is absent, even in the face of the Jendrassic maneuver, the 
reflex is considered absent (1). 
Patients screening positive on the clinical portion of the MNSI (greater 
than 2 points on an 8 points scale) were considered neuropathic and 
referred for administration of the Michigan Diabetic Neuropathy Score 
(MDNS). 
C-The MDNS consists of two parts, clinical neurological examination 
followed by simplified non-invasive nerve conduction measurements.  
I-The clinical neurological examination includes: 
1- Sensation, (vibration, pin prick and a 10-gm. filament). 
  - Vibration Sensation: done as under MNSI 
  - 10 g filament 
The procedure: 
For this examination, it was important that the patient's foot be 
supported (i.e. allow the sole of the foot to rest on a flat, warm surface).The 
filament initially prestressed (4-6 perpendicular applications to the dorsum 
of the great toe of the examiner's first finger). The filament is then applied to 
the dorsum of the great toe midway between the nail fold and the DIP joint 
without holding the toe directly. The filament was applied perpendicularly 
and briefly, (< 1 second) with an even pressure. When the filament bends, 
the force of 10 grams has been applied. The patient, whose eyes were closed, 
was asked to respond yes if he/ she feel the filament.  
The test done for both right and left big toe 
• 8 correct responses out of the 10 applications were considered normal  
-----------------(0) 
• One to seven correct responses indicates reduced sensation----- (1) 
• No correct answers translated into absent sensation------------ (2) 
- Pin prick on dorsum of great toe (right and left). 
  Prickling pain sensation was evaluated subjectively using a disposable 
safety pin. Patients were asked to correctly distinguish, with their eyes 
closed, prickling pain from simple touch on the dorsum of the great toe 
• If Pin prick on dorsum of great toe was painful -------------- (0) 
• If Pin prick on dorsum of great toe was not painful---------- (2) 
2- Muscle strength. Strength was assessed in the designated muscle groups 
using the Medical Research Council Score (355) (both right and left foot 
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examined).  
Muscle strength was scored as (0) for normal, (1) for mild-moderate, and (2) 
for severe weakness, while complete loss of strength was scored as (3). 
3- Tendon reflexes.      
      -Muscle Stretch Reflexes, done as under MNSI. In addition to the ankle 
reflexes, biceps, triceps and quadriceps (knee) reflexes were also elicited 
bilaterally.  
As mentioned before if the reflex was obtained, it is graded as present (0). If 
the reflex is absent, the patient was asked to perform the Jendrassic 
maneuver (i.e. hooking the fingers together and pulling) or clenching the 
jaw. Reflexes elicited with the Jendrassic maneuver or jaw clenching alone 
were designed "present with reinforcement" (1). If the reflex was absent, 
even in the face of the reinforcement maneuver, the reflex was considered 
absent (2).              
II-Electrophysiology (Nerve Conduction Study) 
The MDNS included non invasive nerve conduction measurements for 
sural, peroneal motor, median sensory and motor, and ulnar sensory  
Nerve conduction studies were done for each patient using Medelec Saphire 
II, by Medelec Vickers Medical WOKING, SURREY, ENGLAND. 1996.  
 Sural, peroneal motor, median sensory and motor, and ulnar sensory was 
graded separately:  
. Normal values ------------------- (0)  
. Abnormal values ---------------- (1) 
Each patient is then given a composite score based on the number of 
abnormal nerve conduction and number of points scored on the clinical 
examination. 
For example, if a patient had abnormal conduction in 2 nerves and 12 points 
on the clinical examination, he would have received a score of 2.12. 
We have devised a staging system for diabetic neuropathy based on the 
patient's composite MDNS (Table E).  
• Stage 0 or no neuropathy is defined by   abnormal conduction in no 
more than 1 nerve                                             
• Stage 1 or mild neuropathy is defined by   abnormal conduction in 2 
nerves                                                          
•  Stage 2 or moderate neuropathy is defined by abnormal conduction in 
3 or 4 nerves 
• Stage 3 or severe neuropathy is defined by abnormal conduction in all 
5 nerves     
     Within each stage, the severity of neuropathy is further quantitated by the 
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patient's clinical score, which can range from 0 to 46 points (355).  
Electrophysiological studies objectively document the presence and severity 
of any peripheral nerve dysfunction (356). 
The motor nerve conduction study involves stimulating with supra-maximal 
intensity (20 to30 percent above stimulus intensity required to elicit a 
maximal response) (356).  
The procedure of nerves study  
The motor response was recorded from a distal muscle innervated by 
the test nerve employing the belly-tendon method (Fig.1). This involves 
placing the active recording electrode (G1; black) on the midpoint of the 
muscle belly (where the nerve endings terminate on the muscle) and the 
reference electrode (G2; white) on the tendon, with this arrangement the 
recorded response is a biphasic potential with an initial larger upward 
(negative) deflection (Fig.2). The evoked motor response is called a 
compound muscle action potential (CMAP) 
 
 
 
 
 
 
 
 
 
Fig. 1: Diagrammatic illustration of electrode placement for nerve 
conduction studies 
 
Antidromic sensory study (A); Orthodromic sensory study (B); and motor 
nerve conduction study (C). (Gı = active recording electrode; G2= reference 
recording electrode; G0 = ground electrode; S= stimulating electrode; S1= 
distal stimulation site; S2 = proximal stimulation site. Cathode is black; 
anode is white.) 
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Fig. 2: Measured parameters of a compound motor action potential 
(CMAP) 
The conduction velocity (CV) in motor fibers was calculated indirectly: 
 (m/sec)latency    distal -) (m/seclatency    Proximal
sites  gstimulatin  distal  and  proximalbetween     (mm)  distance CV(m/sec) =  
The latency, amplitude, and duration are measured as shown in (Figure2). 
Standard distances between the most distal stimulating site and the active 
recording electrode enable meaningful interpretation of distal latency 
measurements, since the latency is directly proportional to the distance. The 
recommended standard distance for median nerve was 6.5 cm, ulnar nerve 
7cm, peroneal nerve 9 cm, and sural nerve 14 cm. The distances for sensory 
median and ulnar nerves were 14 cm.    
Sensory nerve conduction studies are more sensitive than motor nerve 
conduction studies to detecting mild peripheral nerve dysfunction. 
Recording of sensory responses done by orthodromic (toward the spinal 
cord in the direction of physiologic conduction) with digital nerve 
stimulation (Fig.3).The amplification setting was 5 to 10 µV/cm     
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: Measured parameters of a sensory nerve action potential (SNAP) 
Ulnar nerve sensory conduction: 
Orthodromic conduction study was performed using surface stimulation and 
recording. 
1. Stimulation (Fig 4) 
- Placed the ring cathode near the fifth proximal interphalangeal joint. 
- Placed the ring anode around the fifth distal interphalangeal joint.  
2. Ground is placed on the dorsum of the hand.  
3. Recording electrode placement: G1 end of the bare electrode is placed 10 
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to 14cm proximal to the ring cathode over the ulnar nerve near the proximal 
wrist crease. 
 
 
 
 
 
 
 
 
Fig. 4: Electrode placement for orthodromic recording of ulnar nerve 
sensory responses. 
 
Similar procedure was performed for median nerve sensory conduction. 
 
 Sural nerve sensory conduction: 
Antidromic sensory 
1. Recording electrode placement 
- The G1 electrode placed behind the lateral malleolus (Fig. 
5). 
- The G2 electrode 3 cm distal to the G1 electrode. 
2. Ground: placed close to the recording electrode. 
3. Stimulated with the cathode located in the midcalf, 14cm proximal to 
the G1 recording electrode (Fig.6).  
 
Antidromal conduction study was performed using surface stimulation and 
recording electrode 
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Fig. 5: Recording   electrode placement for the sural nerve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: Stimulating electrode placement for the sural nerve in midcalf. 
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Peroneal nerve motor conduction 
Procedure 
   1. Recording electrode placement (Fig.7). 
      a. G1 recording electrode was placed over the extensor digitorum brevis 
muscle 
      b. G2 recording electrode over the fifth toe 
2. Ground was placed close to the recording electrodes 
3. Stimulation 
      a. Dorsal aspect of distal lower leg between the tendons of tibialis 
anterior (medially) and the extensor hallucis (laterally), 9 cm proximal to the 
active recording electrode (Fig. 7) 
       b. 3 to 4 cm distal to the proximal tip of the fibula head (Fig. 8) 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: Electrode placement for recording from the extensor digitorum 
brevis and distal stimulation of the deep peroneal nerve. 
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Fig. 8: Stimulation of the peroneal nerve just distal to the fibular head. 
Median nerve motor study. 
Procedure 
1. Recording electrode placement (Fig. 9) 
      a. G1 was placed over the abductor pollicis brevis. 
      b. G2 was placed over proximal phalanx of the thumb. 
2. Ground was placed over the dorsum of the hand. 
3. Stimulation 
      a. Midwrist: palmar aspect, between the tendons of the flexor 
carpiradialis (laterally) and palmaris longus (medially), with the cathode 
6.5cm proximal to G1 (Fig. 9) 
      b. Elbow: just medial to the palpable brachial artery (Fig. 10) 
 
Fig. 9: Electrode placement for recording from the abductor pollicis 
brevis and stimulation of the median nerve at the wrist. 
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Fig. 10: Stimulation of the median nerve in the antecubital fossa. 
 
 
Sensory and motor evoked amplitudes, distal latencies and conduction 
velocities are measured maintaining the lower extremity at 30°C and the 
upper extremity at 32°C. We don’t have normal standard measurement of 
NCV study for Yemeni people, so we used the normal values as shown in 
(Table F). 
D- Laboratory investigations: 
• Fasting blood glucose using a photometer with calibration.  
Patient is asked to come fasting for at least 8 hours, and venous blood 
is drawn. The criteria for Diabetes Mellitus as recommended for field 
studies by the American Diabetes Association (The Expert Committee 
on the Diagnosis and Classification of Diabetes Mellitus 1997) and 
considered by WHO (Alberti KGMM & Zimmet PZ 1998) was used, 
were a blood glucose of more than or equal 7 mmol was considered 
diabetic (Referred to in our study as raised blood glucose as opposed to 
normal blood glucose).  
• 2h. Post prandial blood sugar test two hours after 75 gram oral 
glucose load. 
• HbA1c %. 
Glycohemoglobin is formed progressively and irreversibly in the erythrocyte 
during its 120 days life. The red cell glycohemoglobin concentration is 
depend on the average of blood glucose concentration over a period of 
weeks, and is stable for the life of cell. Therefore, measurement of 
glycohemoglobin (HbA1c), as percent of total hemoglobin, provides a 
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valuable method for assessing the long term control of diabetics respond to 
treatment. 
An excellent correlation between HbA1c concentration and diabetic control 
has reported. They concluded that the determination of HbA1c, rather than 
HbA1c (a fraction of HbA1c) could be used for clinical purposes (357) 
NycoCard® HbA1c by: 
AXIS-SHIELD PoC AS 
N-0504 Oslo, Norway 
PRODUCT DESCRIPTION 
Intended use  
NycoCard® HbA1c is a rapid in vitro test for the measurement of glycated 
haemoglobin in human blood  
Test principle 
NycoCard® HbA1c is a boronate affinity assay. The kid contains test 
devices with a porous membrane filter, test tubes pre-filled with reagent and 
a washing solution. The reagent contains agents that lyse erythrocytes and 
precipitate haemoglobin specially, as well as a blue boronic acid conjugate 
that binds cis-diols of glycated haemoglobin.  
When blood is added to the reagent, the erythrocytes immediately lyse. All 
haemoglobin precipitates. The boronic acid conjugate binds to the cis-diol 
configuration of glycate haemoglobin. 
An aliquot of the reaction mixture is added to the test device, and all the 
precipitated haemoglobin, conjugate-bound and unbound, remains on top of 
the filter. Any excess of colored conjugate is removed with the washing 
solution. 
The precipitate is evaluated by measuring the blue (glycated haemoglobin) 
and the red (total haemoglobin) color intensity with the NycoCard® 
READERII, the ratio between them being proportional to the percentage of 
HbA1c in the sample.    
Materials required 
. Capillary tube or pipette (5 µL) for sampling 
. Pipette (25 µL) and pipette tips for the application of reaction mixture and 
R2/Washing Solution. 
. NycoCard READER II for measurement of the test result. 
Analytical specificity 
 NycoCard HbA1c measures the total glycated haemoglobin (GHb), but 
reports a standardized HbA1c value. 
TEST PROCEDURE 
Capillary blood and venous blood with or without anticoagulant (EDTA, 
heparin and NaF) can be used. 
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1. Precipitation of haemoglobin 
 Add 5 µL whole blood to the test tube pre-field with R1/Reagent.Mix well. 
Leave the tube for minimum 2 minutes, maximum 3 minutes. 
Note! Equilibrate the R1/Reagent to room temperature (20-25 ºС) before 
use. 
2. Application of sample 
 Remix to obtain a homogenous suspension. Apply 25 µL of the reaction 
mixture to a TD/Test Device by holding the pipette approx. 0.5 cm above 
the test well. Empty the pipette quickly in the middle of the test well. 
Allow the reaction mixture to soak completely into the membrane 
(approx. 10 seconds). 
3. Application of R2/Washing Solution 
Apply 25 µL R2/Washing Solution to the TD/Test Device. Allow the 
washing solution to soak completely into the membrane. Wait for 
minimum 10 seconds. 
4. Test result measurement 
Read the test result within 5 minutes using NycoCard READER II.   
Expected values: 
       Satisfactory                            < 8% 
       Unsatisfactory                        8.0-9.0% 
       Poor control                            >9.0% 
• Total cholesterol. 
• HDL-C 
• LDL-C 
• Triglyceride 
• Uric acid 
• Serum creatinine 
• Urinary Albumin/creatinine Ratio: (mg/g) 
                  =   
  Measurement of urine protein concentration by 
ALCYON 300 
ABBOTT Laboratories 
Abbott Park 
IL 60064 USA 
Biosystems 
PROTEIN 
PYROGALLOL RED 
DIAGNOSTIC CHARACTERISTICS  
The glomeruli behave as ultrafilters for the plasma proteins. The degree to 
which individual protein are normally filtered through the membrane is a 
(g/L)Ex retion  CreatininUrinary 
mg/L) (Excretion Albumin Urinary 
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function of their mass and charge, as well as of their plasma concentration.  
Increased concentration of protein in urine ( proteinuria) can occur due to 
hemorrhage, increased glomerular permeability, defective tubular 
reabsorption, increased concentration in the plasma of abnormal low-
molecular-weight protein (such as immunoglobulin light chains), and 
abnormal secretion of protein into the urinary tract (358, 359). 
. PRINCIPLE OF THE METHOD 
Protein in the sample reacts with pyrogallol red and molybdate in acid 
medium forming a colored complex which can be measured by 
spectrophotometery (360, 361) 
. COMPOSITION 
A. Reagent. Pyrogallol red 60 µmol/L, sodium molybdate 40 µmol/L, 
succinate 50 mmol/L, PH 2.3, detergent. 
S. Protein (Urine) Standard. Bovine albumin. Concentration is given on 
the label. Concentration value is traceable to the Standard Reference 
Material 927 (National Institute of Standards and Technology, USA). 
KOWELL  
USA  
- Analyzer, spectrophotometer or photometer able to read at 600 ± 10 nm 
SAMPLES 
Urine collected by standard procedures.  Collect a 24-hour urine specimen, 
measure the volume and store at 2-8ºС. Stable for 8 days 
PROCEDURE 
1. Pipette into labeled test tubes  
Black               Standard                 Sample 
    Distilled water            20 µL                     ----                      -----        
    Protein (Urine)     -----                      20µL                    ---- 
    Sample                   ----                        -----                     20µL 
     Reagent (A)            1.0 ml                   1.0 ml                  1.0 ml 
2. Mix thoroughly and incubate for 10 minutes at 37ºС. 
3. Read the absorbance (A) of the Standard and the Sample at 600 nm 
against the Blank. The color is stable 30 minutes. 
CALCULATIONS 
The protein concentration in the sample is calculated using the following 
general formula: 
protein)(mg/24h  Sample C volume(L)urineh  24 (mg/L)X Standard C
StandardA 
 SampleA =x  
Measurement of urine and serum creatinine concentration by 
ALCYON 300 
ABBOTT Laboratories 
Abbott Park 
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IL 60064 USA 
CREATININE liquicolor 
Jaffé Reaction 
Photometric Colorimetric Test for Endpoint Measurement of Creatinine, 
Method with Deproteinisation 
Methods (362, 363) 
Creatinine forms in alkaline solution an orange-red colored complex with 
picric acid. The absorbance of this complex is proportional to the creatinine 
concentration in the sample. 
Principle  
Creatinine +Picric acid     ?  Creatinine-picrate complex 
Reagent Preparation 
Mix PIC and NaOH in the ratio 1+1 
STD is ready for use. 
Specimen 
Serum, heparinised plasma or urine 
Stability: 24 hours at 2…8ºС 
Dilute urine 1 + 49 with dist. water. 
Deproteinisation/Dilution 
Use trichloroacetic acid (1.2 mol/l) as deproteinising solution  
Calculation 
1. Serum/plasma 
dlmg
STD
samplesC /*0.2 ∆Α
∆Α=  
2. Urine 
dlmg
STD
samplesC /*100 ∆Α
∆Α=  
Creatinine concentration in 24 h urine: 
c = mg/dl x ml urine/24 h x 0.01 {mg/24 h} 
   1440 x serum /dlcreatinine mg
h urine/24 ml x urine /dlcreatinine mgClearance Creatinine =  {ml/min} 
Reference Values (362, 363) 
Serum                                                     µmol/l 
Men                                                         53-97 
Women                                                    44-80 
Urine                                            1000-1500 mg/24 hours 
 
E- ECG done for each patient to detect ischemic heart diseases. 
Echocardiogram for some patients by cardiologist to detect and confirm the 
diagnosis of IHD 
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F- Skull CT. scan done by an independent expert radiologist for some 
patients if there was suspicious of stroke.  
G-Vascular Doppler Study done by Multi DOPPLE® II. Manufactured by: 
Hunt Leigh Healthcare Ltd., Diagnostic Products Division 35 Portman moor 
Road Cardiff CF24 5HN UK, to detect the presence of peripheral arteries 
occlusion diseases 
H- Fundus examination by using direct ophthalmoscopy. This test was done 
by ophthalmologist for all patients to detect retinopathy and its degree 
The most commonly used being handheld ophthalmoscope designed for 
direct magnified (14×) view. The source of illumination is projected by 
means of a mirror or prism coinciding with the observer's line of vision 
through the aperture.   
 
 
 
 
Statistical Methods 
 The data was processed and analyzed by SPSS (Statistical 
Package for Social Science, Ver. 13)  
Data analysis used: 
 a) Descriptive statistics: such as mean SD, Percentage (%), etc.  
b) Analytic statistics: The statistical tests used in this thesis are: 
 1- t-test for continuous variable  
2- χ2 –test (chi-square) for categorical variables  
3 - 95% Confidence Interval for Mean. 
5 - Odds Ratio-test also done. 
  Epi-Info version 6 statistical package WHO program 2002, used 
to test the difference between males and females patients                                
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Multivariate and univariate analysis was done to examine the 
risk factors of diabetic Polyneuropathy in type 2 diabetes 
mellitus Yemeni patients 
Significance was considered when P-value in just<0.05. 
p=0.000→ highly significant. 
P=less than 0.05→ significant. 
P=more than 0.05→ non significant. 
Michigan Diabetic Neuropathy Score (MDNS) and nerve 
conduction assessments to confirm the diagnosis of diabetic 
neuropathy and determine its stages 
Statistical analysis for prevalence of diabetic polyneuropathy 
and its risk factors in type 2 diabetes mellitus including clinical 
examination results and the relation to age group, sex, 
hyperglycemia, total cholesterol, HDL, LDL, triglyceride, 
duration of diabetes mellitus results, qat, and smoking.  
The prevalence was expressed as percentage of total in type 2 
diabetes mellitus. 
 
100x 
   studies diabetes 2  typeTotal
Neuropathy Diabetic  
Statistical analysis for stages of diabetic polyneuropathy 
including clinical examination results and nerve conduction 
studies results. 
Association of risk factors of diabetic polyneuropathy were 
tested by using clinical examination results and laboratory test 
results  
Statistically analysis for signs and symptoms of diabetic 
polyneuropathy were tested by using clinical examination 
results and the history of diabetic Polyneuropathy results 
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Results 
This study includes 155 patients presented to a diabetic center 
in Sana'a Yemen with type 2 diabetes mellitus  
Demographic data (Table 1) 
Clinical data of patients 
Age and sex of type 2 diabetic patients  
Age and sex distribution are shown on (table 1). Among 
diabetic patients type 2 there were 76 males 49.0% and 79 
females 51.0% (Fig. 1) 
Diabetic patients type 2 show value of age range between 28-
88 years with a mean of 55.81±0.862 years. The mean age for 
males was 57.33±1.31, and the mean age for females was 
54.32±1.11. The 95%CI for males (54.72-59.93), higher than for 
females (52.12-56.53), with no significant difference between 
them (Table 1)  
The majority of type 2 diabetic patients were above the 45 
years old,  33.5% patients were between 45-54 years, 29.7% 
between 55-64 years, and 25.25% above 65 years old. The lesser 
group in, age less than 45 years, were 11.6 % (Fig 2).Figure 3 
shown that females were affected equally in the age below 45 
years, but females were affected more in the age group 45-55, 
while males were affected more above the age of 55 years ( 
Fig. 3).      
Duration of diabetes mellitus in type 2 diabetic patients (table 
1) 
Diabetes mellitus duration of type 2 Yemeni patients rang from 
1-33 years with a mean of 10.43±0.59 years, (11.35±.98 years for 
males, and 9.57±.67) years for females) with no significant 
difference between them. The 95% CI for males (9.39-13.31) 
was higher than for females (8.23-10.91).  
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Biochemical findings in type 2 diabetic patients (table 1)             
    
. The fasting blood glucose was range from 3.00-25.00mmol/l. 
The mean fasting blood glucose for all type 2 diabetic patients 
was 10.05±.34 mmol/l, (10.35±.51 mmol/l was for male, and 
9.83±.48 mmol/l was for female), with no significant difference.  
. The 2 hours Postprandial blood glucose of the diabetic 
patients was range from 4.00-66.60mmol/l, with mean of 
16.62±.56 mmol/l. The mean 2hPBG for males was 17.20±.94 
mmol/l and 16.24±.64mmol/l for females, with no significant 
difference.        
. The HbA1c% of diabetic patients ranged from 6-14% with 
mean of 8.93±.13%. The mean of males was 8.96±.19% and 
8.90±.18% for females with no significant difference.  
. The total cholesterol of type 2 diabetic patients ranged from 
2.50-10.00 mmol/l, with mean of 5.11±.10 mmol/l. The mean for 
males was 4.78±.12 mmol/l, and 5.42±.14 mmol/l for females, 
with a highly significant difference between males and females 
(p=0.001). 
. High density lipid of type 2 diabetic patients ranged from .50-
2.20 mmol/l, with mean of 1.05±.02mmol/l. The mean for males 
was 1.01±.02 mmol/l, and 1.09±.02 mmol/l for females, with a 
highly significant difference between both sexes (p=0.006).  
. Low density lipid of the diabetic patients ranged from 0.5-
8.00mmol/l. with mean of 3.26±.09 mmol/l. The mean for males 
was 3.04±.11mmol/l, and was 3.44±.14 mmol/l for females. The 
95% CI of males was 2.82-3.26, while for females was 3.16-
3.72.The test shows significant difference between the two 
sexes (p=0.018). 
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.Triglyceride of these diabetic patients ranged from .50-6.00 
mmol/l with mean of 1.92±.09 mmol/l. The mean for males was 
1.77±.12 mmol/l, and 2.05±.13 mmol/l for female. The test 
showed no significant difference. 
.The creatinine serum level of these diabetic patients ranged 
from 39.00-356.00µmol/l, with mean of 95.86±2.77 µmol/l. The 
mean for males was 100.31±2.14 µmol/l, and 92.07±5.12 µmol/l 
for females. No significant difference between males and 
females.   
Family history of type 2 diabetic patients  
Family history of diabetes mellitus was positive in 85 diabetic 
patients represent 54.8% of diabetic type 2 patients, (41 males 
patients represent 53.9% and 44 females patients represent 
55.7%), with no significant difference.   
Chronic complications of type 2 diabetes mellitus (Fig4,Table 2) 
The coexistence of type 2 diabetes mellitus, peripheral arteries 
occlusion disease, ischemic heart disease, diseases of the 
kidney and the eye, hypertension, stroke and polyneuropathy 
in this study is shown in Table 2, and Fig 4.  
1-polyneuropathy  
Diabetic polyneuropathy occurred in 100 patients with type 2 
diabetes mellitus, representing 64.50 %. 55 of them were males 
(72.37% of total males), and 45 were females (56.96 % of total 
females). The test shows significant difference between the two 
sexes (p=0.045) (Table 2, Fig. 5). 
According to Michigan Diabetic Neuropathy Score, diabetic 
polyneuropathy staged to mild polyneuropathy were 40 
patients 40.0% (20 were males 36.4%, and 20 were females 
44.4%), moderate polyneuropathy were 35 patients 35.0% (22 
were males 40.0%, and 13 were females 28.9%), and 25 patients 
25.0% (13 were males 23.6%, and 12 were females 26.7%), were 
with severe polyneuropathy (Table: 3).The test shown no 
significant difference. 
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2-Hypertension       
In the same Table 2, hypertension was found in 61 diabetic 
patients 39.40%, 22 patients were males (28.95%), and 39 
patients were females (49.37%), with significant difference 
between males and females as shown in the Table 2 (P=0.009). 
                             
3-Ischemic heart diseases   
    Ischemic heart diseases occurred in 47 diabetic patients 
30.30%, 
29 patients were males38.16%, and 18 were females 22.78%. 
The test indicate significant difference between the two sexes 
as shown in Table 2 (P=0.037). 
4-Stroke 
Stroke was fount in 8 patients with diabetes mellitus 5.20 %, 7 
patients were males 9.21%, and 1 patient was female 1.27%. 
There is significant difference between males and females as 
seen in Table 2 (P=0.025). 
5-Peripheral arteries occlusion disease (PAOD) 
In table 2: Peripheral arterial diseases found in 19 diabetic 
patients 12.30%, 13 patients were males 17.11%, and 6 patients 
were females 7.59%. 
6-Retinopathy 
 Retinopathy was found in 62 diabetic patients 40.0 %of total 
patients with diabetes mellitus, 33 patients were males 43.42% 
and 29 patients were females 36.71%                                              
                                       
7-Nephropathy (SVDK) 
Nephropathy was found in 49 of type 2 diabetes mellitus 
patients, represent 31.60%, 20 patients 26.30% were males and 
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29 patients 36.70% were females, with no significant difference 
between males and females. 
  
 
 
 
 
  Risk factors of diabetic polyneuropathy prevalence 
and their stages  
• Age 
       The mean age for patients with diabetic polyneuropathy 
was 58.01±1.05years, while for diabetic patients without 
polyneuropathy was 51.80±1.35years.The figure indicate a 
highly significant difference between the two groups (Fig. 6)  
Table 4, 5 showed that most of diabetic polyneuropathy 
occurred in older age. The peak age was found above the 
age of 55 years, where we found 32 patients 69.6% (15 patients 
46.9% mild, 10 patients 31.3% moderate and 7 patients 21.9% 
severe) in between  55-64years and 32 patients 82.1% (7 
patients 21.9% mild, 12 patients 37.5% moderate, and 13 
patients 40.6% severe) ≥ 65 years old.  
The low figures were found in the age group (<45years), and 
(45-54years), accounted for 8 patients 44.4% (5 patients 62.5% 
mild, 2 patients 25.0% moderate, and 1 patient 12.5% severe), 
and 28 patients 53.8% (13 patients46.4% mild, 11 patients 39.3% 
moderate, and 4 patients 14.3% severe), respectively. This study 
shown increase the prevalence of diabetic polyneuropathy 
and its severity stages with increase the age of the patients 
(p=0.009, p=0.005). 
• Sex 
Diabetic polyneuropathy occurred in 100 type 2 diabetic 
patients represent 64.5%.were 55 of them males 72.4%(20 
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patients mild, 22 patients moderate, 13 patients severe), and 45 
were females 57.0 % (2o patients mild, 13 patients moderate, 12 
patients severe). This study shows   significantly higher 
prevalence of diabetic polyneuropathy in males more than 
females. (p=0.045)(Table 3, 6)( Fig. 7).  
 
 
• Duration of DM      
The majority of diabetic polyneuropathy occurred with long 
duration of diabetes mellitus. The peak was found in 54 patients 
representing 83.1% diabetic patients with duration of diabetes 
mellitus more than 10 years (15 patients 27.8% mild, 22 patients 
40.7% moderate, and 17 patients 31.5% severe), and 33 
patients represent 61.1% found in diabetic patients with 
duration of diabetes mellitus between 5-10years (15 patients 
45.5% mild, 12 patients 36.4% moderate, and 6 patients 18.2% 
severe). The low figures were found in low duration of diabetes 
mellitus <5%, accounted for 13 patients 36.1% (10 patients 76.9% 
mild, 1 patient 7.7% moderate, and 2 patients 15.4% severe), 
where the peak duration of diabetic patients without 
polyneuropathy found in less than 5 years duration of  the 
diabetes mellitus. The study shows a significant increase in the 
prevalence and severity stages of diabetic polyneuropathy 
with increase in the duration of diabetes mellitus (p=0.000, 
p=0.004)(Table 7, 8). 
• Hyperglycemia: 
-Fasting blood glucose 
 Most of diabetic polyneuropathy 43 patients 76.8% had fasting 
blood glucose > 10 mmol/l (16 patients 37.2% mild, 17 patients 
39.5% moderate, and 10 patients 23.3% severe), 29 patients 
63.0% had blood  
glucose between 8-10 mmol/l (12 patients 41.4% mild, 11 
patients 37.9% moderate, and 6 patients 20.7% severe), and 28 
patients 52.8% had FBG < 8 mmol/l (12 patients 42.9% mild, 7 
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patients 25.0% moderate, and 9 patients 32.1% severe).This 
study shows a significant increase in the prevalence of diabetic 
polyneuropathy with the increase of the fasting blood glucose 
concentration where p=value was 0.032 (Table 9, 10). 
 
 
-HbA1c % 
About HbA1c percent, the most of diabetic polyneuropathy 
patients (47 patients) represent 78.3% occurred in poor 
controlled group (>9% HbAIc), (18 patients 38.3% mild, 17 
patients 36.2% moderate, and 12 patients 25.5% severe) and 8-
9% HbA1c group was 32 patients represent 61.5% (14 patients 
43.8% mild, 11 patients 34.4% moderate, and 7 patients 21.9% 
severe). The low figure was found in good controlled group 
(<8% HbA1c), 21 patients represent 50.0% (8 patients 38.1% 
mild, 7 patient 33.3% moderate, and 6 patients 28.6% severe). 
Our study shows significant increase in the prevalence of 
diabetic polyneuropathy with the increase in HbA1c percent 
(p=0.01) (Table 11, 12). 
- 2 h. Postprandial blood glucose  
  In Patients with diabetic polyneuropathy we found 97 patients 
(65.5%) 
have abnormal postprandial blood glucose (≥7.8 mmol/l), (40 
patients 41.2% mild, 33 patients 34.0%  moderate , and 24 
patients 24.7% severe), while only 2 patients have normal PPBG 
(Table 13, 14). 
• Retinopathy (Fig. 8) 
Small vessel disease of the eye was present in 62 diabetic 
patients, 54 patients (87.1%), having diabetic polyneuropathy 
(13 patients 24.1% mild, 22 patients 40.7% moderate, and 19 
patients  35.2% severe), while 8 patients 12.9% were having no 
DPN. The study shows significantly association of retinopathy 
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with diabetic polyneuropathy and associated with its severity 
stages (p=0.000, p=0.001)(Table 15, 16).  
• Nephropathy (Fig. 8) 
Nephropathy was found in 49 of type 2 diabetes mellitus 
patients, 38 patients with diabetic polyneuropathy 77.6% of 
total patients affected, where 11 patients 28.9% were mild, 11 
patients 28.9% were moderate, and 16 patients 42.1% were 
severe diabetic polyneuropathy. The test shows a significant 
association of nephropathy and diabetic polyneuropathy with 
its severity stages (p=0.021, p=0.008)(Table 17, 18).  
• Hypertension (Fig. 8) 
Blood pressure was high in 61 diabetic patients, 44 patients 
(72.1%) had diabetic polyneuropathy (18 patients 40.9% mild, 
14 patients 31.8% moderate, and 12 patients 27.3% severe) 
while 17 patients were with no DPN. There is association 
between hypertension and diabetic polyneuropathy, but not 
significant (Table 19, 20). 
• IHD (Fig. 8) 
Ischemic heart disease was present in 47 diabetic patients, 35 
patients 74.5%, were with polyneuropathy (16 patients 45.7% 
mild, 14 patients 40.0% moderate, and 5 patients 14.3% severe), 
and 12 diabetic patients 25.5%, were without polyneuropathy 
There is association between ischemic heart disease and 
diabetic polyneuropathy, but not significant (Table 21, 22).              
         
• STROKE (Fig. 8) 
 Stroke was present in 8 diabetic patients, 7 patients 87.5% were 
with diabetic polyneuropathy (3 patients 42.9% mild, 3 patients 
42.9% moderate and 1 patient 14.3% severe), and only one 
diabetic patient 12.5% was without PN. No significant 
correlation with diabetic polyneuropathy (Table 23, 24).  
• PAOD (Fig. 8) 
   Peripheral arteries occlusive disease was present in 19 
diabetic patients, 17 patient 89.5% with diabetic 
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polyneuropathy (2 patients 11.8% mild, 5 patients 29.4% 
moderate, 10 patients 58.8% severe), and 2 patients without DP. 
There was significant correlation between the prevalence of 
diabetic polyneuropathy and its severity stages with the 
presence of PAOD (p=0.014, p=0.001)(Table 25, 26). 
 
• Hyperlipidemia: 
- Total cholesterol 
  Total cholesterol was high in 17 diabetic patients, 11 
patients with diabetic polyneuropathy 64.7% (3 patients 27.3% 
mild, 3 patients 27.3% moderate, and 5 patients 45.5% severe), 
while 6 patients 35.3% without diabetic polyneuropathy were 
having increase in total cholesterol(Table 27, 28)   
- HDL 
High density lipid concentration was abnormal in 1 patient  had 
severe diabetic polyneuropathy, while it was normal in all 
patients without diabetic polyneuropathy (Table 29, 30).  
- LDL 
Low density lipid concentration was abnormal in 10 diabetic 
patients, 7 patients (72.7%) with diabetic polyneuropathy (4 
patients 50.0% mild, 1 patients 14.3% moderate, and 2 patients 
28.6% severe), while 3 patients (30.0%), were without 
polyneuropathy (Table 31,32). 
- Triglyceride 
 Triglyceride concentration was abnormal in 84 diabetic 
patients, 50 patients with diabetic polyneuropathy 59.5%(19 
patients 38.0% mild, 20 patients 40.0% moderate, and 11 
patients 22.0% severe), and was abnormal in 34 patients (40.5%) 
without diabetic polyneuropathy(Table 33,34) 
• Current smoking cigarette (Fig. 9) 
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Diabetic patients who were smoking   counted 37 patients 
23.9% (males and females), 24 patients 64.9% were with 
diabetic polyneuropathy (11 patients 45.8% mild, 10 patients 
41.7% moderate, and 3 patients 12.5% severe) while 13 smoking 
diabetic patients 35.1% were without diabetic polyneuropathy 
(Table 35, 36). 
 
 
• Current chewing qat (Fig. 10) 
Diabetic patients who were chewing qat were 123 diabetic 
patients, 74 patients 60.2% with diabetic polyneuropathy ( 30 
patients 40.5% mild, 24 patients 32.4% moderate, and 20 
patients 27.0% severe) while 49 patients 39.8% without diabetic 
polyneuropathy (Table 37,38). This study shows significant 
increase the prevalence of diabetic polyneuropathy in patients 
chewing qat, which may indicate the relation between qat 
chewing and the prevalence of diabetic polyneuropathy.  
Family history of DM  
Diabetic patients who had positive family history were 85 
patients, 60 patients 70.6% with DPNP, have positive family 
history of DM, (25 patients were mild 41.7%, 21 patients were 
moderate 35.0%, 14 patients were severe 23.3%), while 25 
patients 29.4% have positive family history without diabetic 
polyneuropathy (Table 39,40). P-value was 0.05  
 
 The univariate test (Table 41) shown that age, sex, duration of 
DM, PAOD, SVDE, SVDK, qat chewing, and FBG, were the 
significant risk factors of diabetic polyneuropathy, while the 
multivariate test (Table 42), shown that, sex, duration of DM, SVDE, qat 
chewing, FBG, and HbA1c were significant risk factors of diabetic 
polyneuropathy.                             
Symptoms of Patients with DPN (Table 43)                           
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1- Numbness sensation was found in 81 of diabetic 
polyneuropathy patients 81.0%, while in 28 patients without 
diabetic polyneuropathy, which indicate increased 
significantly in the diabetic polyneuropathy patients (p=000). 
2- Burning sensation was found in 74 of diabetic 
polyneuropathy patients 74.0%, while present in 37 of 
patients without diabetic polyneuropathy. 
3- Prickling sensation was found in 76 of diabetic 
polyneuropathy patients 76.0%, while present only in 32 
patients without diabetic polyneuropathy. The test shown 
significant increased of prickling sensation in diabetic 
polyneuropathy patients (p=021). 
4- Cramp was found in 40 patients of diabetic 
polyneuropathy 40.0%  
5- Sensitivity to touch 
57 of diabetic polyneuropathy patients (57.0%) had sensitivity to 
touch 
6- Open sore foot:  
24 patients (24.0%) with diabetic polyneuropathy had open 
sore foot 
7- Weak all over most of time: 
The majority of diabetic polyneuropathy were feeling of 
weakness all over most of the time, 83 patients (83.0%).The test 
indicated significant increased the feeling of weak over most of 
time in diabetic polyneuropathy (p=0.045). 
8- Worseness of symptoms at night: 
The majority of diabetic polyneuropathy patients were 
complaining of worseness of symptoms at night were 73 
patients (73.0%). 
9- Dry skin 
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38 patients (38.0%) with diabetic polyneuropathy were feeling 
of so dry skin on the feet,   
10- The ability to sense the feet when walking: 
The majority of diabetic polyneuropathy patients were having 
the ability to sense the feet when walking, 89 patients (89.0%). 
Only 11 diabetic polyneuropathy (11.0%) were unable to sense 
the feet when walking. 
11- Amputation: 
Amputation was present in 3 diabetic polyneuropathy patients 
(3.0%).  
 
 
 
Neurological signs of diabetic polyneuropathy patients (Table 
44) 
• Appearance of feet: 
 67 of diabetic polyneuropathy patients (67.0%) were with 
abnormal feet appearance. The table shows highly significant 
increased the abnormal appearance of feet in diabetic 
polyneuropathy patients (p=0.000).  
• Ulceration: 
Only 3 diabetic polyneuropathy patients have feet ulceration. 
• Vibration: 
The vibration test showed that diabetic polyneuropathy 
patients have abnormal vibration test were 98 (98.0%), (70 
patients70.0% have absent vibration test, and 28 patients 28.0% 
have decreases in vibration test). The table showed highly 
significantly increased the abnormal vibration test in diabetic 
polyneuropathy in compare with no diabetic polyneuropathy 
patients (p=0.000). 
• 10 g filament 
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The 10 g Filament test showed that it was absent in 21 diabetic 
polyneuropathy patients 21.0%, and decreased in 24 diabetic 
polyneuropathy patients 24.0%, which also significantly 
increased in diabetic polyneuropathy patients (p=0.000).  
• Pin prick sensation on great toe: 
This test showed that 60 of diabetic polyneuropathy patients 
60.0% have not painful sensation when examined by pin prick 
on great toe, which indicate highly significant increased in 
diabetic polyneuropathy patients (p=0.000).     
• Toes spread: 
The test showed that 47of diabetic polyneuropathy patients 
47.0% have weakness in toes spread; most of them had mild to 
moderate weakness, while only 4 patients with no diabetic 
polyneuropathy had weakness. There were significant 
difference between the two groups (P=0.000). 
• Great toe extension: 
The test showed that 28 diabetic polyneuropathy patients 
28.0% had weakness in great toe extension. Only 3 patients with 
no diabetic polyneuropathy had weakness. There were 
significant difference between the two groups (P=0.000). 
• Ankle dorsiflexion: 
The test showed that 10 patients with diabetic polyneuropathy 
had weakness (10.0%). Most of them had mild to moderate 
weakness, while only one patient with no diabetic 
polyneuropathy had weakness. There were no significant 
difference between the two groups (P=0.051). 
In this study, distal weakness of lower limbs occurred in diabetic 
polyneuropathy patients. Most of the weakness was when 
patient tried to spread the fingers of the feet, rather than 
extension the great toe, and to less extend when doing ankle 
dorsiflexion. In general the weakness was significantly more in 
diabetic polyneuropathy patients as compared with non 
diabetic polyneuropathy patients. 
• Reflexes:   
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- Biceps brachii reflex in diabetic polyneuropathy patients was 
absent in 12 patients (12.0%), while absent only in 2 patients 
without diabetic polyneuropathy.There is significant difference 
between the two groups (p=0.007). 
 - Triceps brachii reflex in diabetic polyneuropathy was absent 
in 14 presents (14.0%), while absent only in 4 patients without 
diabetic polyneuropathy. No significant difference. 
 - Quadriceps reflex in diabetic polyneuropathy was absent in 
34 patients (34.0%), while absent in 7 patients without diabetic 
polyneuropathy. There is significant difference between the 
two groups (p=0.000). 
 - Ankle reflex in diabetic polyneuropathy was absent in 60 
patients (60.0%), while absent in 13 patients without diabetic 
polyneuropathy. It was highly significant more in diabetic 
polyneuropathy patients as compared with non diabetic 
polyneuropathy patients (p=0.000). 
Nerve conduction study: (Table 45) 
.The test showed normal sensory nerve conduction of median 
nerve in 50 patients (50.0%), and abnormal in 50 patients 
(50.0%) having diabetic polyneuropathy. The table shows 
significant different between the two gpoups (p=0.000). 
.The test shows normal motor nerve conduction of median 
nerve in 54 patients (54.0%), and abnormal in 46 patients 
(46.0%) having diabetic polyneuropathy. This indicate 
significant difference between the two groups (p=0.000). 
.The sensory nerve conduction of ulnar nerve was normal in 50 
patients (50.0%), and abnormal in 50 patients (50.0%) had 
diabetic polyneuropathy. The study shown significant 
difference between the two groups (p=0.000). 
.The motor nerve conduction of peroneal nerve was normal in 6 
patients (6.0%), and abnormal in 94 patients (94.0%) had 
diabetic polyneuropathy. The table shows highly increased 
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incidence of motor nerve conduction abnormalities of 
peroneal nerve in diabetic polyneuropathy patients (p=0.000). 
.The sensory nerve conduction of sural nerve was normal in 14 
patients (14.0%), and abnormal in 86 patients (86.0%) with   
diabetic polyneuropathy. The study shows also high significant 
increased incidence of sensory sural nerve abnormality in 
diabetic polyneuropathy patients (p=0.000).  
The table showed that the lower limbs were more involved in 
diabetic polyneuropathy than upper limbs. 
Table (1) Basic characteristic of study population of 
type 2 diabetic Yemeni patients    (no=155) 
 
Male(no=76) Female(no=79) 
 
Factors mean±SE 95%CI mean±SE 95%CI p-value 
Age 57.33±1.31 54.72- 59.93 54.32±1.11 52.12-56.53 0.083 
Duration 11.35±.98 9.39-13.31 9.57±.67 8.23-10.91 0.127 
FBG 10.35±.51 9.34-11.36 9.83±.48 8.88-10.78 0.397 
2hPBG 17.20±.94 15.34-19.06 16.24±.64 14.96-17.51 0.311 
HbA1c 8.96±.19 8.58-9.33 8.90±.18 8.55-9.26 0.841 
T.ch 4.78±.12 4.54-5.03 5.42±.14 5.15-5.70 0.001 
HDL 1.01±.02 0.96-1.05 1.09±.02 1.05-1.13 0.006 
LDL 3.04±.11 2.82-3.26 3.44±.14 3.16-3.72 0.018 
Trig. 1.77±.12 1.52-2.02 2.05±.13 1.79-2.32 0.120 
Creatinine 100.31±2.14 96.05-104.58 92.07±5.12 81.87-102.28 0.115 
p-value <.05 
 
 
Fig. 1: The distribution of type 2 diabetic patients 
according to sex   No=155 
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Fig. 2: The distribution of type 2 diabetic patients in 
relation to age group   no=155 
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Fig 3: The distribution of type 2 DM in relation to age 
and sex no=155 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig4: The percentage of diabetic complications in type 
2 diabetes mellitus patients no=155 
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Table 2: Complications of type 2 diabetes mellitus 
No=155 
Sex Group Total=155 
male=76 Female=79 
Variable 
 
Count Col % Count Col % 
Count Col % 
χ² 
 
P-value 
PAOD 13 17.11% 6 7.59% 19 12.30% 3.37 0.066 
SVDE 33 43.42% 29 36.71% 62 40.0% 0.73 0.394 
SVDK 20 26.30% 29 36.70% 49 31.60% 1.94 0.164 
HTN 22 28.95% 39 49.37% 61 39.40% 6.77 0.009 
STROKE 7 9.21% 1 1.27% 8 5.20% 4.99 0.025 
IHD 29 38.16% 18 22.78% 47 30.30% 4.33 0.037 
DPN 55 72.37% 45 56.96% 100 64.50% 4.02 0.045 
 
 
Fig.5: The prevalence of diabetic polyneuropathy in 
type 2 diabetic patients no=155 
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Table 3: Prevalence of diabetic polyneuropathy stages 
severity and the  relation to sex   no=100 
 
  
 
 
  male=55 female=45 Total χ² P-value 
  n % n % n % 
mild 20 36.4% 20 44.4% 40 40.0% 
moderate 22 40.0% 13 28.9% 35 35.0%  
severe 13 23.6% 12 26.7% 25 25.0% 
Group Total 55 100.00% 54 100.00% 100 100.00% 
1.368 0.505 
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Risk Factors of DPN 
 
Fig 6: The mean age of diabetic polyneuropathy 
patients as compare to the mean age of diabetic with 
no DPNP 
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Table 4: The prevalence of diabetic polyneuropathy in 
relation to age groups no=155 
 
Diabetic Polyneuropathy 
Variable 
No=55 Yes=100 Total x² Sig. 
Count 10 8 18 
< 45 
% 55.6% 44.4% 100.0% 
Age 
45 - 54 Count 24 28 52 
11.504 0.009 
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% 46.2% 53.8% 100.0% 
Count 14 32 46 
55 - 64 
% 30.4% 69.6% 100.0% 
Count 7 32 39 
65 + 
% 17.9% 82.1% 100.0% 
Count 55 100 155 
 Total 
% 35.5% 64.5% 100.0% 
 * sig.       
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Table 5: The prevalence of diabetic polyneuropathy 
severity stages in relation to age group no=100 
 
 
Diabetic polyneuropathy 
Variable 
mild=40 moderate=35 severe=25 Total=100 x² Sig. 
Count 5 2 1 8 
< 45 
% 62.5% 25.0% 12.5% 100.0% 
Count 13 11 4 28 
45 - 54 
% 46.4% 39.3% 14.3% 100.0% 
Count 15 10 7 32 
55 - 64 
% 46.9% 31.3% 21.9% 100.0% 
Count 7 12 13 32 
Age 
65 + 
% 21.9% 37.5% 40.6% 100.0% 
Count 40 35 25 100 
Total 
% 40.0% 35.0% 25.0% 100.0% 
9.905 0.005 
* sig. 
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Table 6: The prevalence of diabetic polyneuropathy in 
relation to sex        No=155 
 
Diabetic Polyneuropathy 
Variable 
No=55 Yes=100 Total x² Sig. 
Count 21 55 76 
male 
% 27.6% 72.4% 100.0% 
Count 34 45 79 
female 
% 43.0% 57.0% 100.0% 
Count 55 100 155 
Sex 
Total 
% 35.5% 64.5% 100.0% 
4.016* 0.045 
 * sig.       
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Fig.7: The distribution of diabetic polyneuropathy in 
diabetic patients according to sex 
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Table 7: The prevalence of diabetic polyneuropathy in 
relation to duration of diabetes mellitus no=155 
 
 
 
 
Diabetic Polyneuropathy 
Variable 
No=55 Yes=100 Total      x² Sig. 
Count 23 13 36 
< 5 
% 63.9% 36.1% 100.0% 
Count 21 33 54 
5 - 10 
% 38.9% 61.1% 100.0% 
Count 11 54 65 
> 10 
% 16.9% 83.1% 100.0% 
Count 55 100 155 
Duration 
of DM 
Total 
% 35.5% 64.5% 100.0% 
22.743 0.000 
* sig. 
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Table 8: The prevalence of diabetic polyneuropathy 
severity stages in relation to duration of diabetes 
mellitus no=100 
 
 
Diabetic Polyneuropathy 
Variable 
Mild 
=40 
moderate
=35 
Severe
=25 
Total x² Sig. 
Count 10 1 2 13 
< 5 
% 76.9% 7.7% 15.4% 100.0% 
Count 15 12 6 33 
Duration 
of DM 
5 - 10 
% 45.5% 36.4% 18.2% 100.0% 
11.990 0.004 
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Count 15 22 17 54 
> 10 
% 27.8% 40.7% 31.5% 100.0% 
Count 40 35 25 100 
Total 
% 40.0% 35.0% 25.0% 100.0% 
* sig. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 9: The prevalence of diabetic polyneuropathy in 
relation to fasting blood glucose serum level no=155 
 
Variable Diabetic Polyneuropathy 
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No=55 Yes=100 Total x² Sig. 
Count 25 28 53 
< 8 
% 47.2% 52.8% 100.0% 
Count 17 29 46 
8 - 10 
% 37.0% 63.0% 100.0% 
Count 13 43 56 
> 10 
% 23.2% 76.8% 100.0% 
Count 55 100 155 
FBG 
Total 
% 35.5% 64.5% 100.0% 
6.888* 0.032 
 * sig.       
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Table 10: The prevalence of diabetic polyneuropathy 
severity stages in relation to fasting blood glucose 
serum level   no=100 
 
Diabetic polyneuropathy 
 
Variable 
Mild 
=40 
Moderate 
=35 
Severe 
=25 
Total    x²    Sig. 
Count 12 7 9 28 
< 8 
% 42.9% 25.0% 32.1% 100.0% 
Count 12 11 6 29 
8 - 10 
% 41.4% 37.9% 20.7% 100.0% 
Count 16 17 10 43 
> 10 
% 37.2% 39.5% 23.3% 100.0% 
Count 40 35 25 100 
FBG 
Total 
% 40.0% 35.0% 25% 100.0% 
2.118 0.714 
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Table 11: The prevalence of diabetic polyneuropathy in 
relation to HbA1c%    no=155 
 
 
 
Diabetic Polyneuropathy 
Variable  Count 
No=55 Yes=100 Total       x² Sig. 
Count 21 21 42 Good 
 
<8% 
% 50.0% 50.0% 100.0% 
Count 20 32 52 Unsatisfactory 
 
8-9% 
% 38.5% 61.5% 100.0% 
Count 13 47 60 
 
 
 
 
 
 
HbA1c Poor 
 
>9% 
% 21.7% 78.3% 100.0% 
Count 54 100 154  Total 
% 35.1% 64.9% 100.0% 
9.108 0.011 
 * sig.       
 
Good <8% Unsatisfactory 8-9% Poor >9% 
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Table 12: The prevalence of diabetic polyneuropathy 
severity in relation to HbA1c %    no=100 
 
 
Diabetic polyneuropathy 
Variable 
Mild=40 Moderate=35 Severe=25 Total=100 x² Sig. 
Count 8 7 6 21 Good 
<8% % 38.1% 33.3% 28.6% 100.0% 
Count 14 11 7 32 Unsatisfactory 
8-9% % 43.8% 34.4% 21.9% 100.0% 
Count 18 17 12 47 Poor 
>9% % 38.3% 36.2% 25.5% 100.0% 
Count 40 35 25 100 
HbA1c 
Total 
% 40.0% 35.0% 25.0 % 100.0% 
0.442 0.979
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Table 13: The prevalence of diabetic polyneuropathy in 
relation to 2 hours postprandial blood glucose serum 
level no=155 
Diabetic Polyneuropathy 
Variable  
No=55 Yes=100 Total=155      x² Sig. 
Count 4 2 6 normal 
 
<7.8 
% 66.7% 33.3% 100.0% 
Count 51 97 148 abnormal 
 
≥7.8 
 
% 34.5% 65.5% 100.0% 
Count 55 99 154 
2hPBG 
 
Total 
% 35.7% 64.3% 100.0% 
2.605 0.107
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Table 14: The prevalence of diabetic polyneuropathy 
severity in relation to 2h postprandial blood glucose 
serum level    no=100 
Diabetic polyneuropathy 
Variable 
mild=40 moderate=35 severe=25 Total=100 x² Sig. 
Count 0 1 1 2 normal 
<7.8 
% 0.0% 50.0% 50.0% 100.0% 
Count 40 33 24 97 abnormal 
≥7.8 
 
% 41.2% 34.0% 24.7% 100.0% 
Count 40 34 25 99 
 
 
 
 
2hPBG 
Total 
%  
40.4% 34.3% 25.3% 100.0% 
1.465 
0.481 
 
 
 
 
 
 
 
Fig. 8: The association of diabetic complications with 
diabetic polyneuropathy (Risk factors) no=100 
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Table 15: The prevalence of diabetic polyneuropathy in 
relation to small vessel disease of eye no=155 
 
Diabetic Polyneuropathy 
Variable 
No=55 Yes=100 Total=155 x² Sig. 
Count 47 46 93 Negative 
% 50.5% 49.5% 100.0% 
Count 8 54 62 Positive 
% 12.9% 87.1% 100.0% 
Count 55 100 155 
 
 
 
 
SVDE 
Total 
% 
35.5% 64.5% 100.0% 
23.015* 0.000 
  * sig.             
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Table 16: The prevalence of diabetic polyneuropathy 
severity in relation to small vessels disease of the eye 
no=100 
 
Diabetic polyneuropathy 
Variable 
mild=40 moderate=35 severe=25 Total=100 x² Sig. 
Count 27 13 6 46 Negative 
%  58.7% 28.3% 13.% 100.0% 
Count 13 22 19 54 Positive 
% 24.1% 40.7% 35.2% 100.0% 
Count 40 35 25 155 
SVDE 
Total 
%  40.0% 35.0% 25.0% 100.0% 
13.420 
0.001 
 
  * sig               
 
Table 17: The prevalence of diabetic polyneuropathy in 
relation to small vessel disease of the kidney no=155 
 
Diabetic Polyneuropathy 
Variable 
No=55 Yes=100 Total=155 x² Sig.  
Count 44 62 106  
 
Negative 
% 
41.5% 58.5% 100.0% 
 
 
 
SVDK  Count 11 38 49 
5.318* 0.021 
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Positive 
% 
22.4% 77.6% 100.0% 
 
Count 
55 100 100 
 
 
Total 
% 
35.5% 64.5% 100% 
 
 
Table 18: The prevalence of diabetic polyneuropathy 
severity in relation to small vessels disease of kidney   
no=100 
                                Diabetic polyneuropathy 
Variable 
mild= 
40 
Moderate 
=35 
Severe 
=25 
Total 
=100 
x² Sig. 
Count 29 24 9 62  
 
Negative 
% 46.8% 38.7% 14.5% 100.0% 
Count 11 11 16 38 
 
 
 
 
SVDK 
 
Positive % 28.9% 28.9% 42.1% 100.0% 
Count 40 35 25 100 Total 
% 40.0% 35.0% 25.0% 100.0% 
9.687 
0.008 
 
Sig. 
 
Table 19: The prevalence of diabetic polyneuropathy in 
relation to blood pressure No=155 
Variable 
Diabetic Polyneuropathy 
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No=55 Yes=100 Total=155 x² Sig. 
 
Count 
38 56 94 
Normal 
% 40.4% 59.6% 100.0% 
 
Count 
17 44 61 
Hypertensive 
% 27.9% 72.1% 100.0% 
Count 55 100 155 
 
 
 
 
BP 
Total 
% 35.5% 64.5% 100.0% 
2.548 
0.110 
 
 
Table 20: The prevalence of diabetic polyneuropathy 
severity in relation to blood pressure no=100 
 
Diabetic polyneuropathy 
Variable 
mild=40 moderate=35 severe=25 
Total 
 
=100 
x² Sig. 
Count 22 21 13 56 
Normal 
% 39.3% 37.5% 23.2% 100.0% 
Count 18 14 12 44 
Hypertensive 
% 40.9% 31.8% 27.3% 100.0% 
BP 
Total Count 40 35 25 100 
0.406 0.816 
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% 40.0% 35.5% 25.0% 100.0% 
 
Normal <140/90         Abnormal ≥ 140/90 
Table 21: The prevalence of diabetic polyneuropathy in 
relation to ischemic heart disease no=155 
 
Diabetic Polyneuropathy 
Variable 
No=55 Yes=100 Total=155 x² Sig. 
Count 3 654 108  
 
Negative 
% 39.8% 60.2% 100.0% 
Count 12 35 47  
 
Positive 
% 25.5% 74.5% 100.0% 
Count 55 100 155 
 
 
 
 
 
IHD 
Total 
% 35.5% 64.5% 100.0% 
2.918 0.088 
 
 
Table 22: The prevalence of diabetic polyneuropathy 
severity in relation to relation to ischemic heart disease 
no=100 
Diabetic polyneuropathy 
Variable 
mild=40 moderate=35 severe=25 
Total 
=100 
     x² Sig. 
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Count 24 21 20 65 
Negative 
% 36.9% 32.3% 30.8% 100.0% 
Count 16 14 5 35 
Positive 
% 45.7% 40.0% 14.3% 100.0% 
Count 40 35 25 100 
IHD 
Total 
% 40.0% 35.0% 25.0% 100.0% 
3.297 
0.192 
 
 
Table 23: The prevalence of diabetic polyneuropathy in 
relation to stroke no=155 
Variable Diabetic polyneuropathy 
 
 
 
No=55 Yes=100 Total=155 χ² Sig. 
Positive 1 12.5% 
7 
87.5% 
8 
100.0% 
Negative 54 36.7% 
93 
63.3% 
147 
100.0% 
Stroke 
 
Total 55 35.5% 
100 
64.5% 
155 
100% 
1.946 0.163 
 
 
Table 24: The prevalence of diabetic polyneuropathy 
severity in relation to stroke no=100 
Diabetic polyneuropathy 
Variable 
mild=40 moderate=35 severe=25 Total x² Sig. 
Stroke  Count 37 32 24 93 0.494 0.781 
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Negative 
% 39.8% 34.4% 25.8% 100.0% 
Count 3 3 1 7  
 
Positive 
% 
42.9% 42.9% 14.3% 100.0% 
Count 40 35 25 100 
 
Total 
%  
40.0% 35.0% 25.0% 100.0% 
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Table 25: The prevalence of diabetic poly neuropathy 
in relation to PAOD No=154 
 
Diabetic polyneuropathy 
  No=55 Yes=100 Total=155 x² Sig. 
 
Positive 2 
10.5% 
17 
89.5% 
19 
100.0% 
 
Negative 
53 
39.3% 
 
82 
60.7% 
 
135 
100.0% 
 
 
 
 
5.989 
 
 
 
0.014 PAOD 
 
 
Total 55 
35.7% 
99 
64.3% 
154 
100.0% 
  
 
 
      
 
 
Table 26: The prevalence of diabetic polyneuropathy 
severity in relation to peripheral arteries occlusion 
disease no=100 
 
Diabetic polyneuropathy 
Variable 
mild=40 moderate=35 severe=25 
Total 
 
=100 
      x² Sig. 
 
Count 
38 30 14 82 PAOD 
 
 
Negative  
% 
46.3% 36.6% 17.1% 100.0% 
14.496 0.001 
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Count 
2 5 10 17 
 
 
Positive  
% 
11.8% 29.4% 58.8% 100.0% 
Count 40 35 24 99  
Total 
% 40.4% 35.4% 24.2% 100.0% 
  * sig               
 
Table 27: The relation between diabetic 
polyneuropathy and total cholesterol serum level 
no=155 
Diabetic Polyneuropathy 
Variable 
No=55 Yes=100 Total=155 x² Sig. 
 
Count 
49 89 138 
 
normal 
 
3.9-6.5 
% 35.5% 64.5% 100.0% 
Count 6 11 17  
abnormal 
 
>6.5 
% 35.3% 64.7% 100.0% 
Count 55 100 155 
T.Ch 
Total 
% 35.5% 64.5% 100.0% 
0.000 0.986 
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Table 28: The prevalence of diabetic polyneuropathy 
severity in relation to total cholesterol serum level 
no=100 
Diabetic polyneuropathy 
Variable 
mild=40 moderate=35 severe=25 
Total 
=100 
x² Sig. 
 
Count 
37 32 20 89 
 
 
normal  
% 
41.6% 36.0% 22.5% 100.0% 
 
Count 
3 3 5 11 
 
 
abnormal  
% 
27.3% 27.3% 45.5% 100.0% 
 
Count 
40 35 25 100 
T.Ch 
 
 
Total  
% 
40.0% 35.0% 25.0% 100.0% 
2.780 0.249 
 
 
Table 29: The prevalence of diabetic polyneuropathy in 
relation to high density lipid cholesterol serum level 
no=155 
 
Variable Diabetic Polyneuropathy 
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No=55 Yes=100 Total=155 x² Sig. 
 
Count 
55 99 154 
 
normal 
 
0.9-1.5 
% 35.7% 64.3% 100.0% 
 
Count 
0 1 1 
 
abnormal 
 
<0.9 
% 0.0% 100.0% 100.0% 
 
Count 
55 100 155 
 
 
 
 
 
 
 
 
HDL 
Total 
% 35.5% 64.5% 100.0% 
0.239 0.625 
 
 
Table 30: The prevalence of diabetic polyneuropathy 
severity in relation to high density lipid cholesterol 
serum level   no=100 
Diabetic polyneuropathy 
Variable 
mild=40 moderate=35 severe=25 Total=100 x² Sig. 
 
Count 
40 35 24 99 
 
 
normal 
0.9-1.5 
% 40.4% 35.4% 24.2% 100.0% 
 
 
 
 
HDL  
 0 0 1 1 
3.030 0.220 
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Count  
abnormal 
<0.9 
 
% 
0.0% 0.0% 100.0% 100.0% 
 
Count 
40 34 25 99  
 
Total 
 
% 
40.4% 34.4% 25.3% 100.0% 
Table 31: The prevalence of diabetic polyneuropathy in 
relation to low density lipid cholesterol serum level   
no=155 
Diabetic Polyneuropathy 
Variable 
No=55 Yes=100 Total=155 x² Sig. 
 
Count 
52 92 144 
 
normal 
 
2.8-4.8     
 
%  
36.1% 63.9% 100.0% 
 
Count 
3 7 10 
 
abnorma
l 
>4.8 
 
% 
27.3% 72.7% 100.0% 
 
Count 
55 99 154 
 
 
 
 
LDL 
 
Total 
% 35.7% 64.3% 100.0% 
0.349 0.555 
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Table 32: The prevalence of diabetic polyneuropathy 
severity in relation to low density lipid cholesterol serum 
level   no=100 
Diabetic polyneuropathy 
Variable 
mild=40 moderate=35 severe=25 Total x² Sig. 
 
Count 
36 33 23 92 
 
normal 
 
2.8-4.8     
 
%  
39.1% 35.9% 25.0% 100.0% 
 
Count 
4 1 2 7 
 
abnormal 
 
>4.8 
 
%  
57.1% 14.3% 28.6% 100.0% 
 
Count 
40 34 25 99 
 
 
 
 
 
 
 
LDL 
 
 
Total  
% 
40.4% 34.3% 25.3% 100.0% 
0.466 0.792 
 
 
Table 33: The prevalence of diabetic polyneuropathy in 
relation to triglycerides serum level No=155 
 
Diabetic Polyneuropathy 
Variable 
No=55 Yes=100 
Total 
=155 
x² Sig. 
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Count 21 50 71 normal 
 
0.46-1.7 % 29.0% 70.4% 100.% 
Count 34 50 84 abnormal 
 
>1.7 % 40.5% 59.5% 100.% 
Count 55 100 155 
 
 
 
 
Triglycerides 
 
Total % 35.5% 64.5% 100.% 
1.996 0.158 
 
 
Table 34: The prevalence of diabetic polyneuropathy 
severity in relation to triglycerides serum level no=100 
 
Diabetic polyneuropathy 
Variable 
mild=40 moderate=35 severe=25 Total x² Sig. 
Count 21 15 14 50  
normal 
 
0.46-1.7 
%  
42.0% 30.0% 28.0% 100.0% 
Count 19 20 11 50  
abnormal 
 
>1.7 
%  
38.0% 40.0% 22.0-% 100.0% 
Trig 
Total Count 40 35 25 100 
1.174 0.556
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%  40.0% 35.0% 25.0% 100.0% 
 
 
Table 35: The prevalence of diabetic polyneuropathy in 
relation to smoking no=150 
 
Diabetic Polyneuropathy 
Variable 
No=55 Yes=100 Total x² Sig. 
Count 13 24 37 
YES 
% 35.1% 64.9% 100.0% 
Count 42 76 118 
NO 
% 35.6% 64.4% 100.0% 
Count 55 100 155 
Smoke 
Total 
% 35.5% 64.5% 100.0% 
0.003 0.959 
 
 
 
Table 36: The prevalence of diabetic polyneuropathy 
severity in relation to smoking no=100 
Diabetic polyneuropathy 
Variable 
mild=40 moderate=35 severe=25 Total=100 x² Sig. 
  Count 11 10 3 24 2.643 0.267
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43.2%
67.6%
56.8%
32.4%
0%
10%
20%
30%
40%
50%
60%
70%
male female
Smoke
-ve +ve
 
YES 
% 45.8% 41.7% 12.5% 100.0% 
Count 29 25 22 76  
 
NO 
% 38.2% 32.9% 28.9% 100.0% 
Count 40 35 25 100 
 
 
 
 
 
 
Smoke 
 
Total % 40.0% 35.0% 25.0% 100.0% 
 
 
Fig 9: The association of diabetic polyneuropathy and 
smoking 
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Table 37: The prevalence of diabetic polyneuropathy in 
relation to qat chewing no=150 
 
 
Diabetic Polyneuropathy 
Variable 
No=55 Yes=100 Total=150 x² Sig. 
Count 49 74 123 
YES 
% within Qat 39.8% 60.2% 100.0% 
Count 6 26 32 
NO 
% within Qat 18.8% 81.3% 100.0% 
Count 55 100 155 
 
 
 
 
 
Qat 
Total 
% within Qat 35.5% 64.5% 100.0% 
4.933* 0.026 
  * sig.             
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31.3%
53.7%
68.8%
46.3%
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-ve +ve
Table 38: The prevalence of diabetic polyneuropathy 
severity in relation to qat chewing no=100 
 
Diabetic polyneuropathy 
Variable 
mild=40 moderate=35 severe=25 Total x² Sig. 
Count 30 24 20 74 
YES 
% 40.5% 32.4% 27.0% 100.0% 
Count 10 11 5 26 
NO 
% 38.5% 42.3% 19.2% 100.0% 
Count 40 35 25 100 
Qat 
Total 
% 40.0% 35.0% 25.0% 100.0% 
1.025 0.599 
 
 
Table 10: The association of diabetic polyneuropathy 
and Qat Chewing  
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Table 39: The prevalence of diabetic polyneuropathy in 
relation to family history of DM no=150 
 
 
 
polyneuropathy 
Variable 
No=55 Yes=100 Total no. χ² Sig. 
Count 30 40 70 
Negative 
% within 
FH 42.9% 57.1% 100.0% 
Count 25 60 85 
FH 
Positive 
% within 
FH 29.4% 70.6% 100.0% 
Count 55 100 155 
0.093 0.058 
Total 
% within 
FH 35.5% 64.5% 100.0%   
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Table 40: The prevalence of diabetic polyneuropathy 
severity stages in relation to family history of DM  
no=100 
 
 
polyneuropathy  
Variable 
mild moderate severe 
Total χ² Sig. 
 Negative Count 15 14 11 40 0.271 0.873 
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%  37.5% 35.0% 27.5% 100.0% 
Count 25 21 14 60 
FH 
Positive 
%  41.7% 35.0% 23.3% 100.0% 
Count 40 35 25 100 
Total 
%  40.0% 35.0% 25.0% 100.0% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 41: Univariate analysis of risk factors of diabetic 
polyneuropathy 
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Variable  Risk Yes No P-value 
Age 
>54 years 64 21 0.002 
Sex 
Male 55 21 0.046 
Duration 
>5 years 87 32 0.000 
Family History 
Positive 60 25 0.083 
Smoking 
(Now) 24 13 0.959 
Demographic Data 
and Social habits 
Qat chewing 
Yes 74 49 0.031 
IHD 
+ve 35 12 0.090 
Stroke 
+ve 7 1 0.195 
PAOD 
+ve 17 2 0.027 
SVDE 
+ve 54 8 0.000 
SVDK 
+ve 38 11 0.023 
Systemic Diseases 
Hypertension 
Yes 44 17 0.112 
FBG 
≥8 72 30 0.030 
2HBG 
≥12 97 51 0.275 
HbA1c 
>7% 94 44 0.060 
T. Cholesterol 
>6.5 11 6 0.986 
LDL 
>4.8 8 3 0.697 
Laboratory 
Investigations 
Triglycerides 
>1.7 52 34 0.240 
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Table 42: Multivariate risk factors of diabetic 
polyneuropathy     
 
 
95.0% CI. for EXP(B) 
Variable B S.E. df Sig. OR 
Lower Upper 
Age 
>54 
0.819 0.429 1 0.056 2.268 0.979 5.257 
 
Sex  
(Male) 
1.305 0.464 1 0.005 3.687 1.484 9.160 
Duration 
>5 
1.164 0.501 1 0.020 3.203 1.201 8.546 
SVDE 
 
1.430 0.507 1 0.005 4.180 1.549 11.281 
HDL-C 
 
1.046 0.588 1 0.075 0.351 0.111 1.113 
 
Qat 
chewing 
2.227 0.739 1 0.003 0.108 0.025 0.459 
FBG 
 
1.004 0.471 1 0.033 2.729 1.083 6.873 
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Table 43:  Neurological symptoms in type 2 diabetic 
patient with and without diabetic polyneuropathy 
no=155 
 
>8 
HbA1c 
>7% 
2.711 1.106 1 0.014 15.045 1.721 131.559 
Diabetic polyneuropathy 
symptoms 
Total % No=55 Yes=100 P-V. 
Cramp Yes 61 39.4% 21 40 0.825 
Numbness Yes 109 70.3% 28 81 0.000 
Burning sensation Yes 111 71.6% 37 74 0.374 
Prickle sensation Yes 108 69.7% 32 76 0.021 
Sensitive to touch Yes 82 52.9% 25 57 0.168 
Open sore foot Yes 31 20.0% 7 24 0.93 
Weak all the time Yes 121 78.1% 38 83 0.045 
Worse at night Yes 107 69.0% 34 73 0.150 
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Dry skin Yes 56 36.1% 18 38 0.513 
Sense of feet when walk No 14 9.0% 3 11 0.381 
Amputation Yes 3 1.9% 0 3 0.553 
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Table 44: Neurological signs in type 2 diabetes mellitus 
with and without diabetic polyneuropathy no=155 
 
 
 
Diabetic Polyneuropathy 
Variable Total 
No Yes 
p-value 
Appearance of feet Abnormal 75 8 67 0.000 
Ulceration Yes 3 0 3 0.553 
decreased 60 32 28 
Vibration 
Absent 82 12 70 
0.000 
decreased 27 3 24 
10 gr. filament 
Absent& 23 2 21 
0.000 
Pin prick on great toe Not painful 66 6 60 0.000 
Finger spread Weakness 51 4 47 0.000 
Great toe extension Weakness 31 3 28 0.000 
Ankle dorsiflexion Weakness 11 1 10 0.051 
Biceps brachii 
reflexes Absent 14 2 12 
0.007 
 
Triceps brachii 
reflexes Absent 18 4 14 0.14 
Quadriceps femoris 
reflexes Absent 41 7 34 0.000 
Achilles reflexes Absent 73 13 60 0.000 
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Table 45: Nerve conduction study of diabetic 
polyneuropathy patients no=100 
 
 
 
 
 
 
 
NC Normal result 
 
Abnormal result 
 p value  NC total 
% No. % No. 
Nerves 
0.0000 100 6.0% 6 94.0% 94 Peroneal n. motor 
0.0000 100 14.0% 14 86.0% 86 
Sural n. 
sensory 
0.000 100 50.0% 50 50.0% 50 
Median n. 
sensory 
0.0000 100 50.0% 50 50.0% 50 
Ulnar n. 
sensory 
0.0000 100 54.0% 54 46.0% 46 
Median n. 
motor 
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Discussion 
 
NIDDM is most common after middle age and occurs 
most often at 50-70 years of age (14). Neuropathy is the most 
common complication and greatest source of morbidity and 
mortality in diabetic patients, affecting up to 50% of patients 
(103). 
Chronic sensorimotor neuropathy is the most common 
manifestation of the DNs which is usually insidious in onset and 
may be the presenting feature in people with type 2diabetes 
(241). 
Diabetic peripheral neuropathy is a complex disorder in 
which the disease process may affect different sets of nerve 
fibers to different degrees in different individuals. Thus, one 
individual may have an abnormality of large fiber sensory 
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function, whilst another may have a predominantly small-fiber 
neuropathy. This feature of neuropathy can cause problems in 
the selection of a single test to screen a population. This lack of 
certainty over the value of individual tests for the assessment of 
diabetic neuropathy has led to the recommendation that 
several different tests should be performed, and that diabetic 
neuropathy should only be diagnosed when more than one is 
abnormal (88) 
In our study we investigated the chronic complications of 
diabetes mellitus, seen in many diabetic patients (Table 2) 
We noticed 62 of diabetic patients had SVDE; 
representing 40.0% of total diabetic patients (33 males, and 29 
females) 
Klein R. et al. noticed that the prevalence of diabetic 
retinopathy is highest in early onset insulin-treated subjects and 
lowest in late-onset diabetic subjects. Macular edema is more 
common in late onset diabetes (97).  
In the US study of type 2 diabetes, diabetic retinopathy 
was seen in ~20% of patients with type 2 diabetes at time of 
diagnosis, and this figure increased to 60-85% after 15years. PDR 
is present in 3-4% of patients in <4 years, and after 15 years, in 5-
20% (364). Twenty years after the onset of diabetes, almost all 
the patients with IDDM and over 60% of patients with NIDDM will 
have some degree of retinopathy (14). These results were 
nearly similar to our result where diabetic retinopathy was 
common with diabetic patients and increase with increase the 
duration of DM.  
In our study, 49 diabetic patients had SVDK, which 
represent 31.60% of total diabetic patients, (20 males 26.30%, 
and 29 females 36.70%) 
 F.A. Gries et al. stated that diabetic nephropathy is a 
microvascular disease of the glumerulus. It begins with hyper 
filtration followed by protienuria, hypertension, and progressive 
renal failure (44).  
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RALPH A. et al. shown that diabetic nephropathy 
develops in ~50% of patients with type 1diabetes mellitus who 
have had diabetes for 20 years. Clinically significant renal 
disease is less common in type 2 diabetes mellitus, occurring in 
15-20% of individuals (365), which is less than in our study 
(31.60%). 
Humphrey DJ. et al. showed that, end-stage renal disease 
after 30 years of diabetes is more often present in IDDM (>20%) 
than in NIDDM (10%) (366). RALPH A. et al, found that about 30-
50% of all patients on chronic dialysis have diabetes. Since 
type 2 diabetes is much more frequent than type 1 diabetes, it 
contributes to the majority of these subjects (365).This indicated 
that diabetic nephropathy is also a common complication of 
diabetic patients.  
RALPH A. et al. showed that hypertension is a 
characteristic feature of diabetic nephropathy and is the most 
important factor known to accelerate the progression of renal 
failure. They noticed also that in type 2 diabetes, hypertension 
may occur at any time and more closely parallels the patient’s 
age and obesity index (365). 
In this study, 61 diabetic patients had hypertension, 
representing 39.35% of total diabetic patients where females 
were more than males (39 females 49.37% and 22 males 
28.95%), it is significantly increased in females (p<0.009).This 
may be because female patients more obese with less physical 
activities.  
Gunaid et al. 1997 has shown that hypertension was 
recognized in 24.2% of diabetic population aged 20 to ≥65 
years, a slightly females predominance was noticed (25.95% in 
females versus 23.2% in males %) (58). This percentage was less 
than in our result, which may be explained by involving 
younger age in their study, and the different method used. 
 In the last study  about the prevalence of known 
diabetes and hypertension in republic of Yemen (A.A Gunaid, 
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2002), indicates that hypertension was more frequent than 
diabetes mellitus(14% versus 7%) and that both had co-
morbidity with each other (3%) and with ischemic heart 
disease(2%) and stroke (1%)(57). 
The World Health Authority estimated in 1977 that type 2 
diabetes accounted for 97% of all cases of diabetes world-
wide (367), meaning that overall figures for patients with 
diabetes and hypertension will be very similar to those for type 
2diabetes plus hypertension.  
In UK study of 3648 patients with newly-diagnosed type 2 
diabetes, 39% had blood pressure of at least 160/90mmHg 
(368). The association was stronger in women with type 2 
diabetes, 45% of whom had hypertension, compared with 35% 
of the men (369). This study showed results nearly similar to our 
results. 
In our study 47 diabetic patients had IHD, representing 
30.30% of total diabetic patients (29 males, and 18 females), 
with significant increase in males (p=0.045), which may be due 
to increased males cigarette smoking  
Gunaid et al.1997 found that, large vessel disease was 
observed in 28% of the entire diabetic population investigated 
(707subjects), with a higher frequency in males (34.9%) than 
females (17.8%). Coronary artery disease (CAD) was the most 
common form of LVD reported. It accounted for 44% of all LVD-
positive cases in males and for 55% of LVD-positive cases in 
females (58). 
F.A. Gries, J. Eckel, P. Rosen, and D. Ziegler study showed 
that the major clinical complications of macro-angiopathy are 
coronary artery disease, stroke, and amputation (44). Rendel 
M. et al. Showed that coronary artery disease is 3.3 times more 
frequent in diabetic than nondiabetic people (370). F.A. Gries 
et al. noticed that myocardial infarction is 3.7 times more 
frequent in diabetic men and 5.9 times more frequent in 
diabetic women (44). Manson JH. et al. study mentioned that 
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(371) the increase was 6.7 times in type 2 and 12.2 times in type 
1 diabetic woman 
 In US studies showed that angina pectoris, a cardinal 
manifestation of ischemic heart disease, it extremely common 
in diabetic patients, with prevalence estimates approaching 
40% of patients. However, many patients with diabetes 
experience episodes of silent ischemia and suffer a worse 
prognosis after development of ischemic heart disease than 
their nondiabetic counterparts (372). 
ANJLI MAROO. et al. showed that diabetes accelerates 
coronary artery disease. Mortality from CAD is two fold greater 
in people with type 2 diabetes. More than 35% of patients >55 
years of age who  
 sustain acute myocardial infarction have diabetes and insulin 
resistance (373). 
In general most studies indicated that IHD were common 
complication, with more predominant in males diabetic 
patients, however, our study shown slightly decreased 
percentage than US study, this may be our patients were less 
obese 
In this study, 19 diabetic patients had PAOD, representing 
12.30% of total diabetic patients (13 males, and 6 females), 
and lower-extremity peripheral arterial disease is among the 
most important reasons for nonhealing ulceration, pain, and 
amputation in individuals with and without diabetes.  
GARY GIBBONS. et al. In population-based studies showed 
that pulse deficits were found in ~10% of diabetes subjects and 
absent pulses was found in ~20-30%.  PAD result in decreased 
arterial perfusion to the lower extremity and the foot (374), 
while PAD in Yemeni diabetic patients it represent 12.26% with 
no significant value difference between male and female. It 
was less prevalence in Yemeni patient, which may be due to 
defect in early diagnosis, or due to good physical activities. 
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In this study, 8 diabetic patients had stroke, representing 
5.20% of total diabetic patients (7males, and 1 females), which 
is also significant increased males than females (P=.025).   
F.A. Gries. et al. showed that stroke is about twice as 
frequent as in the general population, and two out of three 
amputations are performed in diabetic people (44). Large 
population studies done by PJ Watkins, P K Thomas have 
shown that stroke are more frequent and have a higher 
mortality in patient with diabetes. These studies have disclosed 
an increased in relative risk in female as compared with the 
diabetic population. Thus in a study in Sweden, the highest rise 
was 6-fold in diabetic male but 13-fold in diabetic females (40)  
Dyck PJ, Kratz KM, et al. found that neuropathies are 
among the most common of all the long-term complications of 
diabetes, affecting up to 50% of patients (103). 
In this study, the diabetic patients with diabetic 
polyneuropathy were 100 patients; representing 64.52% of total 
diabetic patients. It is significantly increased in males than 
females (P=0.045), which indicate a slight increase in our study 
as compared with the previous study  
  In general in this study the complications of diabetes 
mellitus showed males to be affected more than females, 
except SVDK and hypertension, where females were affected 
more than males 
The prevalence of diabetic polyneuropathy and its 
severity were the main goal of this study. 
In this study the prevalence diabetic polyneuropathy in 
155 type 2 diabetes Yemeni patients was 64.5 %, diagnosed by 
Michigan Neuropathy Program. It represents two thirds of type 
2 diabetic patients.  
The Michigan Neuropathy Program (NCS+MDNI), staged 
diabetic polyneuropathy to mild 40 patients of DPN (40.0%) (2 
abnormal nerves and 7-12 clinical rates), moderate 35 patients 
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of DPN (35.0%) (3-4 abnormal nerves and 13-29 clinical rates), 
and severe 25 patients of  DPN (25%) (5 abnormal nerves and 
30-46 clinical rates).The diabetic patients had no diabetic 
polyneuropathy were 55 patients (35.48%) (0-1 abnormal nerve 
+ 0-6 clinical rates) 
In the study done in Yemen by Gunaid et al., 1997, 
peripheral neuropathy was noticed in 40.7% of the diabetic 
population investigated (1074 subjects), mostly among non-
obese NIDDM patients. They used subjective criteria (pins and 
needles, numbness, painful syndrome, and muscle weakness), 
and objective criteria (reduced cutaneous sensibility to touch 
and pinprick in a stocking and glove distribution, decreased 
vibration perception in the limbs, mild distal muscular weakness 
and reduced or absent ankle reflexes (58). The result was less 
than in our study. This may be due to different methods used.    
Herman WH, et al. Study shown that the prevalence of 
distal symmetric polyneuropathy in subject with established  
type 2 diabetes was 22% in Egypt (using VPT) by population 
screening 1998 (167), Nielsen JV. Study shown that the 
prevalence was 20% in Saudi Arabia, 1998, by hospital-base 
study (using absent pin-prick or vibration) (375), which also less 
than in our study, and may explained by different methods 
used for investigations DPN 
Several large studies have examined the prevalence of 
the DPN in hospital-based populations. A number of these are 
in fairly close agreement, and  reveal prevalence of distal 
symmetrical polyneuropathy at approximately 30%, amongst 
both European and African population (153, 154-156) 
However, other hospital-based studies have produced figures 
closer to 20% (157), and a prevalence of 50% was reported 
from US veterans population (158). 
  Some studies report prevalence of around 20% (167, 138, 
139), although a figure as high as 54% in type 1 and 45% in type 
2 diabetic patients was reported from a population based 
sample from Rochester (103), and 42% of a sample of 811 type 
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2 diabetic subjects drawn from 37 UK general practices were 
found to be neuropathic (376). Rochester study used   
electrophysiology as part of the neurological assessment (103)  
Ziegler D. 1994; conclude that diabetic polyneuropathy is 
encountered in at least one-third of the patients with diabetes 
mellitus (284). 
Three large clinic-based studies from Europe reported 
similar figures for the prevalence of neuropathy: the UK 
Diabetic Neuropathy study (n=6487) reported a prevalence of 
28.5 % (270), the Spanish study (n=2644) reported neuropathy in 
22.7% of participants (263), and the Eurodiab IDDM 
Complications (Eurodiab) Study (n= 3250) individuals with type 
1 from 30 European centers reported a prevalence of 28% 
(154).  However, among the 27 European centers included in 
the study, the prevalence ranged from <20% in several centers 
to >50% in two centers (154). 
In the San Luis Valley Diabetes Study (SLVDS) (138), a 
population-based study of type 2 diabetic patients, there was 
an overall prevalence of 28%. In an analysis of baseline data 
from the DCCT (377), “clinically detectable” was found in 39% 
of the participants. 
Melton JL Dyck PJ.1987 study shows that the prevalence 
of neuropathy in diabetic subjects has been estimated to be 
as high as 62 per cent if defined on the basis of subjective 
complaints, 55 per cent if based on signs, and 100 per cent if 
based on motor conduction velocities (129). 
In our study the percentage of mild polyneuropathy was 
25.81%, moderate polyneuropathy was 22.58%, and severe 
polyneuropathy was 16.13% of total NIDDM.  
In Rochester Diabetic Neuropathy Study, 32% of NIDDM 
was subclinical neuropathy, and 13% of NIDDM was mild and 
more severe of distal polyneuropathy. The more severe form of 
polyneuropathy occurred less common in NIDDM. 
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In the small but population-based Rochester diabetic 
neuropathy study (103), more than 60% of patients with 
diabetes had evidence of neuropathy, although severe 
neuropathy was rare. In recently published North-West 
Diabetes Foot Care study, a community-based study in the UK 
with a large cohort of patients (n=9710), more than 22% of 
patients with diabetes had a moderate or severe neuropathic 
deficit (261), which is nearly similar to our finding. 
In general, the differences of these results are because 
diagnostic methodology is far from uniform. Indeed, there are 
hardly any two studies that have used identical methods. 
 Studies examining the prevalence and progression of 
neuropathy are inconsistent because of differences in patient 
selection, differences in defining" neuropathy”, patient attrition 
in prospective studies, and the difficulty in establishing the true 
onset of hyperglycemia in patients with type 2 diabetes 
mellitus. Most studies indicate lesser percentage than our result, 
this may be because we used electrophysiological test which is 
more sensitive test, inadequate glucose control and increased 
diabetic duration in our diabetic patients. 
In this study we investigated the risk factors for diabetic 
polyneuropathy in type 2 diabetes mellitus Yemeni patients. 
Debate continues regarding the precise 
aetiopathogenesis of diabetic neuropathy, and several 
contributory factors have been proposed, the strongest of 
which is hyperglycaemia. There is now some agreement as to 
the risk factors associated with the development of 
neuropathy (171) 
DPN is clearly by associated with certain risk factors. The 
degree of hyperglycemia has been identified as a risk factor in 
both epidemiologic studies and clinical trials. Diabetes 
duration has also been a consistent risk factor. Certain 
conventional cardiovascular disease risk factors, including lipid 
and blood pressure indices, have been identified as risk factors 
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for DPN. Several studies have observed associations of DPN 
with other complications of diabetes. Other risk factors such as 
alcohol consumption and cigarette smoking have been less 
consistent in their associations with DPN (241) 
 Boulton AJM, et al. Adler AL, et al. and Tesfaye S, et al. 
showed in other epidemiologic studies that certain patients 
with diabetes are at particularly high risk of developing 
neuropathy. One of the most important risk factors for diabetic 
neuropathy is inadequate glucose control. The other major risk 
factors are age and increased duration of diabetes. Both 
factors demonstrate a strong positive correlation with a 
significantly higher risk of sensory neuropathy. Vinik AI, et al. 
mentioned also that several studies have reported that high 
diastolic blood pressure, reduced HDL-cholesterol, and raised 
triglycerides are also associated with an increased risk for 
diabetic neuropathy, although not as significantly as age and 
duration of diabetes (151,154. and 158).  
 Andrew J.M. et al. found that the definitive risk factors 
that have been identified have biological plausibility for 
involvement in the pathogenesis of DPN (241).  
In the present study the mean age of diabetic 
polyneuropathy patients was high (58.01±1.05 years), as 
compared with mean age of diabetic patients without 
diabetic polyneuropathy (51.80±1.35 years). 
 The highest prevalence of diabetic polyneuropathy was 
found in age group 55-64 years 32.0%, > 65 years group 32.0%, 
and 45-54 years group 28.0%. The less was found in <45 years 
group 8.0%.  
. Young MJ. et al. found in a large sample (6487 subjects) 
of UK diabetic hospital outpatients, the prevalence of DSP rose 
from 5% in the 20- to -29-year age group to 44% in the 70- to 79-
year age group (153).  Herman WH. et al. Amongst a 
population-based sample from Egypt, found that DSP was 
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detected in 8% of those aged 20-44, and in 23% of those aged 
45 years or over (167).  
The San Luis Valley Study shows that the prevalence of 
diabetic polyneuropathy was lowest in those age 20-44 years 
(10.3%) and highest in those in those age 65-74 years (32.3%) 
(378)  
A number of other studies have also documented age as 
an independent risk factor for DSP neuropathy (138,139, 154, 
and 158). Delcourt C. et al. in an interesting study from France, 
where VPT was adjusted for age, height, and gender, there 
was no relationship between neuropathy and age (157) 
This indicates the influence of age on diabetic 
polyneuropathy prevalence, and consider as risk factor as 
mentioned in many studies. 
Advancing age has been widely reported to increase the 
risk of distal symmetrical polyneuropathy 
In this study the prevalence of diabetic polyneuropathy in 
type 2 diabetes Yemeni patients was 55 (72.6%) for males, and 
45 (57.0%) for females, where males were more affected than 
females, that is going with most of the studies. 
The same result was found in the San Luis Valley Study 
which showed that neuropathy was more common in males 
than in females (34% versus 20.6%) (378), which is also similar to 
our finding. 
Shaw J.E.et al. found that there are no consistent findings 
that would indicate a relationship between gender and the risk 
of DSP (379).  
A significant correlation was found in our study between 
the duration of diabetes and the risk of polyneuropathy 
(p=0.008).  13.0% of diabetic polyneuropathy was ≤ 5 years 
duration of diabetes, to 54.0% in those with diabetes ≥ 10 years 
diabetes, which is nearly similar to the other studies, where the 
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duration was considered as risk factor for the prevalence of 
diabetic polyneuropathy. 
A Previous study done by Gunaid et al. in Yemen found 
the prevalence of peripheral neuropathy in diabetic patients 
was duration dependant and to be significantly associated  
with small vessel disease in general (p<0.05) and SVDE in 
particular(58). 
 Franklin GM, et al. study, found neuropathy was 
significantly related to the duration of diabetes, increasing 
from 16.8% in those with duration of diabetes ≤4 years to 52.6% 
in those with diabetes≥25 years  (378)  
In the UK study, the prevalence of DSP rose from 21% in 
those with a diabetes duration of less than five years to 37% in 
people with a duration of over 10 years (153).In a Spanish 
study, the prevalence rose from 14% at under five years to 44% 
at a duration of more than 30 years (263). 
  Dyck PJ, Kratz KM, Karnes JL, et al. 1993, study showed 
that the prevalence of neuropathy increased from 4% for 
diabetic of short duration (<5 years) to 15% after 20 years of 
diabetes. Half the patients who developed it within 9 years of 
diagnosis of diabetes (103).This result is similar to our finding, 
where about 54.0% of our diabetic polyneuropathy patients 
where with ≥10 years duration of diabetes mellitus. 
All studies showed the effect of duration of diabetes on 
the prevalence of polyneuropathy, and has been a consistent 
risk factor 
Our study showed the increased prevalence of diabetic 
polyneuropathy in relation to fasting blood glucose, post-
prandial blood glucose and HbA1c %. The majority of patients 
had FBG > 8mmol/l, post-prandial blood glucose ≥7.8mmol/L, 
and HbA1c% >8% 
In this study the peak number of diabetic polyneuropathy 
patients was with fasting blood glucose >10 mmol/l, (43 
 164
patients), the lesser group was account 28 patients with 
<8mmol/l fasting blood glucose concentration, while the peak 
number of diabetic polyneuropathy patients was with HbA1c 
>9%, they account 47 patients, then 32 patients lie between 8-
9%, the lesser group was account 21 patients had <8% HbA1c. 
The peak number of diabetic polyneuropathy patients was 
with ≥7.8mmol/l of 2hPBG, they account 97 patients. 
 We noticed that diabetic polyneuropathy prevalence 
was high with the hyperglycemia, which is going with many 
studies.  
Partenen et al. study about the effect of hyperglycemia 
on the prevalence of diabetic polyneuropathy showed that 
strong evidence from studies in both type 1 and type 2 
diabetes (non-insulin dependent) implicates hyperglycemia as 
the pivotal risk factor in the development of neuropathy. 
Partanet J, et al. In a follow-up study of patients with newly 
diagnosed type 2diabetes, (166) showed that nerve 
conduction abnormalities increased from 8% at baseline to 
42% at 10 years; the development of neuropathy was strongly 
associated with poor glycemic control. Similar support comes 
from the UK Prospective Diabetes Study although, in that study, 
measurement of neuropathy was not ideal (379). 
 Richard P, et al. study shows that fasting and post-
prandial blood glucose was more commonly higher in patients 
with polyneuropathy. These findings are supported by the 
positive effect of intensive treatment of diabetes on the 
development and progression of long-term complications of 
the disease (303,2).  
Patient with neuropathy had significantly higher mean 
hemoglobin A1c than those without neuropathy (11.2% versus 
10.2%) (378) 
Partanet J. et al. found that the mean HbA1c was 
approximately 1% higher in men with newly diagnosed type 2 
diabetes who went to develop DSP 10 years later, than in those 
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who did not (166). Adler AL, et al. revealed that the risk of 
developing  DSP (as measured by odd ratio) has been 
calculated to rise by approximately 10-15% for every 1 mmol/l 
rise in fasting plasma glucose or every 1 rise in HbA1c(158,167). 
The importance of hyperglycemia has of course been 
confirmed in interventional studies. The DCCT demonstrated 
that intensive glycemic control led to a 64% reduction in five-
year risk developing DSP (137) in patients with type 1 diabetes. 
The effect of glucose lowering in type 2 diabetes is less clear. 
Dyck PJ, Davis JL, Wilson DM, et al. in longitudinal data 
from the Rochester cohort support the contention that the 
duration and severity of exposure to hyperglycemia are 
related to the severity of neuropathy only (304). Similarly, in 
Partanet J, et al. study of newly diagnosed patients with type 2 
diabetes follow up from baseline and at 5 and 10 years, the 
overall severity, and not the development of neuropathy, was 
related to the degree of hyperglycemia (166). These findings 
were similar to our study where the duration and severity 
exposure to hyperglycemia were related to the severity of 
neuropathy. 
 The correlation of diabetic complications with diabetic 
polyneuropathy was noticed. These finding confirmed in many 
studies, where there was considerable evidence that 
neuropathy is associated with retinopathy, nephropathy, and 
peripheral vascular diseases. Since microvascular disease plays 
a role in retinopathy and nephropathy, it may be involved in 
peripheral neuropathy as well.  
In this study, retinopathy was present in 54 patients with 
diabetic polyneuropathy, representing 87.1% of total positive 
retinopathy, which is highly significant. 44 patients of diabetic 
polyneuropathy had hypertension, representing 72.1% of total 
hypertensive patients. 38 of diabetic polyneuropathy patients 
had nephropathy, which representing 77.6% of total 
nephropathic patients. 35 of diabetic polyneuropathy patients 
had ischemic heart disease, which representing 74.5% of total 
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of IHD. 17 of diabetic polyneuropathy (89.5%) had peripheral 
artery disease, and 7 patients (87.5%) of DPN with stroke.        
Fagerberg reported on 356 Swedish patients in whom 
neuropathy was defined as presence of “definite neurological 
signs"—symptoms alone were not considered sufficient. 
Approximately 70% were thought to have neuropathy. The 
percentages of patients with neuropathy having retinopathy, 
nephropathy and PVD are as follows: 89% with retinopathy, 93% 
with nephropathy, and 66% were with PVD (legs), which 
indicate significant correlation (p=.001) (380)  
This study showed a higher percentage than our study 
Dyck PJ, et al. study, found that of 100 patients with 
neuropathy, 40 had retinopathy and 13 had nephropathy. Of 
100 patients with nephropathy, 75 had retinopathy and 63 had 
neuropathy. Of 100 patients with retinopathy, 40 had 
neuropathy and 12 had nephropathy. This study suggests that 
neuropathy, retinopathy, and nephropathy are statically 
associated (275) 
Dyck working group (117,103) has pointed out that DSDP 
should only be diagnosed when only other diabetic 
complications such diabetic retinopathy or nephropathy can 
also be demonstrated. Only in exceptional cases can DSDP be 
diagnosed in the absence of indications of these other 
complications of diabetes mellitus.  
Dyck PJ, Kratz KM, Karnes JL, et al. In the Rochester 
Diabetes Population Study, showed significant correlations of 
DSDP with retinopathy (p < 0.001) and nephropathy (p = 0.003) 
were observed. These correlations could not be demonstrated 
with other form of diabetic neuropathy (e.g., diabetic 
amyotrophy) (103) 
Dyck PJ, Davis JL, Wilson DM, et al. In Rochester Diabetic 
Neuropathy Study, noticed that mean HbA1c, severity of 
diabetic retinopathy, and a term calculated mean in (24-hour 
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protienuria multiplied by duration of diabetes) were the main 
covariates for severity of DSP at the 7-year follow-up (304).  
In our study 44 of diabetic polyneuropathy patients had 
hypertension which represents 72.1% of total hypertensive 
diabetic patients. This indicates high percent of diabetic 
polyneuropathy with hypertension 
Compelling support for hypertension as a risk factor for 
neuropathy in type 1 diabetes come from the prospective 
Pittsburgh Epidemiology of Diabetes Complication Study (381), 
in which hypertension was the strongest risk factor. This 
observation would certainly seem to lend support to the 
vascular theories of the pathogenesis neuropathy. Further 
support for these vascular theories comes from the Eurodiab 
study (154), which showed not only diastolic blood pressure to 
be a risk factor, but also high-density lipoprotein cholesterol 
and triglycerides. Studies in type 2 diabetes, however, do not 
provide such compelling support, and have conflicting data 
(379), although the observation that treatment with 
angiotensin-converting enzyme (ACE) inhibitors improved 
nerve function in patient with type 1 and type 2 diabetes might 
be seen as further support for the association    
 In Andrew J.M. et al. study, showed that the prevalence 
of neuropathy was related to elevated diastolic blood 
pressure, triglyceride, and decreased HDL cholesterol (241) 
Forest KY. et al. revealed that hypertension is attractive as 
an etiological factor in DSP, as it could be viewed   as lending 
weight to the vascular theory of the pathophysiology of DSP. 
Hypertension has been associated with DSP in several studies. 
However, the UKPDS reported that intensive blood pressure 
lowering with a variety of agents had no effect in ameliorating 
the progression to DSP (169) 
In this study total cholesterol, LDL, and triglycerides were 
higher in diabetic polyneuropathy patients, but not significantly 
so. 
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 Herman WH. et al. mentioned that high total cholesterol 
(167) and Tesfaye S. et al. about elevated triglycerides (154) 
have been reported as independent risk factors for DSP (after 
adjustment for HbA1c, age, and other potential confounders). 
Partanet J, et al. and Shaw JE, et al. noticed in type 2 diabetic 
patients the link between DSP and dyslipidemia must, however, 
remain tentative at this stage, as several studies have failed to 
observe such a relationship (166, 168)  
Smoking was found to carry an independent risk in the 
San Luis Valley study of type 2 diabetes(174), but was actually 
associated with a protective effect in US veterans(158), and 
had only a weak (and not independent) association in the 
study from Mauritius(168). These studies gave different results 
the effect of smoking on the prevalence of DPN. 
In our study 24 of diabetic polyneuropathy patients were 
smoking cigarette, which represent 64.9% of total diabetic 
smoking patients, where males were more than females, but 
no significant difference between diabetic polyneuropathy 
patients and patients without diabetic polyneuropathy.  
We noticed 74 diabetic polyneuropathy patients were 
qat chewing; they represent 60.2% of total diabetic chewing 
qat patients, where male more than females, and it is 
significantly higher in diabetic polyneuropathy as compared 
with patients without diabetic polyneuropathy  (P=.026), 
however, up to now no studies about the relation between qat 
and DPN prevalence.   
 
Neurological signs and symptoms of type 2 diabetic patients 
 
Not every DSDP patient complains of subjective 
symptoms, so these are not absolute diagnostic criteria. On the 
other hand, they are an important indicator that DSDP may be 
present, especially when they are more severe distally (136)  
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The progressive loss of distal cutaneous sensation is the 
hallmark of the form of neuropathy most associated with 
diabetes, symmetric distal polyneuropathy. While individuals 
are usually acutely aware of abnormalities resulting in “positive 
symptoms” such as pain and paresthesia, changes in sensory 
function resulting in “negative symptoms,” such as numbness, 
are often insidious and can remain undetected by both patient 
and physician (379) 
In this study, patients with diabetes mellitus (n=155), 
showed sensory symptoms in the form of numbness in 109 
diabetic patients 70.3%, 81 patients 81.0% had diabetic 
polyneuropathy, which indicated highly significant increase in 
diabetic polyneuropathy patients (p=.000). 
 Burning sensations was present in 111 diabetic patients 
71.6%, 74 patients 74% had diabetic polyneuropathy.  
Prickle sensation was present in 108 diabetic patients 
69.7%, 76 patients 76% had diabetic polyneuropathy, which 
indicated significant increased in diabetic polyneuropathy 
patients (P=.021).  
Cramp was present in 61 diabetic patients 39.4%, 40 
patients 40% had diabetic polyneuropathy.   
82 of diabetic patients 52.9% had sensitivity to touch, 57 of 
them had diabetic polyneuropathy.  
Patients had open foot sore, were 31 diabetic patients, 
representing 20.0%, 24 patients (24.0%) had diabetic 
polyneuropathy. 
 The majority of diabetic patients 121(78.1%) felt weakness 
all the time, 83 patients (83.0%) had diabetic polyneuropathy, 
which indicate significant increase in this symptom in diabetic 
polyneuropathy patients (P=.045).          
        "Worse at night", this symptom was found in 107 of diabetic 
patient 69.0%, 73 patients (73.0%) had diabetic 
polyneuropathy.  
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            Dry skin was found in 56 diabetic patients 36.1%, 38 
patients (38.0%) had diabetic polyneuropathy. "Sense of foot 
when walk", 14 diabetic patients were answered no, 11 patients 
had diabetic polyneuropathy. Amputation only present in 3 
patients had diabetic polyneuropathy. 
   In a large population survey Harris et al. reported that, 
36% of the male and 40% of female type 2 patients 
experienced neuropathic symptoms. However, 10% of males 
and 12% of females in the nondiabetic population reported 
similar symptoms. The prevalence was significantly greater 
(p<0.05) in subjects with diabetes as compared with 
nondiabetic subjects but was not significantly different in males 
and females (136). The authors concluded from these results 
that about 20% of the patients with diabetes mellitus have 
subjective symptoms indicative of a diabetic neuropathy. 
In a standardized investigation of diabetic subjects, Dyck's 
working group (141) found symptomatic polyneuropathy 
corresponding to stages N2a (symptoms, signs, and test 
abnormalities) and N2b (N2a plus significant ankle dorsiflexor 
weakness), in only 13%. 
 Jude EB, Boulton AJM, study, up to 50% of diabetic 
polyneuropathy patients may be asymptomatic, 10-20% may 
experience troublesome sensory symptoms that require specific 
treatment (239) 
     Neundörfer B. and P.K.Thomas cases, found that fifty-nine 
(25%) 
out of 230 their cases complained of spontaneous pain (382). 
Of the 100 patients reported by Gibbels and Schliep (383), 59 
patients complained of spontaneous pain, distal pain being 
very much more frequent than proximal pain. Among Bischoffs 
200 patients (384), as many as 78% reported pain. Of these, 25% 
complained of burning pain typical of diabetic 
polyneuropathy. Very divergent figures for pain are reported in 
the literature. These range from the 33% reported by Bonkalo 
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(385), 49% by Feudell (386), and 78% by Daeppen (387) to the 
88.7% by Comensoro (388).  
    Andrew J.M. et al. found that the overall prevalence 
estimate for painful symptoms in the diabetic individuals was 
27%, but the difference in the prevalence rates between those 
with and without diabetes was smaller and tended to decrease 
with age (241). Partanet J, et al. studies (166) have examined 
the prevalence of painful symptoms in clinical settings, and 
estimates have varied from 3 to >20%. This variation probably is 
a function of differing criteria used for painful neuropathy and 
the characteristics of those studies. 
 Cheng WY. et al. study showed that utilizing three 
quantitative sensory measurements in the same individuals, the 
prevalence of hypoesthesia varied from 8 to 34 %( (389). 
Most authors emphasized that pain was more severe 
distally in the lower limbs. These pains sometimes increase and 
subside, becoming worse at night (382). Boulton AJM. found 
that the symptoms of painful DPN are often worse at night 
(390), which is similar to our finding 
 J. E. Shaw. et al. noticed that as signs of an irritation of 
motor Aα fibers, the patients also frequently complained of 
positive motor symptoms. These were mainly cramps (379). In 
B.Neundörfer and P.K. Thomas study, there was 5% as 
compared to 8% of Feudell’s patients (382). In response to 
nonsystematic questioning, 12% of the 100 patients Gibbels and 
Schliep (383) reported corresponding symptoms, as did 21.5% 
of Bischoffs 200 patients (384).In our study cramp was present in 
61 diabetic patients 39.4%, 40 patients were with diabetic 
polyneuropathy, which was higher than other studies. 
Most of the neurological symptoms in our study showed 
higher percentage in compared with other studies, which 
could be due to poor control of blood glucose level and lower 
socioeconomic level of the patients. This variation also 
 172
probably was a function of differing criteria used for painful 
neuropathy and the characteristics of our study.  
In this study 98% of diabetic polyneuropathy had 
abnormal vibration perception threshold (lost in 70%, and 
decreased in 28%), which indicated highly significant 
increased in diabetic polyneuropathy patients as compared 
with no diabetic polyneuropathy patients. 
 B. Neundörfer and P.K. Thomas study, showed that 
vibration sense was affected most frequent 58% of patients 
(382). In Bischoff’s patients, 124 out of 200 patients had a 
sensory disturbance, in most cases loss of vibration sense (52%) 
(384). In San Luis Valley Study 27.8% had definite neuropathy by 
measuring vibration perception threshold. Our study showed 
high percentage of abnormal vibration perception threshold in 
comparison with other studies. This is mostly due to poor control 
of blood glucose level. 
    Motor weakness: 
Motor weakness in diabetic patients has been recognized 
for more than a century. Before the era of insulin treatment, 
paresis of feet and legs was a well-known concomitant of 
diabetes (232). Nowadays, the general opinion is that motor 
disturbances in diabetes are rare and restricted to isolated 
nerve manifestations or to polyneuropathy with distal symmetric 
distributions in long-term patients (391). Motor impairment is 
silent and often unrecognized (392). 
Motor weakness is unusual, although small muscle wasting 
in the feet and also the hands may also be seen in the more 
advanced cases. Any pronounced motor signs should raise the 
possibility of nondiabetic etiology of the neuropathy, especially 
if asymmetrical (103, 260). 
In this study, distal weakness of lower limbs occurred in 
diabetic polyneuropathy patients. Most of the weakness was 
when patient tried to spread the toes of the feet 47 patients 
(47.0%), rather than extension the great toe 28 patients (28.0%), 
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and to less extend when doing ankle dorsiflexion 10 patients 
(10.0%). The weakness was significantly more in diabetic 
polyneuropathy patients as compared with no diabetic 
polyneuropathy patients (P=0.000). 
Gibbels and Schiep found muscle weakness in 72% of the 
cases reported (383). Muscle weakness was generally more 
pronounced distally, particularly affecting muscles innervated 
by the peroneal nerves (382). This difference may be due to the 
different methods of examination used, the understanding and 
cooperation of the patients.   
   
 Tendon reflexes: 
 Neundörfer B. found that in the neurological examination, 
a depression or loss of the tendon reflexes of the lower limbs is 
one of the earliest and most frequent findings in DSDP. This 
finding is not uncommonly the first clue leading to diagnosis of 
diabetes mellitus (393) 
In this study, the Achilles reflexes were lost in 60 patients 
(60.0%) of diabetic polyneuropathy patients (P=0.000). The 
reflexes of upper arms were involved less, where biceps tendon 
reflexes were absent in 12 patients (12%) (P=0.007), triceps 
tendon reflexes were absent in 14 patients (14%).    
B. Neundörfer and P.K. Thomas study, showed that the 
Achilles tendon reflexes were lost in almost all cases, and they 
were absent in 90% of the patients of Gibbels and Schliep (383). 
With one exception, the Achilles tendon reflexes were affected, 
the patellar tendon reflexes were reduced in 65%, and the 
reflexes in the arms were involved very much less often: the 
biceps tendon reflex in 23% and the triceps tendon reflex in 
25%. Of Bischoff’s 200 patients with diabetic neuropathy (384), 
153 had reduced reflexes. The Achilles tendon reflexes were 
involved   most often. These studies gave result nearly similar to 
our study  
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    10 g filament 
The past two decades have witnessed the development 
of a number of commercially available instruments for QST of 
cutaneous functions (379). 
A recent trend is the introduction of simple, handheld QST 
devices, which are inexpensive and easy to operate. Semmes-
Weinstein monofilaments are perhaps the most widely used 
handheld QST instrument for the assessment of large diameter 
fiber function (394). 
The 10-g monofilament is widely used for the clinical 
assessment of neuropathy. 
The filament assesses pressure perception when gentle 
pressure is applied to the handle sufficient to buckle the nylon 
filament. Although filaments of many different sizes are 
available, it is the one that exerts 10 g of pressure, the value 
most commonly used to assess pressure sensation in diabetic 
foot (241) 
In this study, 21 patients (21%) of diabetic polyneuropathy 
patients had lost the 10 g filament sensation, and  24 patients 
(24%) had decreased sensation, while in non diabetic 
polyneuropathy patients it was absent in 2 patients 3.6%, and 
decreased in 3 patients 5.5%.This indicated highly significant 
difference between both groups (P=0.000). 
In our study, pin prick on great toe test shown no painful 
sensation in 66 diabetic patients, 60 patients (60.0%), had 
diabetic polyneuropathy, which indicate highly significant 
increased in diabetic polyneuropathy patients (P=0.000).  
 
The electrophysiological measures in DPN 
Nerve Conduction Study 
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 In the past 5 years, there have been more than 100 
published articles discussing the link between NCV and DPN, 
and this builds on decades of previous research (241).  
NCV provides a sensitive but nonspecific index on the 
onset of DPN and can be valuable in detecting sub clinical 
deficits. The earliest reports of altered NCV in patients without 
clinical symptoms or signs of DPN date back for more than 40 
years and have been confirmed in recent studies (395).  
NCS document the presence, nature, distribution, and 
severity of peripheral nerve impairment (396). The severity of 
disease can be suspected by the degree of abnormality of the 
parameters in the study; in the most severe cases, the motor 
and sensory responses are lost distally in  
the lower limb, and diffuse upper limb changes are observed. 
The extent of disease can be demonstrated by the number 
and distribution of nerves affected. If the changes are within 
the territory of a single nerve, then a mononeuropathy is 
present. When diffuse changes in NCS are observed, then the 
presence of DSP is confirmed (396).  
In this study, the nerves tested for DSP include lower and 
upper limb peripheral nerves. Both motor and sensory nerves 
were studied. The sural nerve, motor peroneal nerve, motor 
and sensory median nerve, and sensory ulnar nerve responses 
were measured. The parameters reported were: distal 
latencies, proximal latencies, amplitudes, and conduction 
velocities.   
In this study, 94% of diabetic polyneuropathy patients had 
abnormalities in motor peroneal nerve response, 86% of DPN 
patients had abnormalities in sensory sural nerve response, 50% 
of DPN patients had abnormalities in sensory median nerve 
response, 46% of DPN patients had abnormalities in motor 
median nerve responses, and 50% of DPN patients had 
abnormalities in sensory ulnar nerve responses. The study 
showed that the lower limbs were involved in diabetic 
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polyneuropathy more than upper limbs. Sensory and motor 
fibers were involved in upper and lower limbs nerves. 
In a study done by Gilliatt and Willison, 1962; LaMontagne 
and Buchthal, 1970; Buchthal and Rosenfalck, 1971) showed 
that abnormalities more commonly occur in sensory than motor 
fibers, in the feet and legs than in the forearms (Kimura et al., 
1979)  
Downie and Newell, 1961; Mulder et al., 1961; Skillman et 
al., Lawrence and Locke, 1962; LaMontagne and Buchthal, 
1970, showed that nerve conduction is significantly lower in 
diabetic patients than in healthy subjects. 
 These studies agree with our results where the 
abnormalities occur in sensory motor fibers, and involve lower 
limbs more than upper limbs.  
 
 
 
Summary and conclusion 
From the results of the present study,  the following 
could be concluded: 
In diabetic patients the mean of total cholesterol, LDL, and HDL 
were higher in female patients as compared with male 
diabetic patients.  
Type 2 diabetic patients had complications as the following, 
64.50% were diabetic polyneuropathy (40.0% mild, 35.0% 
moderate, and 25.0% severe), 40.0% small vessel disease of the 
eye, 39.40 % hypertension,  31.60% small vessels disease of the 
kidney, 30.30% ischemic heart disease, 12.30 % peripheral artery 
occlusion disease, and 5.20 % stroke. 
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Diabetic polyneuropathy is the most common and troublesome 
complication of diabetes mellitus. 
The percentages of female diabetic patients with HTN 
were higher than male diabetic patients. While stroke, IHD, 
and DPN, were higher in male diabetic patients than 
females.  
 Risk factors of diabetic polyneuropathy noticed in this 
study: 
The mean age of patients with diabetic polyneuropathy 
was higher than those without diabetic polyneuropathy 
(58.01±1.05 versus 51.80±1.35). Males had diabetic 
polyneuropathy more than females (55 males 72.4%, 45 
females57.0%). 
The duration of diabetes mellitus in diabetic 
polyneuropathy, was higher in diabetic polyneuropathy 
patients than non diabetic patients. 
 FBG level and HbA1c% were more in diabetic 
polyneuropathy patients as compared with patients without 
diabetic polyneuropathy. 
 The association of SVDE, SVDK, and PAOD with diabetic 
polyneuropathy was significant higher than in those without 
diabetic polyneuropathy 
Total cholesterol, HDL, LDL, and triglycerides were also 
noticed more in diabetic polyneuropathic patients than those 
without diabetic polyneuropathy but no significant difference. 
Qat chewing diabetic patients had prevalence of 
diabetic polyneuropathy more than in patients without 
diabetic polyneuropathy. 
In this study, the most significant risk factors for the 
prevalence of diabetic polyneuropathy were the gender, 
duration of DM, the presence of SVDE, chewing qat, high FBG, 
and high HbA1c%. 
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Nerve conduction studies showed that lower limbs were 
affected more than upper limbs 
The epidemiology and natural history of diabetic 
neuropathy (DN) remain poorly defined, partly because of 
poor patient selection and the variable criteria for what 
constitutes a diagnosis of DN  
It was agreed that neuropathy cannot be diagnosed 
without a careful clinical examination—absence of symptoms 
cannot be equated with absence of neuropathy, as 
asymptomatic neuropathy is common  
It is generally agreed that DN should not be diagnosed on 
the basis of one symptom, sign, or test alone: a minimum of two 
abnormalities (from symptoms, signs, and nerve conduction 
abnormalities, quantitative sensory tests or quantatitative 
autonomic tests) is recommended by Dyck. Certainly, for 
clinical trials or epidemiological studies, one of these two 
abnormalities should include quantitative tests or 
electrophysiology.  
Polyneuropathy affects peripheral nerves symmetrically, 
chiefly those in feet and legs. It is almost always sensory, 
although motor involvement causing weakness and wasting 
occur less often. Diabetic polyneuropathy is usually insidious in 
onset and may be the presenting feature in people with type 2 
diabetes. 
Variable definitions and diagnostic criteria are used for 
neuropathy. Poor ascertainment and paucity of population-
based studies limit the ability to compare reports of the 
prevalence of diabetic neuropathy. However, there is no doubt 
that chronic distal sensorimotor neuropathy is a common 
problem.  
Most common symptoms include burning pain, numbness, 
and prickle sensation. Symptoms usually worsen at night & 
predominantly affect the feet & lower limbs.  
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Nerve conduction studies are mandatory when 
alternative diagnoses in addition to DSP is being considered, 
and remains an essential element of clinical trials in DSP. 
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Recommendations 
We recommend extension of this study in Yemen in order 
to explore more the population distribution of diabetic 
polyneuropathy and its risk factors. Implementation of 
population-based measures for prevention and control of 
diabetes are needed. 
       For all diabetic patients, maintain aggressive control of 
blood glucose, HbA1c, blood pressure, and lipids, with 
pharmacological therapy and/or lifestyle changes. 
        Education of people with diabetes should be started 
before clinical neuropathy is present and should be tailored to 
the individual's circumstances and ability to understand. 
The providers of patient education include: 
. Primary care physician 
. Diabetes specialized nurse 
. Patient support groups (e.g. through diabetes associations) 
It is essential that healthcare personnel have received 
adequate training about neuropathy and its management. 
Patient education may be provided at structured primary 
health care clinics, diabetes education centers or meetings of 
support groups.  
It is recommended that there should be separate programs for 
people with type 2diabetes, as more extensive advice is likely 
to be required for the elderly patients. Providers/patients should 
be involved throughout.     
Every diabetic patient should undergo a careful clinical 
examination of the lower extremities and feet at least once a 
year. Those patients with foot ulcer risk require more frequent 
review, regular podiatric care, and foot care education, as 
there is a suggestion that these steps might result in earlier 
presentation when ulcer develop. 
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Exclusion of other causes, particularly malignant disease and 
toxic causes is of paramount importance. Exclusion of such 
potentially serious conditions such as malignant disease (e.g., 
small-cell carcinoma), toxic causes (e.g., alcohol), and 
infections (diseases such as HIV) is essential.  
Provide explanation, support, and information on particular 
measures, e.g., bed cradle to lift bedclothes off of 
hyperaesthetic skin. 
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